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Tau is a microtubule associated protein found in inclusions in tauopathies including 
Alzheimer’s disease. One known cause of neurodegeneration is an excess of exon 10 
inclusion in tau mRNA which is caused by several mutations in the MAPT gene, 
encoding tau. Processing of the Amyloid Precursor Protein (APP) generates β-
amyloid (Aβ) peptides which are deposited as amyloid plaques in AD brain. APP 
transcripts containing alternatively spliced exon 7 are increased in AD brain and 
processing of APP exon 7 containing protein isoforms may result in increased Aβ 
production. 
 
Recently, the DNA and RNA- binding protein, Tar DNA binding protein of 43 kDa 
(TDP-43) inclusions have been found in 20-35% of AD cases as well as other 
tauopathies. TDP-43 has roles RNA processing regulation including pre-mRNA 
splicing. Cytoplasmic inclusions of TDP-43 result in a loss of nuclear TDP-43 and 
suggest a loss of TDP-43 function that may impair its role in multiple RNA 
processing events. Our hypothesis is that TDP-43 dysfunction affects tau and APP 
RNA processing either directly or indirectly. 
   
We analysed post-mortem from human brain tissue and found an increase in severity 
of tau pathology associated with the presence of TDP-43 inclusions suggesting that 
TDP-43 dysfunction may modify tau pathology in AD brain. We found increased 
expression of tau exon 10 that correlated with increased expression of APP exon 7 in 
a subset of AD cases however there was no association between presence of TDP-43 
inclusions and altered tau or APP splicing.  
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Our results define a subset of AD cases with high levels of tau exon 10 inclusion. 
These finding suggest that therapeutic interventions based on equilibrating splicing 























Chapter one: Introduction 
 
Alzheimer’s disease (AD) is characterised neuropathologically by the accumulation 
of neurofibrilliary tangles (NFT) composed of abnormally phosphorylated 
microtubule associated protein tau and extracellular Aβ plaques composed of 
proteolytic fragments of APP. Protein deposits are the defining feature of the 
majority of neurodegenerative diseases and the identification of different proteins 
found in neuronal deposits has enabled a system of categorisation based on the 
immunoreactivity of nuclear, cytoplasmic or extra-cellular inclusions.  
 
1.1. Frontotemporal Lobar Degeneration  
 
Frontotemporal lobar degeneration (FTLD) is the second commonest form of 
cortical dementia of early-onset (< 65 years of age) after AD. FTLD comprises a 
clinically, genetically and neuropathologically heterogeneous collection of disorders. 
The most common clinical manifestation is behavioural variant FTD (bvFTD) where 
patients present with changes in personality and interpersonal conduct (Piguet et al., 
2011b). Language disorders such as progressive non-fluent aphasia and semantic 
dementia collectively known as primary progressive aphasia (PPA) are also common 
clinical phenotypes in FTLD (Snowden et al., 2007a).  
 
Major progress has been made in identifying the molecular basis of FTLD. There are 
now four known subtypes based on neuropathological inclusion type and these 
represent the most common protein inclusions found in FTLD (Table 1.1). Clinical 
 24
phenotype correlates better with specific patterns of brain atrophy rather than the 












Table 1.1 Genetic correlates of the molecular subtypes of FTLD. Table adapted 
from Rademakers et al. (2012). 
aFTLD-U: atypical frontotemporal lobar degeneration with ubiquitinated inclusion 
AGD: argyrophilic grain disease, BIBD: basophilic inclusion body disease, 
C9ORF72: chromosome 9 open reading frame 72, CBD: cortical basal degeneration, 
CHMP2B: charged multivescicular body protein 2B, FTD-3: frontotemporal 
dementia linked to chromosome 3, FTDP-17: frontotemporal degeneration with 
parkinsonism linked to chromosome 17, FUS: fused in sarcoma, GRN progranulin 
gene, MAPT: microtubule-associated protein tau, MND: motor neuron disease, 
MSTD: multiple system tauopathy with dementia, NFT: neurofibrillary-predominant, 
NIFID: neuronal intermediate filament inclusion disease, PiD: Pick’s disease, PSP: 
progressive supranuclear palsy, TARDBP: tar DNA binding protein gene, UPS: 
ubiquitin proteasome system, VCP: valosin-containing protein, WMT-GGI: white 
matter tauopathy with globular glial inclusions, 3R: tau pathology containing 






FTLD-Tau has tau pathology and account for around 40% of all FTLD cases. These 
include frontotemporal dementia with parkinsonism linked to chromosome 17 
(FTDP-17) caused by hereditary mutations in the MAPT gene and sporadic 
tauopathies such as Cortical Basal Degeneration (CBD) Progressive Supranuclear 
Palsy (PSP) and Pick’s disease (PiD). 
 
Both PSP and CBD are primarily movement disorders but dementia may be a 
prominent symptom in both diseases. PSP patients have postural instability, 
parkinsonism (rigidity and bradykinesia) and difficulty in moving eyes particularly 
in the vertical direction (Litvan et al., 1996). The core clinical features of CBD are 
progressive asymmetrical rigidity, apraxia and progressive aphasia (Kertesz et al., 
2000).  
  
Microscopic examination of PSP brain typically shows rounded or globose 
neurofibrilliary tangles (NFT) often in the globus pallidus while in CBD, ballooned 
neurons are often found in the superior frontal gyrus (Dickson, 1999). Another 
distinguishing feature of the two diseases is the presence of distinctive tufted 
astrocytes in frontal areas in PSP whereas CBD has tau positive processes radially 
arranged around a central astrocyte. These lesions are referred to as astrocytic 
plaques because they have a similar structural pattern to neuritic plaques found in 
AD (Dickson, 1999). PiD is characterised by Pick bodies containing tau and are 
found in frontal and temporal cortices (Piguet et al., 2011a). There is considerable 




Tau-negative FTLD cases where the major ubiquitinated protein was unknown until 
recently were labelled as FTLD with ubiquitinated inclusions (FTLD-U). TDP-43 is 
the major component of ubiquitinated cytoplasmic and intranuclear inclusions found 
in both FTLD-U (now called FTD-TDP and accounting for around 50% of cases) 
and in the majority of non-mutant SOD-1 Amyotrophic Lateral Sclerosis (ALS) 
cases (Neumann et al., 2006). TDP-43 inclusions were initially thought to be a 
specific marker for FTLD-U and ALS however the presence of TDP-43 inclusions 
has been found in other tauopathies which now defines a class of neurological 
diseases collectively known as TDP-proteinopathies. The molecular link between 
FTLD-U and ALS confirmed observations of significant overlap of clinical and 
pathological features in ALS and FTLD-TDP and it has been suggested that these 
two diseases form a continuum and have a common mechanism of 
neurodegeneration (Geser et al., 2010; Geser et al., 2009a). Examination of TDP-43 
distribution in FTLD-TDP, ALS and mixed FTLD/ALS brains showed that in FTLD 
brains, TDP-43 pathology accompanied by neuronal loss and gliosis was found in all 
brain regions including sub-cortical structures such as the basal ganglia and 
amygdala. ALS brains also showed widespread TDP-43 pathology but ALS was 
associated with a higher burden of inclusions in lower motor neuron nuclei (Geser et 
al., 2009b). Mutated genes which give rise phenotypically to FTLD and result in 
neuronal and glial TDP-43 inclusions have been the identified and include 
progranulin (PGRN) and Valosin containing protein (VCP).  
 
Mutations in TARDBP produce TDP-43 inclusions and predominately give rise to 
ALS. However the number of familial cases of ALS (FALS) is small, accounting for 
 28
10% of all ALS cases and mutations in TDP-43 account for 4-6% of FALS cases 
(Andersen and Al-Chalabi, 2011).The recently discovered hexanucleotide repeat 
expansion in the C9ORF72 gene produces TDP-43 inclusions and causes FTLD, 
ALS or mixed FTLD-ALS phenotype (DeJesus-Hernandez et al., 2011; Renton et 
al., 2011). The different mutated genes that give rise to TDP-43 inclusions also result 
in different inclusion morphologies and inclusion types in FTLD-TDP-43 and have 
been categorised (Table 1.2) (Mackenzie et al., 2006; Mackenzie et al., 2011; 
Sampathu et al., 2006). However it is not known if these different morphologies are 
indicative of different disease mechanisms.  
 
 
Table 1.2 Classification system for TDP-43 pathology  
(Taken from Mackenzie et al., (2011)). 
bvFTD: behavioural variant frontotemporal dementia, DN: dystrophic neurites, FTD: 
Frontotemporal dementia, IBMPFD: inclusion body myopathy with Paget’s disease 
of bone and frontotemporal dementia, NCI: neuronal cytoplasmic inclusions, NII: 




A group of FTLD-U cases that were tau- and TDP-43-negative and previously 
characterised by immunoreactivity of neuronal inclusions for ubiquitin have recently 
been identified as having protein inclusions containing Fused in Sarcoma (FUS; also 
known as Translated in Liposarcoma (TLS) (Mackenzie et al., 2011; Neumann et al., 
2009a; Neumann et al., 2009b). Cases included a set of brains with a very 
homogenous clinical and neuropathological phenotype, very early onset (35 years), 
negative family history for dementia and characteristic neuronal intranuclear 
inclusions (NII) (Mackenzie et al., 2008; Roeber et al., 2008). These brains had 
ubiquitin and p62 immunoreactivity a protein involved in the ubiquitin-proteasome 
system, and were termed atypical FTLD-U (aFTLD-U). Other tau- and TDP-43- 
negative cases included neuronal intermediate filament and α-internexin-positive 
inclusions (NIFID) and basophilic inclusion body disease (BIBD) (Munoz et al., 
2009; Neumann et al., 2009b) and these conditions are now considered subtypes of 
FTLD-FUS (Mackenzie et al., 2010) and account for approx 10% of cases in FTLD-
FUS (Urwin et al., 2010). FUS is a DNA and RNA binding protein with similarities 
to TDP-43 (Lagier-Tourenne and Cleveland, 2009). FUS plays a role in alternative 
splicing and transcription and is predominately nuclear, but also shuttles between the 
nucleus and the cytoplasm. FTLD-FUS brains have large cytoplasmic inclusions and 
a small number of nuclear inclusions.  
1.1.5 FTLD-UPS 
The fourth category is FTLD- ubiquitin proteasome system (UPS).These cases are 
tau-, TDP-43- and FUS- negative and inclusions can be demonstrated with 
immunohistochemistry against proteins of the UPS such as p62 (Mackenzie et al., 
2009, 2010). Cases are rare and include a large Danish family and an unrelated 
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Belgian patient with frontotemporal dementia linked to chromosome 3 (FTD-3). A 
mutation in the CHMP2B gene has been identified in FTD-3 cases and is most likely 
to cause disease by altering the endosome-lysosome pathway and autophagy (Isaacs 
et al., 2011; Skibinski et al., 2005; van der Zee et al., 2008b) although CHMP2B 
mutations do not account for all FTLD-UPS cases (Urwin et al., 2010). 
 
In a subset of FTLD-TDP brains, immunoreactivity for p62 has been found at a 
higher intensity than TDP-43, particularly in the cerebellum (Pikkarainen et al., 
2008). The recently discovered hexanucleotide repeat C9ORF72 gene mutation 
predominantly gives rise to TDP-43 inclusions however TDP-43-negative, p62-
positive staining was found in the cerebellum of FTLD brains with C9ORF72 
mutations (Al-Sarraj et al., 2011; King et al., 2011; Murray et al., 2011a). Semi 
quantitative scoring of p62 immunoreactivity and TDP-43 in a subset of these cases 
showed higher p62 immunoreactivity compared to TDP-43 immunoreactivity in the 
frontal and temporal cortices and sub- cortical structures including the hippocampus 
(Troakes et al., 2012). At present the mechanism of neurodegeneration caused by 
C9ORF72 mutations is not known. These findings suggest that components of the 
UPS and lysosomal autophagy pathways are involved, however there may be other 







1.2. RNA processing and alternative splicing 
 
RNA binding proteins (RBP) including TDP-43 and FUS are found in cytoplasmic 
and nuclear inclusions in neurodegenerative disease. The mechanism of 
neurodegeneration is not known however protein sequestration into inclusions may 
result in either a loss of function or potential gain of function of the protein. RBP 
play a role in many levels of RNA regulation and thus has directed attention to the 
role of RNA processing misregulation in the pathogenesis of neurodegenerative 
disease.  
 
RNA is the essential intermediary used to convert specific DNA sequences in the 
nucleus into functional proteins in the cytoplasm. RNA processing is highly complex 
and involves multiple proteins and processes to translate proteins from RNA 
transcripts. Eukaryotic pre-mRNA undergoes multiple post-transcriptional 
processing events including capping, splicing and polyadenylation which occur co-
transcriptionally within the nucleus.  
 
Splicing describes an essential RNA processing event which removes non-coding 
sequences (introns) from pre-mRNA and joins together neighbouring coding 
sequences (exons) to form a mature mRNA. The spliceosome, a multiprotein-
multiRNA complex, performs pre-mRNA splicing in eukaryotic cells. Splicing 
occurs either constitutively where exons of a pre-mRNA are joined together as they 
are ordered on the DNA sequence or alternatively where one or more exons may or 
may not be included in RNA transcripts. A key stage in splicing is exon definition 
where short exon sequences are located amongst vast stretches of intronic RNA. For 
the spliceosome to locate splice sites, splicing regulatory elements (SRE) are used 
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which consist of short cis-sequences on pre-mRNA exons or introns that bind trans-
acting splicing factors. SREs can act to either stimulate (enhancers) or repress 
(silencers) splicing of exons. Splice site selection is hugely complex and still not 
completely specified, however combinatorial control of many influences including 
cis silencer and enhancer elements and local context all play a role (for a recent 
review see (De Conti et al., 2012)).  
 
Alternative Splicing (AS) is a process where particular exons may be included or 
excluded from the final mRNA and is a crucial mechanism for gene regulation and 
for generating proteomic diversity. Recent estimates suggest that around 95% of 
human multi-exon genes are alternatively spliced (Wahl et al., 2009). Determination 
of levels of alternative splicing utilises cis-acting splicing silencers and enhancers at 
the RNA level and the same spliceosomal machinery as constitutive splicing. In 
addition, alternatively spliced variants can be produced according to different 
sequence elements at the DNA level such as promoters and transcriptional enhancers 
(Kornblihtt, 2005). On the trans-acting side, the abundance, cell localisation and 
phosphorylation state of various splicing factors play a major role in expression of 
alternatively spliced transcripts (Park et al., 2004; Zhang et al., 2008b).  
 
Global changes in alternative splicing have been demonstrated in AD brains by RNA 
sequencing and microarrays (Tollervey et al., 2011b; Twine et al., 2011). Tollervey 
et al.,(2011) show that levels of many RBP proteins are altered in neurodegenerative 
disease and that particular splicing factors such as Neuro-oncological ventral 
antigen-1 (Nova 1) can alter alternative splicing of multiple target RNAs in human 
brain. Nova1 and Nova 2 are splicing factors specific to the central nervous system 
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and both regulate alternative splicing by binding specific intronic sequences of 
transcripts containing a YCAY tetramer, where Y indicates a pyrimidine (Ule et al., 
2003). Nova1 and Nova 2 knock-out mice show altered splicing levels in transcripts 
containing the intronic Nova binding sequence (Ule et al., 2003). In Nova 2 
knockout mice a microarray analysis found 591 exons that were differentially spliced 
(Ule et al., 2005). Analysis of the function of the Nova-regulated transcripts showed 
Nova preferentially regulates transcripts encoding proteins that function in the 
synapse and many of these proteins interact with each other (Ule et al., 2005). Fox1 
(also known as A2BP1) and Fox 2 (also known as RBM9) are RBP expressed in 
human brain, heart and skeletal muscle and have a consensus RNA binding 
(U)GCAUG motif (Zhang et al., 2008a). The Fox binding motif is enriched proximal 
to a set of brain specific exons that are alternatively spliced (Sugnet et al., 2006; Yeo 
et al., 2007). Computational analysis of the splicing pattern of exons flanked by the 
Fox 1 and 2 binding motif in human tissue showed that the targets of Fox 1 and 2 
splicing factors play important roles in neuromuscular functions (Zhang et al., 
2008a).   
 
These findings show that many RBP have specific RNA targets containing binding 
motifs. A single splicing factor can coordinate splicing events of very specific 
groups of proteins involved in a functional network. In neurodegenerative disease, 
levels of trans-factors are altered and result in misregulation of RNA processing of 
its gene targets and may alter major functional networks. Many different RNA 
processing steps in a network can be misregulated to cause disease (Anthony and 
Gallo, 2010).  
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1.3. Tar DNA Binding Protein-43 
 
1.3.1. Functional domains of TDP-43 
TDP-43 protein has similar structural properties to the heterogeneous 
ribonucleoprotein (hnRNP) A/B family and TDP-43 had been found to be a RBP 
involved in alternative splicing and transcription (Buratti and Baralle, 2001; Ou et 
al., 1995). It also has multiple roles in RNA processing such as DNA transcription, 
DNA replication and repair, pre-mRNA splicing and stability, mRNA 
export/retention processes and protein translation (Dreyfuss et al., 2002; He and 
Smith, 2009; Prasanth et al., 2005). TDP-43 exerts skipping of exon 9 of cystic 
fibrosis transmembrane conductance regulator (CFTR) by binding to UG repeats on 
the CFTR gene and recruiting an hnRNP A/B inhibitory complex which blocks 
spliceosome assembly (Buratti and Baralle, 2008). The two highly conserved RNA 
recognition motifs (RRM1 and RRM2) allow the protein to bind double stranded 
DNA and single stranded RNA and are required for TDP-43 to regulate alternative 
splicing of target RNAs including CTFR exon 9 skipping (Buratti and Baralle, 2001; 
Ou et al., 1995). TDP-43 has two nuclear localisation signals (NLS) situated between 
the N-terminus and RRM1 (Figure 1.1). The second RNA binding region also 
contains a nuclear export signal (NES). The C-terminal of TDP-43 is predicted to be 
unstructured and has regions rich in glycine/serine and glycine/asparagine (Figure 
1.2). The function of glycine-rich regions (GRR) are not well defined however the 
general properties include protein-protein and protein-DNA interactions (Babu et al., 
2011; Gsponer and Babu, 2009). As they are unstructured, different folding 
conformations may be adopted when interacting with different partners such as 
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proteins, DNA or RNA and this may allow TDP-43 to bind to dispersed UG repeats 
(Rogelj, 2011).  
 
 
Figure 1.1. Exon structure and structural domains of TDP-43 
5’UTR, 5’ untranslated region; GRR, Glycine rich region; RRM RNA recognition 
motif; NES nuclear export signal; NLS nuclear localisation signal; TDPBR TDP-43 
binding region; pA1 polyadenylation site 1. 
 
 
1.3.2 TDP-43 mutations 
Multiple mutations in the TARDBP gene have been found and provide evidence of a 
direct link between TDP-43 dysfunction and neurodegeneration. The majority of 
ALS-linked pathogenic mutations in TDP-43 are found in the GRR (Sreedharan et 
al., 2008). Some TDP-43 mutations result in increased levels of TDP-43 cleavage 
fragments in the presence of a proteasomal inhibitor in lymphoblastoid cell lines 
derived from mutation carriers compared to non-carriers (Kabashi et al., 2008; 
Rutherford et al., 2008). Insoluble C-terminal fragments of 25 kDa and 35 kDa are 
found in homogenates of all brains harbouring TDP-43 inclusions (Neumann et al., 
2006). TDP-43 mutations may promote cleavage of the full length protein into 
fragments that do not function in RNA processing (Buratti and Baralle, 2001) and as 
a consequence result in a loss of TDP-43 function. Some of TDP-43 mutations 
accelerate TDP-43 aggregation in vitro and enhance TDP-43 toxicity in yeast 
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(Johnson et al., 2009) and suggest that gain of toxic function as a mechanism for the 
role of TDP-43 misregulation in neuronal cell death.  
 
1.3.3. Alternative splicing and transcription role for TDP-43 in brain 
Recent functional analyses of TDP-43 role in mice and human cells confirm roles in 
alternative splicing and transcription and show that TDP-43 has multiple targets 
(Polymenidou et al., 2011; Sephton et al., 2011; Tollervey et al., 2011a; Xiao et al., 
2011). Polymenidou et al. (2011) show that TDP-43 downregulation in mice, 
decreases levels of 601 genes and some of these target genes were other RBP 
including Fused in Sarcoma (Fus; also known as Translated in Liposarcoma (Tls) 
and Double-stranded RNA-specific editase 1 (Adarb 1) (Polymenidou et al., 2011). 
This suggests that TDP-43 misregulation in disease has the potential to alter levels 
and splicing of other splicing factors and alter multiple pathways. These authors 
found that genes most altered by TDP-43 downregulation were those involved in 
synaptic activity. Whether these findings are applicable to the human brain is 
arguable because most TDP-43 binding sites are in unconserved intronic regions and 
so TDP-43 targets in mice may be different to those in humans.   
 
RNA targets of TDP-43 binding and regulation have also been studied in more 
physiological relevant tissues including human brain, human embryonic stem cells 
and SH-SY5Y cells by analysis of UV-cross-linking and immunoprecipitation (UV-
CLIP) (Tollervey et al., 2011a; Xiao et al., 2011). These authors found TDP-43 
binds predominantly to intronic UG repeat RNA sequences as previously reported 
(Buratti and Baralle, 2001). Although TDP-43 has specificity for UG repeats 
Tollervey et al., (2011a) show that TDP-43 binds to UG motifs that has other RNA 
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nucleotide sequence interspersed between the UG sequences over a ~200 nucleotide 
region. The majority of TDP-43 binding is to intronic sequences and indicates that 
TDP-43 binds to pre-mRNA in the nucleus. The UV-CLIP technique also confirmed 
previous human targets of TDP-43 binding including FUS, CDK6 and NEFL (Ayala 
et al., 2008; Strong et al., 2007). Knock down of TDP-43 in SH-SY5Y cells showed 
altered splicing in 158 genes measured by microarray. Many of the validated 
alternatively spliced genes that TDP-43 regulates are involved in neuronal 
development (Tollervey et al., 2011a). 
 
1.3.4. TDP-43 role in post-transcriptional regulation 
TDP-43 associates with the Drosha complex which is a large multi-protein complex 
involved in microRNA (miRNA) biogenesis (Buratti et al., 2010; Ling et al., 2010).  
Primary miRNA transcripts are transcribed by RNA polymerase II and can be 
thousands of base pairs in length (Lee et al., 2004). The Drosha complex processes 
these transcripts in the nucleus producing precursor miRNAs (pre-miRNA) which 
are approximately 70 nucleotides in length and characterised by a stem loop 
structure. After nuclear export, pre-miRNAs are cleaved in the cytoplasm by Dicer 
to generate mature miRNA. Generally miRNAs regulate RNA stability by base 
pairing to target mRNAs, usually in the 3’UTR, and repress translation by 
deadenylation of transcripts and subsequent degradation of mRNA targets (Fabian et 
al., 2010; Filipowicz et al., 2008). The 3’ untranslated region (3’UTR) is important 
for the regulation of mRNA stability, and localisation due to the presence of specific 
sequences that govern the spatial and temporal expression of a specific RNA 
(Kuersten and Goodwin, 2003; Xie et al., 2005).  
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Knockdown of TDP-43 in Hep-3B cells down and up- regulated 11 specific miRNAs 
(Buratti et al., 2010). The two most significantly altered miRNAs (let-7b and miR-
663) both contain a UG repeat sequence which is the canonical RNA binding 
sequence for TDP-43 (Buratti and Baralle, 2001). Cyclin-dependent kinase 6 
(CDK6) is one of the targets of let-7b regulation and has previously been found to be 
upregulated following TDP-43 down-regulation (Ayala et al., 2008).   
 
In human spinal cord, TDP-43 binds to and stabilises the 3’UTR of neurofilament 
light (NEFL) possibly for transport of NEFL transcripts into an RNA/ protein 
complex (RNP particle) and translocation to a site of translation (Strong et al., 2007).  
 
Taken together these results show that TDP-43 plays a major role in splicing and 
transcription in the nucleus of neurons. It binds to DNA and regulates transcription 
of many target genes and potentially other splicing factors. TDP-43 binding targets 
are predominantly intronic and usually contain UG repeats however UG repeats may 
be dispersed over many nucleotides. TDP-43 also has a role in post-transcriptional 
events including regulation of microRNA. This suggests that in TDP-43 inclusion 
bearing neurons, the mislocalisation of TDP-43 into cytoplasmic inclusions and 
subsequent loss of nuclear TDP-43 may result in misregulation not only of splicing 






1.3.5. TDP-43 aggregation: stress granules 
Protein aggregation in cells is generally thought to have negative consequences 
however in certain circumstances such as heat stress where cellular damage has 
occurred, particular proteins reversibly aggregate into stress granules (SG) which 
temporarily stop all but the most essential cellular processes. SG are cytoplasmic 
ribonucleoprotein foci which transiently assemble and contain mRNAs, RNA 
binding proteins and stalled translation initiation complexes to slow down growth, 
translation and conserve ATP for the repair of stress-induced damage (Anderson and 
Kedersha, 2002). The translational arrest that accompanies environmental stress is 
selective, while housekeeping transcripts are turned off, translation of heat shock 
proteins is enhanced (Anderson and Kedersha, 2008). T-cell intracellular antigen-1 
(TIA-1) and TIA 1 related protein (TIAR) are markers of SG (Kedersha et al., 1999). 
These RBP shuttle between the nucleus and cytoplasm, however, in response to 
environmental stress they rapidly aggregate in the cytoplasm to form SG (for a 
review see (Anderson and Kedersha, 2008; Thomas et al., 2011)). Nucleation of SGs 
occurs via a reversible protein aggregation mechanism which is dependent on prion- 
related domains present in TIA-1, TIAR and (Gilks et al., 2004). TDP-43 is also 
sequestered into SG after oxidative and environmental stress in vitro. In vitro, TDP-
43 does not play a role in initiating stress granule formation (Colombrita et al., 2009) 
but may modulate stress granule assembly (McDonald et al., 2011). SG composition 
is different according to different environmental stressors and TDP-43 is recruited to 
SGs, in vitro, only in certain stressor conditions (Dewey et al., 2012). For example, 
treatment of HeLa cells with arsenite, an inducer of oxidative stress, causes TDP-43 
recruitment to SGs however arsenite treatment of HEK 293 cells does not recruit 
TDP-43 into SG (Dewey et al., 2011; McDonald et al., 2011) showing that TDP-43 
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is not a core component of SGs. The prion-related domain within TDP-43 C-
terminus most likely mediates interactions with SG (Fuentealba et al., 2010; Liu-
Yesucevitz et al., 2010).  
 
1.3.6 Prion domains of TDP-43 
Prions cause the transmissible spongiform encephalopathies which include scrapie in 
sheep and Creutzfeldt-Jakob disease in humans. The infectious prion particle is a 
misfolded prion protein (PrPsc) which are able to convert natively folded prion 
protein (PrPc) into a misfolded version through the direct interaction with the 
misfolded copy  (Alberti et al., 2009; Chien et al., 2004; Prusiner, 1982; Toombs et 
al., 2010). Prion formation follows a crystallisation-like model in which the PrPsc 
aggregate acts as a nucleus or seed to recruit monomeric PrPc into a growing PrPsc 
polymer (Lansbury Jr and Caughey, 1995). Infection occurs as prionoids break off 
the self-aggregating PrPsc polymer and become seeds in their own right. Prions are 
an infectious agent capable of transference across species, “prionoid” describes a 
prion-like process where infection occurs within a single tissue or organism and does 
not transfer to other organisms (Aguzzi, 2009; Aguzzi and Rajendran, 2009).  
 
Around 1% of all proteins have a prion domain and there is a 12 fold enrichment for 
proteins that have a RRM, for example FUS and many hnRNP proteins have prion-





Figure 1.2. The glycine rich and prion domain of TDP-43; taken from Rogelj et 
al., (2011). 
Asparagines are labelled in blue, glutamines in purple, serines in pink, glycines in 
red and arginines in green. The amino acids in TDP-43 affected by mutations are 
underlined and shaded in yellow 
 
 
The C-terminal domain of TDP-43 containing the prion-like domain plays a critical 
role in TDP-43 proteinopathies, with detergent insoluble C-terminal fragments of 25-
35kDa found in homogenates of all brains harbouring TDP-43 inclusions (Neumann 
et al., 2007b; Neumann et al., 2006). Overexpression of C-terminal TDP-43 
constructs designed to mimic the 25 and 35kDa TDP-43 fragments in disease cause 
cytoplasmic inclusion formation that co-stain with SG markers in human 
neuroblastoma cells (Liu-Yesucevitz et al., 2010). Expression of peptides containing 
12 repeated sequences of the TDP-43 prion domain (residues 331-369) result in 
aggregates in US02 cells, HEK 293 cells and rat primary neurons (Budini et al., 
2012). The aggregates contain endogenous TDP-43 and these results suggest that the 
prion domain of TDP-43 is critical for aggregation.  
 
In other studies, nuclear TDP-43 CTFs generated with an inducible tobacco etch 
virus which cleaves TDP-43 at the second RRM were transported to the cytoplasm, 
however these fragments were degraded and showed no aggregation (Pesiridis et al., 
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2011). These authors show that TDP-43 CTF inclusion formation in vitro requires 
“two hits”, TDP-43 cleavage and an additional stressor such as depletion or 
inhibition of RNA transport for TDP-43 aggregates to form (Pesiridis et al., 2011).  
 
The majority of ALS-linked pathogenic mutations found in TDP-43 are in the GGR 
and the effects of these mutations are diverse (Gendron et al., 2012). In vitro, 
transfection of four different TDP-43 mutations increased the number of cells with 
TDP-43 inclusions compared to cells transfected with wild type TDP-43 in cells 
treated with arsenite. Mutant TDP-43 colocalised with TIA-1 showing that TDP-43 
inclusions were associated with SGs in vitro (Liu-Yesucevitz et al., 2010). 
Colocalisation of TDP-43 inclusions and SG markers was also demonstrated in 
human brain tissue from ALS and FTLD cases (Liu-Yesucevitz et al., 2010), 
however no colocalisation between TDP-43 inclusions and components of SG has 
been found in ALS brain in other studies (Colombrita et al., 2009; Neumann et al., 
2007a; Nijholt et al., 2012). 
 
These findings suggest possible mechanisms for TDP-43 inclusion formation. TDP-
43 inclusions colocalise with some SG markers and this shows that an altered stress 
response could cause cytoplasmic accumulation of TDP-43 (Dewey et al., 2012). In 
brains from patients harbouring TDP-43 mutations, the increased aggregation 
properties of particular TDP-43 mutations could result in defects in SG assembly or 
disassembly. The “two hit” hypothesis suggests that TDP-43 cleavage and chronic 
cellular stress such as that brought about by aging and environmental stressors could 
increase SG formation and seed TDP-43 aggregation (Dewey et al., 2012; 
Polymenidou and Cleveland, 2011).  
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Evidence for a prion-like propagation of many aggregated proteins has been found in 
neurodegenerative disease linked proteins including tau and TDP-43, (for reviews 
see (Aguzzi and Rajendran, 2009; Hardy, 2005; Polymenidou and Cleveland, 2011; 
Soto, 2012)). The prionoid hypothesis for TDP-43 inclusion propagation is 
controversial, however it remains a compelling hypothesis for the clinically observed 
spread of pathology in FTLD, ALS and TDP-43 inclusions in AD (Furukawa et al., 
2011; Udan and Baloh, 2011). 
1.4. TDP-43 Autoregulation Mechanisms 
 
mRNAs primarily function as templates for protein synthesis and therefore cells 
have evolved translation-dependent quality control mechanisms to dispose of 
defective mRNAs that would synthesize abnormal proteins. Nonsense mediated 
decay (NMD) eliminates mRNAs that prematurely terminate translation and thus 
reduce the potentially toxic effects of defective transcripts that are routinely 
generated during gene expression and pre-mRNA splicing (Maquat et al., 2010; 
Schoenberg and Maquat, 2012). The NMD pathway is also utilised to regulate levels 
of many splicing factors by coupling alternative splicing with NMD (AS-NMD) 
(McGlincy and Smith, 2008). It is now known that all members of the human and 
mouse heterogenous ribonuclear proteins (hnRNPs), of which TDP-43 is a member, 
and serine-arginine (SR) proteins are maintained by autoregulatory and cross-
regulatory pathways using AS-NMD. An example of AS-NMD that has been 
demonstrated for SRP55 involves the protein binding to the nascent SRP55 RNA 
transcript and splicing a cryptic exon containing a termination codon (TC; also 
known as a nonsense codon) into the transcript. For SRP55 the “poison exon” is 
 44
spliced into the transcript between exon 2 and 3, the normal SRP55 transcript 
contains 6 exons (Lareau et al., 2007). The spliceosome leaves an exon junction 
complex (EJC) marker at each exon-exon junction of the spliced mRNA (Le Hir et 
al., 2001; Le Hir et al., 2000). During the pioneer round of translation the ribosome 
removes the EJCs. In the SRP55 example, the ribosome will terminate translation at 
the first TC encountered, which is the TC contained in the poison exon. The TC in 
the poison exon is regarded as a premature termination codon (PTC) since there are 
EJCs remaining on the transcript marking exon-exon boundaries and therefore 
proteins within the EJC including Upf3 and Upf2 recruit Upf1 which triggers NMD 
degradation of the transcript (for reviews and references see (Maquat and Gong, 
2009; Saltzman et al., 2008)).  
 
Many variations on this basic autoregulatory mechanism are used by the different 
hnRNP and SR proteins and all result in an autoregulatory feedback loop to maintain 
constant levels of RBP. What is striking is the level of conservation of these 
mechanisms used for AS-NMD. Exons and flanking intronic regions involved in AS-
NMD coincide with extreme sequence conservation regions called ultraconserved 
elements (Lareau et al., 2007; Ni et al., 2007; Saltzman et al., 2008) and show that 
AS-NMD is a ubiquitous mechanism shared by organisms from flies to man.  
 
Analysis of TDP-43 autoregulation in HEK 293 cells is presented in depth in two 
papers by the Baralle group, Ayala et al., (2011) and Avendaño-Vázquez et al., 
(2012) and their notation is used for the following summary (see also Figure 1.3). 
Binding activity of TDP-43 protein to copies of its RNA transcript is mediated by 
RRM1, the C-terminal domain and regions within the 3’UTR TDPBR. 
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Downregulation of TDP-43 transcript is dependent on binding sites located in the 
TDP-43 3’UTR known as the TDP-43 binding region (TDPBR). Using cross linking 
immunoprecipitation (CLIP), (Ayala et al., 2011) show that most TDP-43 protein 
binding to the TDP-43 transcript occurs within a 34 nucleotide sequence within the 
3’UTR TDPBR. TDP-43 protein specifically binds the TDPBR but with less 
efficiency than the canonical RNA TDP-43 binding sequence (UG repeats), however 
this is in line with a less efficient binding region for autoregulatory purposes (Ayala 
et al., 2011).  
 
 
Figure 1.3. 3’UTR splicing of TDP-43. 
The 3’UTR of TDP-43 has four polyadenylation sites and in HEK cells there is a 
preference for the first (pA1) and fourth (pA4) to be used (Ayala et al., 2011). 
 
 
The Baralle group identified two TDP-43 transcripts that are potentially the products 
of autoregulatory splicing. The TDP-43 V2 isoform has two cryptic introns 6 and 7 
spliced in the 3’UTR. The 5’splice site in intron 6 starts around 118 base pairs from 
the beginning of exon 6 and removes the TDP-43 glycine rich domain, the Q/N rich 
“prion domain”, the termination codon and around 540 bp of 3’UTR. The intron 7 
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splice site starts in 3’UTR and splices out the TDPBR and the first poly-adenylation 
site (pA1) and since pA1 is spliced, the V2 transcript utilises either pA2 or pA4. 
 
A number of mechanisms for detection and degradation of PTC containing 
transcripts that are targeted to the NMD pathway have been proposed (Bhuvanagiri 
et al., 2010; Brogna and Wen, 2009). Transcripts that have introns spliced in the 
3’UTR usually trigger degradation via the NMD pathway and this may be due to the 
presence of an EJC beyond the authentic canonical stop codon which is interpreted 
as premature because splicing junctions are not normally present beyond a stop 
codon (Giorgi et al., 2007; Lareau et al., 2007). Ayala et al. (2011) found that the V2 
transcript was subject to NMD, transcript levels were increased when the NMD 
pathway was inhibited by cycloheximide or by knockdown of the crucial NMD 
pathway component, Upf1, in HEK293 cells. Splicing of intron 6 also removes the 
authentic stop codon and therefore the V2 transcript may also be subject to 
degradation via the non-stop decay pathway however this is unlikely because there 
are downstream stop codons that would substitute for the authentic stop codon. Non-
stop decay is a translation-dependent degradation pathway for transcripts that lack 
stop codons which may arise due to mutations, premature polyadenylation or 
transcriptional arrest (Klauer and van Hoof, 2012).  
 
In HEK 293 cells with tetracyline inducible TDP-43 expression, the V2 transcript is 
not detected when overexpression of TDP-43 is induced in their system suggesting 
that the V2 transcript is not the major form of autoregulation for TDP-43. Instead the 
authors demonstrate that a novel mechanism of autoregulation occurs in TDP-43 
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where intron 7 is spliced out of the 3’UTR and the transcript (pA2) is retained in the 
nucleus and thus is not available for translation. 
 
NMD coupled with AS regulates gene expression and provides an additional layer of 
post-transcriptional regulation in many RBP. TDP-43 transcripts shows complex 
3’UTR splicing which results in autoregulation of TDP-43 transcript levels. Levels 
of TDP-43 proteins are tightly regulated and loss of TDP-43 in mice is lethal, 
whereas overexpression of human TDP-43 in mice is toxic (Cannon et al., 2012; 
Wils et al., 2010; Wu et al., 2010). These findings suggest that the nuclear clearance 
of TDP-43 protein in TDP-43 proteinopathies could feedback to alter levels of its 
own transcript. The consequences of the reduction of nuclear TDP-43 protein has on 
autoregulation of TDP-43 transcript levels are not known but misregulation of TDP-
43 may contribute to neurodegeneration. 
 
 
1.5. The microtubule-associated protein tau 
 
Microtubule (MT) stability and mechanical properties are regulated by interactions 
with accessory proteins such as the microtubule-associated proteins (MAPs). 
Microtubules are an important component of the cytoskeleton and play a role in cell 
shape organisation, mitosis, intracellular transport amongst other functions.  MAPT, 
the gene name for tau protein, was first co-purified with microtubules and linked to 
the discovery of microtubule self-assembly. The stabilisation and polymerisation of 
MTs along axons is a well characterised function of tau.  
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1.5.1. Tau expression and alternative splicing 
The MAPT gene consists of 16 exons, with exons -1 and 16 transcribed but not 
translated (Andreadis et al., 1992). Eight of the 16 exons are potentially alternatively 
spliced (2, 3, 4a, 6, 8, 10, 13, and 14) which results in protein isoforms ranging in 
size from 58 kDa to 110 kDa. The 110 kDa “big tau” isoform contains exon 4a and 
is expressed exclusively in the retina and the PNS (Andreadis, 2005). Tau exons 2, 3 
and 10 are alternatively spliced in the human adult CNS.  
 
Tau isoforms expressed in the CNS have either three or four MT binding repeats (3R 
or 4R tau respectively) and the isoforms containing four repeats has a higher affinity 
for MTs compared to the 3R isoform (Butner and Kirschner, 1991; Goode et al., 
2000; Trinczek et al., 1995). Exons 2 and 3 code for acidic inserts in the N-terminal 
projection domain. Exon 3 is never expressed without exon 2 and, on the basis of 
how many N-terminal domains present (2-3-, 2+3- and 2+3+), are termed 0N, 1N 
and 2N respectively and appear in the brain with prevalence 1N > 0N > 2N 
(Andreadis, 2005).  
 
Foetal expression of tau is exclusively 0N3R in humans (Takuma et al., 2003) while 
in human adults six isoforms are expressed by different combinations of exon 10 and 
the two N-terminal exons. 3R and 4R transcripts are distributed and expressed at 
similar levels in the adult brain as measured by in situ hybridisation, except for the 
granule cells of the dentate gyrus which had almost exclusive 3R expression 
(Goedert et al., 1989). Total levels of tau RNA and protein are differentially 
expressed in different brain regions with a 1.5 fold increase in RNA expression in 
the frontal cortex, the brain area with the highest expression, compared to white 
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Figure 1.4. Exon structure and alternative splicing of the MAPT gene 
Alternative splicing of exons 2, 3, and 10 generates six tau isoforms in the human 
CNS. Isoforms differ by the presence of exons 2 and 3 in the N- terminus, and exon 
10 in the C-terminus containing either three (3R) or four (4R) microtubule-binding 





1.5.2. Tau function 
Tau exon 10 (E10) codes for one of four imperfect MT repeat binding domains, all 
of which are highly conserved in vertebrates. The repeats bind to MTs and tau 
isoforms affect this function to different degrees (Drechsel et al., 1992; Trinczek et 
al., 1995). Affinity for MT is altered by the number of MT binding repeat domains 
present on the protein. 4R tau binds to MT more efficiently than 3R tau (Butner and 
Kirschner, 1991; Goode et al., 2000; Trinczek et al., 1995). Tau has multiple 
phosphorylation sites and MT binding is regulated by phosphorylation (Bramblett et 
al., 1993; Hanger et al., 1998; Lindwall and Cole, 1984). Generally higher 
phosphorylation equates to less MT binding.  
 
MAPs, including tau, regulate axonal transport of mitochondria, via motor proteins 
such as kinesin. Tau competes with motor proteins for binding to the microtubule 
surface (Dixit et al., 2008) and MAPs may even block the path of motor proteins 
(Mandelkow et al., 2004). Expression of 4R tau isoforms in vitro causes more 
mitochondrial clustering than 3R tau expression in primary neurons (Stoothoff et al., 
2009) suggesting that the stronger affinity 4R tau has for MT causes more motor 
protein pausing compared to 3R tau.  
 
The N-terminal projection domain, which contains alternatively spliced exons 2 and 
3, mediates interactions with the plasma membrane (Brandt et al., 1995) and the 
length of the projection domain also determines spacing between MTs for tau as well 
as other MAPs (Chen et al., 1992).  
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1.5.3. MAPT mutations in FTDP-17 
 
Mutations in MAPT cause FTDP-17 and the functional consequences of FTDP-17 
mutations fall into two categories: those with a primary effect at the protein level and 
those influencing the alternative splicing of tau pre-mRNA. The majority of 
mutations acting at the protein level alter the MT binding properties and reduce tau 
protein binding and affinity for MT (Hong et al., 1998), suggesting that the 
interaction of tau with MT is crucial for preventing the self-assembly of tau 
(Hasegawa et al., 1998). Mutations acting at the RNA level alter the ratio of 4R/3R 
tau isoforms (Hutton et al., 1998). Around half of the known tau mutations have their 
primary effect at the RNA level altering splicing usually by increasing tau transcripts 
containing exon 10 although others have the opposite effect and increase 3R 
transcripts (Goedert, 2005). Tau splicing mutations cause FTDP-17 possibly by 
destabilising a predicted stem-loop structure at the exon 10- intron 10 boundary 
which alters exon 10 splicing (Hutton et al., 1998; Spillantini et al., 1998b; Varani et 
al., 1999). Most of the work that supports formation of the stem loop has been done 
in vitro and these structures may not form in vivo because multiple splicing proteins 
bind to pre-mRNA and prevent the formation of secondary structures (Caffrey and 
Wade-Martins, 2007). An alternative theory is that intron 10 contains cis-sequences 
that bind trans-acting factors and these ssites are altered by mutations (Andreadis, 
2006; D'Souza et al., 1999; D'Souza and Schellenberg, 2000).  
 
Mutations that occur in intron 10 are labelled according to the number of nucleotide 
they are from the 3’ end of exon 10. The intronic 10+16 mutation and the intronic 
10+14 mutation result in a 4R/3R ratio of ~2-6 compared to control of ~1 measured 
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by RT-PCR in the frontal cortex and cerebellum (Hong et al., 1998; Hutton et al., 
1998). Splicing regulation of tau exon 10 is multilayered and weak splice sites flank 
tau exon 10 and may allow the subtle spatial and temporal regulation of 3R and 4R 
isoforms. Known splicing regulatory elements within exon 10 include three ESEs at 
the 5’ end and one centrally located ESS and these bind splicing factors including 
Tra2beta and SF2/ASF (Caffrey and Wade-Martins, 2007; Glatz et al., 2006; Kondo 
et al., 2004).   
 
Volumetric analysis by MRI imaging of brains with different MAPT mutations show 
that generally FTDP-17 mutations result in atrophy in the temporal cortex however 
the different types of MAPT mutations result in different patterns of atrophy 
(Whitwell et al., 2009). For mutations that alter tau splicing, the medial temporal 
lobe is the main area of atrophy while brains with mutations causing reduced MT 
binding show more widespread atrophy including the frontal lobe and the lateral 
temporal lobe (Whitwell et al., 2009).  
 
The severity of tau pathology and the morphology of inclusions is heterogenous even 
within brains harbouring the same mutation. The neuronal pathology of 12 brains all 
with the 10+16 tau mutation, which increases 4R tau transcripts, was assessed and 
the authors found that the frontal pole, temporal pole and the medial temporal lobe 
were severely affected with tau positive neuronal and glial inclusions, with a 
selective preservation of the posterior part of the superior temporal gyrus in four 
cases (Lantos et al., 2002). These authors note that the brain samples examined 
showed considerable differences in severity of the tau inclusions suggesting that 
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even for a dominant mutation other factors such as epigenetic factors and 
environment can alter pathology to a considerable degree.  
1.5.4. Tau aggregation 
Neuropathological examination of FTDP-17 cases shows abundant phosphorylated 
filamentous tau pathology, however the morphology of the tau filaments is 
determined, to a significant degree, as to whether the mutation alters splicing of exon 
10 or MT binding of tau (Goedert, 2005; Goedert and Jakes, 2005).  
 
For mutations that cause splicing mutations, twisted ribbon structures have been 
found (Crowther and Goedert, 2000) whereas mutations that result in loss of MT 
binding (P301L) irregularly twisted ribbons and straight filaments have been 
reported (Spillantini et al., 1998a) (Spillantini et al., 1998b). 
 
Tau aggregation is dependent on the assembly of a nucleus or seed onto which tau 
monomers can grow (Friedhoff et al., 1998; Guo and Lee, 2011). The assembly of 
tau monomers into filaments, results in the formation of a cross-β sheet structure 
which is a feature of all fibrils belonging to the amyloid class (Barghorn and 
Mandelkow, 2002). The seeds act as a template, recruiting more tau however the 
fibrillar structure of the aggregates is dependent on the whether the seed is composed 
of exclusive 3R exclusive 4R or a mixture of 3 and 4R tau (Dinkel et al., 2011; Yu et 
al., 2012). 
 
The association between splicing imbalances at the RNA level and deposition of 4R 
insoluble protein in FTDP-17 cases (Connell et al., 2005; Umeda et al., 2004) 
suggests that an excess of a particular translated tau isoform can seed tau 
 54
aggregation. In AD both 4R and 3R tau is found in tau aggregates and suggests that a 
different pathways toward tau aggregation are involved in different tauopathies. 
 
1.5.5. Exon 10 expression in tauopathies 
Imbalances in tau 4R/3R RNA splicing ratio have been demonstrated in post-mortem 
brain samples of patients with neurodegenerative tauopathies such as corticobasal 
degeneration (CBD), progressive supra-nuclear palsy (PSP) and Pick’s disease (PiD) 
(Chambers et al., 1999; Takanashi et al., 2002; Umeda et al., 2004). The altered 
4R/3R tau ratio is also found in insoluble protein deposits in tauopathy brains (Buée 
and Delacourte, 1999; Gibb et al., 2004; Hanger et al., 2002). In PSP and CBD a 
predominance of 4Rtau isoforms are found and in PiD there is a predominance of 3R 
isoforms although 4R isoforms are also present in some cases (Arai et al., 2001; 
King et al., 2001). Arai et al., (2001) report that in their PiD brains they found thorn 
shaped astrocytes that stain for 4R tau similar to those found in dementia pugilistica, 
AD and PSP and they suggest that these inclusions may be the source of 4R tau 
isoforms in PiD.  
 
In AD, conflicting results have been reported regarding tau alternative splice isoform 
expression, with some studies reporting an equal tau 4R to 3R RNA ratio 
(Boutajangout et al., 2004; Chambers et al., 1999; Connell et al., 2005; Ingelsson et 
al., 2006; Umeda et al., 2004) and other reports where increases in 4R tau transcripts 
have been found (Glatz et al., 2006; Yasojima et al., 1999). The conflicting results 
may be due to small differences in tau splicing ratios in AD that conventional RT-
PCR methods are not sensitive enough to detect (Conrad et al., 2007). With more 
targeted techniques, tau splicing imbalances have been found in a subset of neurons 
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harbouring tau pathology. For example, Ginsberg et al. (2006) micro-aspirated single 
cells from the nucleus basalis which are cholinergic neurons previously shown to 
contain tau aggregates in AD and mildly cognitively impaired (MCI) cases. Levels 
of 4R and 3R tau isoforms were measured by microarray analysis and they found 3R 
tau transcripts reduced in both AD and MCI patients. Conrad et al. (2007) use single 
molecule profiling to detect levels of all six tau transcripts expressed in control and 
AD brains. Patient cDNA was PCR-amplified in a gel matrix containing PCR 
primers and reagents which give rise to a polymerasation colony (polony) containing 
all six tau isoforms. Polonies were probed with exon specific coloured fluorophores 
and tau isoform expression were quantified in 250-2500 polonies (Conrad et al., 
2007; Zhu et al., 2003). A 1.3 fold increase in 4R tau was found in AD samples 
compared controls with 4R0N isoforms contributing to the increase. They also found 
a 1.6 fold decrease in exon 2 containing transcripts with 2N3R and 1N3R isoforms 
being significantly reduced in AD brains. These results suggest that AD tangle 
bearing neurons show increases in 4R tau transcripts. RNA extracted from a brain 
sample will typically contain both tangle bearing and non-tangle bearing neurons and 
when quantified with conventional RT-PCR based methods, small differences in 
RNA transcript levels may be averaged out.  
 
These findings show an association between tau splicing imbalances, particularly 
increases in 4R transcripts, and post-mortem confirmed tauopathy and suggests that 
tau splicing ratio imbalances are a risk factor for tauopathy. In AD contradictory 
finding regarding levels of tau exon 10 have been reported, however using sensitive 
techniques, increases in exon 10 transcripts have been found in tangle bearing 
neurons (Conrad et al., 2007; Ginsberg et al., 2006).  
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1.5.6. Tau haplotypes 
Genetic variation in the MAPT gene contributes to the risk of developing 
neurodegenerative disease. H1 and H2 SNPs that define the MAPT haplotype extend 
over 2 million bases (2Mb) and include many genes other than MAPT (Pittman et al., 
2005). A 900kb inversion in the 17q21 region of chromosome 17 which includes the 
MAPT gene results in two major tau haplotypes H1 and H2. Tau H1 and H2 
haplotypes differ only in their intronic sequence and are defined by SNPs spanning 
the whole MAPT gene and include a 238bp intronic deletion in H2. In addition to the 
H1 and H2 haplotype defining SNPs there exist SNPs that vary only on the H1 
background, the H2 haplotype is largely invariant (Pittman et al., 2004). Three H1-
specific SNPs, that define the H1c subhaplotype, and span a 56.3kb region upstream 
of MAPT exon 1 to the 3’ region of intron 9 were found to be highly associated with 
PSP and CBD (Pittman et al., 2005; Rademakers et al., 2005). In addition, multiple 
MAPT loci spanning 20kb either side of the MAPT gene were found to be associated 
with AD in a gene-wide analysis of data from a genome-wide association study 
(GWAS) (Gerrish et al., 2012). Taken together these results suggest that MAPT risk-
causing SNPs span regions that are potentially involved in both transcription and/or 
splicing regulation of tau (Pittman et al., 2005). To test if tau transcription was 
altered in the H1c haplotype, Myers et al. (2007) used qRT- PCR to measure total 
tau levels and found that the presence of at least one H1c allele increased total 
MAPT expression by 11-13% in frontal and temporal cortex in AD and control 
brains. Additionally, the authors found that the H1c allele increased 4R tau isoform 
expression in the same sample set by approximately 25% (Myers et al., 2007).  
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Another study determining exon 10 splicing and transcriptional differences in H1 
and H2 tau haplotypes used a method where cDNA from H1/H2 heterozygotes in 
control human frontal cortex and the globus pallidus were PCR amplified with 
primers that span exonic SNPs that distinguish H1 and H2 tau haplotypes in either 
exon 1 or exon 9 (Caffrey et al., 2006). The PCR products were used as templates for 
primer extension and these products were quantified by matrix-assisted laser 
desorption/ionisation-time of flight mass spectrometry (MALDI-ToF). No 
differences were found in total tau expression between H1 and H2 in both brain 
regions. However Caffrey et al., (2006) found 1.43 fold increases in 4R tau in the H1 
haplotype compared to H2 in the globus pallidus and 1.29 fold increases in 4R 
transcripts in the frontal cortex (Caffrey et al., 2006). In a further study, the authors 
used the same method to measure tau haplotype expression differences in tau exons 
2 and 3 with sets of PCR primers for each of the three tau N-terminal transcripts (0N, 
1N and 2N). Caffrey et al. (2008) found two-fold increases in the 2N transcripts in 
H2 haplotypes in the frontal cortex and the globus pallidus. The H2 haplotype is 
negatively associated with PSP and CBD and therefore considered protective. 
 
Using exon arrays, Trabzuni et al. (2012) found increases in tau exon 3 expression in 
H2 haplotypes and neither 4R nor total MAPT expression was increased in H1 or 
H1c haplotypes in human brain samples from various regions including frontal, 
temporal and occipital cortex, hippocampus, thalamus and cerebellum. At present 
these findings consistently point to a protective effect of the H2 allele conferred by 
increases in tau exon three. There are no consistent findings regarding the 





The two major neuropathological hallmarks in the AD brain are the presence of 
senile plaques and neurofibrillary tangles. Senile plaques are composed mainly of 
insoluble Aβ peptides derived from proteolytic cleavage of Amyloid Precursor 
Protein (APP). There are two different routes for APP proteolysis. The non-
amyloidogenic pathway involves α-secretase cleavage within the Aβ region resulting 
in a secreted N-terminal APP fragment (sAPPα) and a membrane bound C-terminal 
fragment (C83 or CTFα). Alternatively the amyloidogenic route occurs through 
intramembranous cleavage by β-secretase producing a β C-terminal fragment (C99 
or CTFβ) and a secreted N-terminal fragment (sAPPβ). The CTFβ is cleaved by γ-
secretase to produce Aβ.  
 
APP was initially identified as a cell surface receptor (Kang et al., 1987) and it may 
play a role in other functions such as cell adhesion (Ghiso et al., 1992) and neurite 
outgrowth (Small et al., 1999) however it is not clear, at present, what the major 
roles are of the full length protein or the secreted fragments in the CNS.  
 
Three major APP isoforms are produced from the alternative splicing of exon seven 
and eight (APP770) exon seven (APP751) and neither seven or eight (APP695). 
Exon seven codes for a Kunitz family of protease inhibitors domain (KPI) domain 
and the presence or absence of this domain is the main difference between the APP 
isoforms. Exon eight codes for a chondroitin sulphate glycosaminoglycan (CS GAG) 
attachment site (Jacobsen and Iverfeldt, 2009).  Very low quantities of an APP 
transcript APP714 are produced in the human CNS, which is the result of alternative 
splicing of exon eight alone (Golde et al., 1990). 
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Although there has been conflicting evidence regarding differential expression of 
APP isoforms in AD (for review see Panegyres et al. (2000)), more recently a 
number of studies have found consistent increases in expression of APPKPI, 
APP770 and APP751, isoforms in AD brains compared to controls (Matsui et al., 
2007; Preece et al., 2004) or diminished APP695 expression in AD (Tharp et al., 
2012). 
 
Matsui et al., (2007) found that NSE, a marker for neurons, decreased in AD brains 
while GFAP, an astrocyte marker, increased. There were no differences in total APP 
expression in controls and AD measured by qRT-PCR although there was a 
significant increase in APPKPI containing isoforms in AD brains at the RNA and 
protein level, and the increased APPKPI expression correlated with increased GFAP. 
The authors conclude that the increase in APPKPI (APP770 and APP751) and 
decrease in APP695  reflects the loss of neurons and subsequent gliosis found in AD 
brains. In view of the findings that astrocyte expression of APP is extremely low 
(Guo et al., 2012), the origin of the increases in KPI-containing APP transcripts  
found in AD is, at present, not clear. Altered levels of splicing factors in disease may 
play a role in changing APP isoform ratios (Donev et al., 2007). 
 
The different processing pathways for APP containing the KPI domain, may impact 
on the disease process. In transfected cells, KPI-containing APP proteins are 
processed differently with APP751 expressing cells producing less sAPPα compared 
to APP695 expressing cells (Ho et al., 1996). Cells transfected with APP770 secreted 
more Aβ than cells transfected with either APP751 or APP695 (Donev et al., 2007), 
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these findings suggest that the APP KPI domain diminishes α-cleavage and results in 
more Aβ production. 
 
The KPI-containing APP isoforms have previously been reported to be 
predominately expressed in astrocytes (Chauvet et al., 1997; LeBlanc et al., 1997; 
Tran, 2011; Yasuoka et al., 2004), however, it has recently been demonstrated by 
immunohistochemistry that in fact astrocyte APP expression is extremely low, at 
least in mice (Guo et al., 2012).  
1.7. Alzheimer’s Disease 
 
Alzheimer’s disease (AD) is a neurodegenerative disorder that is characterised 
clinically by progressive impairments in memory and cognition. AD is the most 
common cause of dementia accounting for between 60-80% of dementia cases. The 
two hallmark characteristic pathologies in AD are:  
1) Alzheimer-type plaques composed predominately of extracellular amyloid- beta 
(Aβ), also containing hyperphosphorylated tau-positive dystrophic neurites. 
2) intraneuronal neurofibrilliary tangles (NFT) made up of paired helical filaments of 
abnormally hyperphosphorylated microtubule associated protein tau (MAPT).  
 
On the basis of studies that measure quantity and location of neurofibrillary 
pathologies (NFT and NT) (Braak and Braak, 1991; Braak et al., 2011) and amyloid 
plaques (Alafuzoff et al., 2009; Thal et al., 2002; Thal et al., 2000) in AD, staging 
systems have been developed that differentiate initial, intermediate and advanced 
stages of AD. The insoluble fibrous protein deposits in AD progressively accumulate 
and are distributed in a characteristic pattern. Initially Aβ deposits and 
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neurofibrillary lesions develop concomitantly although at different locations in the 
brain with Aβ plaques starting in cortical regions and NFT initiating in the 
noradrenergic projection neurons of the locus coeruleus (Braak et al., 2011). The 
severity of the amyloid pathology correlates with neurofibrillary lesions in AD brain 
(Thal et al., 2002). 
 
Tau pathology is a useful marker for AD progression because NFT density is 
correlated with disruption of specific neuronal circuits and cognitive decline 
(Giannakopoulos et al., 2007; Nelson et al., 2012; Nelson et al., 2009). Although this 
correlation suggests that tau deposition may mediate AD-associated toxicity the links 
between tau aggregation, clinical symptoms and toxicity is at present not clear. 
 
Ultrastructural analysis of mature tau filaments isolated from AD brain show that the 
tau protein deposits appear as two protofilaments wound around each other and these 
fibrillar structures are called paired helical filaments (PHF). PHF-tau may be 
preceded by pretangles (Bancher et al., 1989; Braak et al., 1994) or granular 
oligomeric tau (Maeda et al., 2007) both of which differ morphologically from 
fibrillar tau but all tau aggregates share a β-sheet structure as with other 
amyloidogenic proteins (Sahara et al., 2008). The bulk of tau protein inclusions in 
AD are made up of neuro-fibrillary tangles (NFT) in cell bodies and neuropil threads 
(NT) in dendrites (Mitchell et al., 2000). Neuritic plaques display clusters of radially 




Mutations in Presenilin (PSEN) and APP genes cause AD however the frequency of 
these mutations is very uncommon. The vast majority of AD cases are sporadic and 
in a recent GWA study, common SNPs at PSEN1, PSEN2 and APP did not show any 
association with AD, showing that common genetic variation at these loci are not a 
risk factor for sporadic AD while SNPs across the whole MAPT locus confer a small 
amount of risk for sporadic AD (Gerrish et al., 2012). The most highly associated 
gene for sporadic AD is Apolipoprotein E4 (ApoE).  Three common isoforms 
apoE2, apoE3 and apoE4, determined at the DNA level by the ε2,ε3, and ε4 alleles 
of the APOE gene. The ε4 isoform is the strongest predisposing allele while the ε2 
allele is protective (Corder et al., 1994; Corder et al., 1993). Compared to individuals 
with no ε4 alleles, the increased risk for AD is 2-3 fold in people with a single 
APOE ε4 allele and ~12 fold in ε4 homozygotes (Bertram et al., 2007; Roses, 1996).  
Other genetic risk factors for sporadic AD include clusterin (CLU) and bridging 
integrator 1 (BIN1) (Harold et al., 2009) amongst others, see 
http://www.alzforum.org/ for the latest GWAS results. The contribution of each of 
these individual genes to risk of AD is very small however their combined effect, 
possibly converging in a single pathway, may play a larger role in AD pathogenesis.  
 
1.7.1. TDP 43 in AD 
Around 20-35% of AD cases, in addition to tau neurofibrilliary tangles (NFT) and 
Aß plaques, also have TDP-43 inclusions (Amador-Ortiz et al., 2007; Arai et al., 
2009; Higashi et al., 2007; Hu et al., 2008; Kadokura et al., 2009; Uryu et al., 2008).  
Amador- Ortiz et al., (2007) found all AD brains that were TDP-43 positive had 
TDP-43 inclusions in the entorhinal cortex with variable pathology outside the 
limbic regions. Two AD-TDP subtypes were identified, “limbic” type with 
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inclusions only in the limbic structures such as the amygdala, hippocampus and 
entorhinal cortex and “diffuse” with additional frontal and temporal cortical TDP-43 
inclusions, subsequently an “amygdala only” type has also been identified  (Hu et 
al., 2008). Diffuse type AD TDP-43 positive brains had significantly more TDP-43 
immunoreactivity in the cingulate gyrus and nucleus accumbens than limbic type 
suggesting that the severity of TDP-43 pathology was greater in the diffuse type 
compared to the limbic type (Amador-Ortiz et al., 2007). These authors also noted 
that a small number of NFTs had TDP-43 positive immunoreactivity and with 
double labelling for phospho-tau (CP-13) and TDP-43 immunoreactivity they found 
two different patterns of colocalisation, in some neurons there was double labelling 
of the inclusion with overlap of the two epitopes however more commonly the two 
epitopes were only partially overlapping. 
 
The significance of TDP-43 inclusions in AD is not known however there is 
evidence to suggest that the presence of TDP-43 inclusions may alter both pathology 
and clinical symptoms of AD patients. 
1.7.2. TDP-43 may alter tau pathology in AD  
Tau pathology has a well established topographical progression and a number of 
researchers report a very similar progression of TDP-43 pathology in AD spreading 
from limbic structures to association cortices (Higashi et al., 2007; Hu et al., 2008; 
King et al., 2010) and suggests possible additive effects between tau and TDP-43 
pathologies. 
 
Many studies find that high proportions of AD brains with TDP-43 also have 
hippocampal sclerosis (HS) and may be due to the combination of tau and TDP-43 
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pathologies (Probst et al., 2007). HS refers to extensive neuronal loss in the 
subiculum and CA1 region of the hippocampus and in young patients is often 
associated with temporal lobe epilepsy (Probst et al., 2007; Zarow et al., 2008). In 
older patients, HS is often associated with other neurodegenerative diseases 
including AD, vascular dementia and FTLD-TDP. HS in the context of AD, where 
extensive NFT pathology in the hippocampus is observed, is regarded as neuronal 
cell loss disproportionate with the degree of NFT tau pathology present (Amador-
Ortiz et al., 2007; Pao et al., 2011) although some investigators do not recognise HS 
in the setting of other neurodegenerative diseases such as AD (Lippa and Dickson, 
2004).  
 
Figure 1.5. Hippocampal Sclerosis is characterised by selective neuronal loss in 
CA1 with relative preservation of neurons in CA3. From Dickson et al. (2010). 
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A range of 29% to 100% of AD brains with TDP-43 pathology are reported to also 
have HS and, where reported, is significantly more common in TDP-43 
pathologically immunoreactive brains than in TDP-43-negative brains (Amador-
Ortiz et al., 2007; Bigio et al., 2010; Davidson et al., 2011; Dickson et al., 2010; 
Josephs et al., 2008).  
 
Although high rates of HS may be observed in FTLD-TDP (Blass et al., 2004; 
Josephs and Dickson, 2007; Pao et al., 2011), HS is more often associated with TDP-
43 inclusions in AD (Probst et al., 2007) and has been found in other tauopathies 
such as PSP (Yokota et al., 2010). 
 
On the basis that tight correlations exist between HS and TDP-43 pathology in AD, 
some researchers consider that AD with HS and TDP-43 inclusions is a distinct 
subtype of AD (Robinson et al., 2011). Other researchers note that the correlation 
between HS and TDP-43 is not absolute and that many cases of HS do not have any 
TDP-43 pathology and suggest that HS in AD is a coincidence of two common 
pathologies (Davidson et al., 2011). However the prevalence of TDP-43 pathological 
immunoreactivity in HS-positive brains may be underestimated in some studies that 
assess HS only from one brain hemisphere because, in some cases, HS is only 
present unilaterally (Nelson et al., 2011; Probst et al., 2007; Zarow et al., 2012). 
 
It is unclear why TDP-43 inclusions occur in sporadic tauopathies however it may be 
accounted for by genetic risk factors. Mutations in the progranulin gene (PGRN) 
result in haploinsufficiency of progranulin expression and cause FTLD-TDP (Baker 
et al., 2006). A 3’ untranslated region (UTR) single nucleotide polymorphism (SNP), 
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which is predicted to block a microRNA binding site in the progranulin gene, has 
been associated with FTLD-TDP and may increase risk of developing disease 
(Rademakers et al., 2008) although this finding has not been replicated (Simón-
Sánchez et al., 2009). The PGRN 3’UTR SNP was also associated with HS in AD 
cases with TDP-43 inclusions (Dickson et al., 2010). Genetic variation in genes in 
which mutations have previously shown to cause TDP-43 pathology may increase 
the risk for developing TDP-43 pathology. 
1.7.2. TDP-43 may alter clinical symptoms in AD 
A major question that arises is whether TDP-43 pathology contributes to AD 
pathology and/or clinical symptoms. Most AD patients have an amnestic 
presentation where memory loss is the most dominant presenting symptom and is 
severe before other deficits emerge. However, AD is clinically heterogenous 
(Snowden et al., 2007b; Stopford et al., 2008) and at autopsy, some patients that 
present with language or behavioural problems more typical of FTLD- tau or FTLD-
TDP, show AD pathology (Bigio et al., 2010). AD patients with a language 
phenotype (primary progressive aphasia; PPA) have previously shown no correlation 
between distribution of AD pathology (tau and Aβ) and clinical symptoms (Galton et 
al., 2000; Mesulam et al., 2008; Munoz et al., 2007). Bigio et al., (2010) tested if the 
atypical PPA phenotype found in a subset of AD patients could be accounted for by 
concomitant TDP-43. No correlation was found between distribution of TDP-43 
pathology and atypical AD clinical symptoms for PPA however TDP-43 pathology 
was associated neuronal loss in the hippocampal region and suggests that TDP-43 




MRI scanning of AD brains showed that those with TDP-43 inclusions had a lower 
hippocampal volume than AD brains without TDP-43 inclusions (Josephs et al., 
2008). HS was significantly more prevalent in the TDP-43 positive group than the 
TDP-43 negative group. The authors report that within the group of subjects with 
TDP-43 pathology there were no differences in hippocampal loss in those with and 
without HS which suggests that TDP-43 pathology, independent of HS, is associated 
with hippocampal atrophy. The presence of TDP-43 also impacts memory and 
cognition. TDP-43 immunoreactive brains had clinically worse dementia with lower 
Mini-Mental State Examination and Boston Naming test scores than those without 
TDP-43 pathology (Josephs et al., 2008). In this study the AD TDP-43 positive cases 
were older at disease onset and at death however the lower memory and cognitive 
scores were significantly lower when adjusted for age at death and therefore suggests 
that disease duration was not impacting on clinical measures.  
 
A consistent finding across MRI and neuropathology studies is that TDP-43 in AD 
results in neuronal loss in the hippocampus and correlates with loss of memory. The 
mechanism of how TDP-43 may interact with or exacerbate tau pathology in the 









1.8. Aims of this thesis 
 
Intracellular neurofibrillary tangles composed of hyperphosphorylated tau and 
extracellular plaques composed of Aβ derived from proteolytic processing of APP 
are the two hallmark pathologies of AD. TDP-43 inclusions are also found in a 
subset of AD cases. TDP-43 has a role in multiple RNA processing events including 
splicing. In brain with TDP-43 inclusions dysfunction of TDP-43 may result in 
altered RNA processing. Altered splicing ratios of both tau and APP have been 
associated with AD however these results have been inconsistently found. 
 
Our hypothesis is that TDP-43 dysfunction affects tau and APP RNA processing 
either directly or indirectly and increases disease severity. 
 
The aim of this thesis is to correlate AD molecular pathology with the presence of 
TDP-43 pathology. 
 
The specific objectives are: 
 
To measure isoform ratios of tau exon 10 from control and AD brains with and 
without TDP-43 inclusions. 
 
To measure isoform ratios of APP exon 7 and 8 from control and AD brains with 
and without TDP-43 inclusions. 
 
To characterise TDP-43 3’UTR isoform ratios involved in TDP-43 autoregulation, 
from control, FTLD and AD brains with and without TDP-43 inclusions.  
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Chapter two: Material and Methods 
2.1. Materials 
 
Molecular biology, microbiology and cell culture reagents were purchased from 
Invitrogen Ltd (Paisley, UK) unless otherwise stated. All other chemicals were 
purchased from Sigma-Aldrich Ltd (Dorset, UK) except where indicated. Ultrapure 
water from an Elga Maxima water purification system was used to prepare stock and 
buffer solutions. 
2.1.1. General reagents and stock solutions 
Agarose 
Ammonium persulphate , 10% (w/v) (National Diagnostics Ltd., Yorkshire, UK) 
Ampicillin, 100mg/ml in ultra-pure water 
Ammonium persulphate (APS) 
Beta-mercaptoethanol (Merck Biosciences, Hertfordshire, UK) 
Bromophenol blue, 0.5% (w/v) 
Bovine albumin (Thermo Scientific) 
Chloroform 
Dithiothreitol (DTT) 
Ethanol , 99% (v/v) (Merck Biosciences, Hertfordshire, UK) 
Ethidium Bromide (10mg/ml) 






Isopropanol (Merck Biosciences, Hertfordshire, UK) 
Methanol, 100% (v/v) (Merck Biosciences, Hertfordshire, UK) 
N,N,N’,N’-tetra-methylethylenediamine (TEMED) (National Diagnostics Ltd.) 




Polyoxethelene sorbitan monolaurate (Tween 20) 
Sodium dodecyl sulphate (SDS) (National Diagnostics Ltd.) 
Sodium lauroyl sarcosinate (sarkosyl) 
SYBR Green (Roche Diagnostics) 
Tetramethylethylenediamine (TEMED) (National Diagnostics Ltd.) 
TRIS (hydroxymethyl) aminomethane hydrochloride 
Trizol ® reagent (Invitrogen) 
Trypsin-EDTA 
X-gal (Promega, Southampton, UK ) 
 
2.1.2. Bacterial strains 
Escherichia coli (E.coli) host strain, JM109 (Promega, Southampton, UK ) was used 
to amplify plasmids. 
2.1.3. Bacterial culture media and reagents 
Luria- Bertani (LB) broth base 
A pre-mixed powder consisting of (per one litre): 1% (w/v) SELECT Peptone 140, 
0.5% (w/v) NaCl and 0.5% SELECT yeast extract, pH 7.0 was purchased. A 2% 
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(w/V) solution was prepared in 1 litre culture flasks and autoclaved at 121ºC for 15 
mins. 
 
LB ampicillin (LB-amp) medium 
A Nalgene syringe filter, 0.2 µm pore size was used to prepare filter-sterilised stock 
of ampicillin, 100mg/ml in ultra-pure water. A final concentration of 100µg/ml was 
added to autoclaved LB. 
 
LB-agar 
A pre-mixed powder consisting of 1.2% (w/v) SELECT-agar in LB was purchased. 
A 3.2 % (w/v) solution of LB-agar was prepared in ultra-pure water and autoclaved 
at 121ºC for 15 mins. 
 
LB-amp agar 
Ampicillin stock solution was added to cooled, autoclaved LB-agar to give a final 
concentration of 100µg/ml.  20ml of LB-amp agar was poured into 10cm diameter 
sterile Petri dishes and allowed to cool. 
 
2.1.4. Solutions for the preparation of plasmid DNA 
Miniprep 
All solutions were purchased as part of a QIAprep® Spin Miniprep Kit (Qiagen, 
West Sussex, UK). 
2.1.5. DNA analysis solutions  
Tris-acetate-EDTA (TAE) 50x 




Agarose gel loading solution 6x 
0.25% (w/v) orange G 
40% (w/v) sucrose 
 
DNA size markers 
Quick-load™ 1kb DNA ladder (New England Biolabs, Hertfordshire, UK): 10002,  
8001, 6001, 5001, 4001, 3001, 2000, 1500, 1000, 500 bp fragments. The 3001 bp 
fragment is of a higher concentration for easy identification. 
 
Quick-load™ 100 bp DNA ladder (New England Biolabs, Hertfordshire, UK): 1517, 
1200, 1000,  900, 800, 700, 600, 500, 400, 300, 200, 100 bp fragments. The 1000 
and 500bp fragments are of a higher concentration for easy identification. 
 
QIAquick gel extraction/reaction cleanup kit 
QIAquick kit (Qiagen) was used to extract and purify DNA from agarose gels. 
2.1.6. DNA analysis solutions 
DNA extraction 
DNA was extracted from cells with proteinase K (Qiagen). RNA was degraded with 





2.1.7. RNA analysis solutions 
RNA extraction 
RNA was extracted from cells using Trizol® reagent, a solution of phenol and 




DNA was degraded by with Turbo DNAse kits (Ambion, UK). 
2.1.8. Reverse transcription solutions 
Reverse transcription (RT) was perforemed using a kit (Applied Biosystems, 
Cheshire, UK). The reagents are listed as final concentrations with stock 
concentrations in brackets. Non-DEPC treated, nuclease free water was purchased 
from Ambion Ltd. (Cheshire, UK). 
-1x RT buffer (10x RT buffer:  500 mM KCl, 100mM Tris-HCl, pH 8.3) 
-55mM magnesium chloride (25mM) 
-500 µM of each deoxyNTPs (dNTPs) (dNTP mixture containing 2.5 mM of aATP, 
dCTP, dGTP and dDTP) 
- 25µM oligo-dT (dT16) (50 µM in 10mM Tris-HCl pH 8.3) 
- 0.4 U/µl RNase inhibitor (20 U/µl in 20 mM HEPES-KOH, pH 7.6, 50 mM KCl, 
8mM DTT, 50 % (v/v) glycerol) 
- 1.25 U/µl Multiscribe Reverse Transcriptase (50 U/µl)   
2.1.9. PCR solutions 
Taq polymerase in storage buffer B 
PCR was carried out using Taq DNA polymerase in storage buffer B (Promega). Taq 
DNA polymerase is a thermostable enzyme that replicates DNA at 74ºC and exhibits 
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a half-life of 40 mins at 95 ºC. Taq catalyses the polymerisation of nucleotides into 
duplex DNA in the 5’ to 3’ direction in the presence of magnesium. 
 
Taq DNA polymerase 5x buffer 
Containing (working concentration 1:10) 
50mM KCl 
10 mM Tris-HCl  pH 9.0 
1.5 MgCl2 
1% (v/v) Triton X-100 
 
2’-Deoxynucleoside  5’-triphosphates (dNTPs) 
Each nucleotide  (Amersham Pharmacia Biotech UK Ltd., Buckinghamshire, UK) 
was supplied as a 100mM solution in sterile ultra-pure water (pH 7.5). A 12.5x stock 
solution containing 2.5 mM of each dNTP was prepared by mixing 5µl of dATP, 
dCTP, dGTP and dTTP with 180ul of sterile H2O 
 
Primers 
Primers were synthesised by MWG-Biotech and diluted to a working stock solution 
of 2 µM for end point RT-PC or 10µM for qRT-PCR. Primers for target genes 
(MAPT and APP) were designed to span exon-exon boundaries to avoid 
amplification from genomic DNA. qRT-PCR cDNA products were all ~100 bp. 





DY682 labelled primers. 
The technique used in our analysis of tau exons 2,3and 10, APP exons 7 and 8 and 
TDP-43 3’UTR expression was to label the forward primer with a DY682 
fluorophore which incorporates into PCR products during RT-PCR. Analysis by 
quantifying the fluorophore signal is more accurate than using DNA intercalators 
such as ethidium bromide because one transcript contains one fluorophore and 
therefore the fluorophore signal measured is proportional to transcript number not 
transcript size.  
 
Quantitative reverse transcription polymerase chain reaction 
FastStart SYBR Green 2x Master Mix containing 2mM ROX (Roche, UK) was used 


















Exon 4 5’-GCCCAATACGACCAAATCC-3’ 
              166 
Exon 6 5’-AGCCACATCGCTCAGACAC-3’ 
Tau 9-13 
Exon 9 5’-DY682- CTGAAGCACCAGCCAGGAGG-3’ E10+     368 






2N         284   
1N         197     
0N         110 Exon 4 5’-GGGGTGTCTCCAATGCCTGCTTCT-3’ 
Total tau 
Exon 11/12 5’-CCATCATAAACCAGGAGGTGGCC-3’ 
              148 
Exon 12/13 5’-GGTCAGCTTGTGGGTTTCAATCTT-3’ 
APP exon 7 & 
8 
Exon 6 5’-DY682-CACCACAGAGTCTGTGGAAG-3’ APP770  313 
APP751  256  
APP695    88    
Exon 9 5’-AGGTGTCTCGAGATACTTGTC-3’ 
Total APP 
Exon 3/4 5’-CGCTGCTTAGTTGGTGAGTTTG-3’ 
                140 
Exon 4/5 5’-CTCTTCTCACTGCATGTCTCTTTGG-3’ 
TDP 3’UTR 
3’UTR 5’-GAACTGCTGTTTGCCTGATTGG-3’ 3’UTR   1176 
pA2         472 3’UTR 5’-CTGCTATGAATTCTTTGCATTCAGG-3’ 
 
Table 2.1. Primers used in RT-PCR splicing analyses and qRT-PCR 
 
2.1.10. SDS-polyacrylamide gel electrophoresis (SDS-PAGE) solutions 
Tris-HCl SDS stock buffers 
The Tris-HCl SDS stock buffers used for the preparation of the resolving and 
stacking gels were purchased from National Diagnostics Ltd. ProtoGel™ Resolving 
Buffer solution consisted of 1.5 M Tris-HCl (pH 8.8) and 0.1% (w/v) SDS, whereas 
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ProtoGel™ Stacking Buffer consisted of 0.5 M Tris-HCl (pH 6.8) and 0.1% (w/v) 
SDS. 
 
Acrylamide working stock 
Acrylamide stock was purchased as ProtoGel™ solution (National Diagnostics Ltd.) 
and consists of  
- 30% (w/v) acrylamide 
- 0.8% (w/v) bis-acrylamide 
 
Laemmli sample buffer 6x 
1.5 M Tris 0.5M pH 6.8 
30% (w/v) SDS 
10% (w/v) bromophenol blue 
5% (v/v) glycerol 
5% (v/v) DTT 
 
Resolving gel,  pH 8.8 
- 10% (w/v) bis-acrylamide 
- 25% (v/v) resolving buffer 
- 0.01% (w/v) APS 
- 0.1% (v/v) TEMED 
 
Running buffer (10x), pH 8.3 
- 0.25 M Tris-HCl 
-1.92 M Glycine 
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- 1% (w/v) SDS 
 
Stacking gel, pH 6.8 
- 4% (w/v) bis-acrylamide 
- 25% (v/v) stacking buffer 
- 0.075% (w/v) APS 
- 0.15% (v/v) TEMED 
 
2.1.11. Protein molecular weight markers  
Precision Plus Protein Stadards (all blue) were purchased from Bio-Rad Laboratories 
Ltd. and contained ten proteins of 10 kDa, 15 kDa, 20 kDa, 25 kDa, 37 kDa, 50 kDa, 
75 kDa, 100 kDa, 150 kDa, and 250 kDa. The 25 kDa, 50 kDa, and 75 kDa proteins 
serve as a reference bands because they are three times as intense as the other bands. 
 
2.1.12. Western blotting and immuno-detection solutions  
Electro-blotting transfer buffer 
- 25 mM Tris-HCl (pH 8.3) 
- 192 mM Glycine 
- 20% (v/v) methanol 
 
Blocking solution 
5% (w/v) skimmed milk powder in PBS- Tween-20 [0.1 % (w/v)] 
 
Primary antibody incubation solution 
5% (w/v) skimmed milk powder in PBS- Tween-20 [0.1 % (w/v)] 
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Secondary antibody incubation solution 





Antibodies Species Epitope Origin Dilution 
Total tau Rabbit polyclonal 
C-terminus aa 
243-441 DAKO 1:10,000 
GAPDH Mouse 







TDP-43  Rabbit polyclonal serines 409/410 cosmobio 1:4000 
SECONDARY ANTIBODIES 
Name Antibody Origin Dilution  




monoclonal Molecular probes 1:10,000  
 
Table 2.2. Antibodies used in this study. 
 
2.1.14. Cell culture 
All medium used for the culture of cell lines supplemented with: 
- 2mM L-glutamine 
- Penicillin (100 units/ml) 
- Streptomycin (100 µg/ml) 
 
Medium for SH-SY5Y cells 
DMEM/ F12 
15% (v/v) FBS 
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Hank’s balanced salt solution (HBSS) 
HBSS was purchased from Invitrogen Ltd. as a 1x solution without calcium chloride, 
magnesium chloride, or magnesium sulphate. This solution was used for washing 
cells before trypsinisation. 
Trypsin solution 
Trypsin-EDTA (TE) was purchased from Invitrogen Ltd. as a solution containing 
0.05% (w/v) TE in PBS. 
 
2.1.15. Miscellaneous stock solutions 
Phosphate Balanced Solution (PBS) 
PBS tablets were purchased from Sigma Aldrich Co. Ltd. One tablet was dissolved 
in 200 ml of H2O to give a final concentration of: 
0.01 M phosphate buffer pH 7.4 
0.0027 M potassium chloride 
0.137 M sodium chloride 
 
2.1.16. Human brain tissue 
Human brain tissue was obtained from neurologically normal (control) and 
individuals with AD (Braak stages V- VI) from the London Neurodegenerative 
Disease MRC Brain Bank, Institute of Psychiatry, King’s College London, (Ethical 
Committee Protocol 174/02). Staging of AD cases and definitive diagnosis for AD 
cases with and without TDP-43 inclusions were made according to established 
neuropathological criteria by neuropathologists at Kings College Hospital. 
Dissection was carried out by Dr Tibor Hortobágyi and Claire Troakes. 
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Tissue was collected and stored in tubes at -70ºC until analysis. 200 and 100mg of 
tissue was dissected. 100mg was put directly into matrix lysing-D tubes (Qbiogene) 
and used for RNA extraction using the FastPrep sample preparation system. Brain 
regions selected include Frontal lobe BA 8/9, Temporal lobe BA 21, Amygdala, 
Hippocampus and Cerebellum.  
 
BB case No. PM diagnosis Age Sex PMD hours    pH Braak 
stage 
A239/03 Control 78 M 9.5 6.63  
A359/08 Control 80 F 3 6.4  
A308/09 Control 66 M 52 6.66  
A292/09 Control 38 F 43 6.85  
A123/09 Control 78 M 24 6.28  
A113/09 Control 18 M 24.5 6.44  
A048/09 Control 81 M 18 6.72  
A063/10 Control 90 F 50 5.94  
A057/10 Control 92 F 48 6.08  
A310/09 Control 84 F 35 6.11  
A303/09 Control 80 M 60 5.19  
A065/11 Control 97 M 44 6.26  
A346/10 Control 84 F 34 5.74  
A136/10 Control 89 F 41 6.43  
A144/10 Control 92 F 23 6.57  
A249/07 ADTDP+ 74 M 69 6.77 6 
A205/07 ADTDP+ 73 M 24.5 6.37 6 
A349/08 ADTDP+ 86 F 14 6.56 6 
A348/07 ADTDP+ 85 M 16 6.4 4 
A063/09 ADTDP+ 89 M 62 6.82 5 
A076/09 ADTDP+ 97 M 16.5 6.18 5 
A169/10 ADTDP+ 85 F 10 6.85 5 
A114/10 ADTDP+ 86 M 45 7.1 6 
A283/09 ADTDP+ 77 M 9.5 7.12 5 
A188/10 ADTDP+ 69 M 120 6.61 6 
A168/10 ADTDP+ 88 F 33 6.74 6 
A267/09 ADTDP+ 90 F 70 5.98 5 
A122/09 ADTDP+ 68 F 10.5 6.84 6 
A308/07 ADTDP+ 83 F 76 6.56 6 
A037/04 ADTDP- 96 F 39 6.62 N/A 
A039/02 ADTDP- 92 F 4 6.63 N/A 
A331/07 ADTDP- 80 F 12.5 6.48 5 
A098/04 ADTDP- 84 M 73 6.86 6 
A191/07 ADTDP- 69 F 16.3 7.43 6 
A192/07 ADTDP- 96 F 19 6.57 5 
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A210/05 ADTDP- 84 F 24 6.57 5 
A240/06 ADTDP- 97 F 12 6.9 5 
A141/07 ADTDP- 80 M 41 6.33 6 
A050/04 ADTDP- 91 F 28.5 6.64 N/A 
A058/07 ADTDP- 81 M 74 6.76 6 
A160/06 ADTDP- 71 M 32 6.42 6 
A187/07 ADTDP- 82 F 69 6.67 5 
A122/04 ADTDP- 86 M 25.5 6.72 5 
A065/04 ADTDP- 91 F 28.5 6.19 6 
A123/99 FTDP-17 60 M 3 5.96  
A174/99 FTDP-17 63 F 22 6.82  
A074/00 FTDP-17 67 M 35 6.01  
A171/02 FTDP-17 71 M 5 6.68  
A070/99 FTDP-17 52 F 72 6.61  
A388/94 DM1 58 M 12 7  
 





2.2.1. RNA extraction from human post-mortem brain tissue 
All RNA methods were carried out with RNase free plasticware and RNase free non-
DEPC treated water (Ambion). 
 
Total RNA was isolated from frozen blocks of human brain. Samples were 
homogenised in matrix lysing-D tubes in conjunction with the Fastprep sample 
preparation system. Total RNA was extracted with Qiagen RNeasy lipid tissue kit as 
follows. 
 
1 ml of 4°C Qiazol lysis solution (containing phenol and guanidine thiocyanate) was 
added to lysing matrix-d tubes (qbiogene) containing approximately 100 mg of brain 
tissue. Matrix d tubes contain ceramic beads that homogenize the sample when used 
in conjunction with Fastprep 24 machine. Total RNA was extracted from the 
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homogenised samples using the Qiagen RNeasy lipid tissue kit according to the 
manufacturer’s protocol. RNA was eluted in 40 µl of RNase free water and 
contaminant DNA removed using DNA free kit (Ambion) according to the 
manufacturer’s instructions. RNase-free tubes (for storage of RNA), lysis solution, 
buffers and RNase free water (for elution) are provided with the Qiagen RNeasy 
lipid tissue kit. 
 
2.2.2. RNA isolation from rat and mouse brain tissue 
Total RNA was isolated from frozen blocks of mouse brain and rat brain (snap 
frozen in liquid nitrogen) using the Qiagen RNeasy lipid tissue kit using the same 
protocol as for the human brain samples except we used a mortar and pestle instead 
of the matrix lysing-D tubes for homogenisation of these samples. Approximately 
100 mg of brain tissue (kept on dry ice before use) was homogenised in 1 ml of 4ºC 
Qiazol lysis solution. The brain tissue was homogenised immediately, approximately 
20 strokes, on ice and RNA extracted as for the human samples.  
 
2.2.3. Total RNA isolation from SH-SY5Y cells 
SH-SY5Y cells were grown in a monolayer in 6-well plates and lysed with 1ml of 
Trizol® reagent (Invitrogen Ltd.) added directly onto each well. Cells were lysed by 
passin the cells through a pipette several times. Homogenised cells were incubated at 
room temperature for 5 mins to break nucleic acid-protein complexes in the cells. 
200µl chloroform was added to the homogenate and vortexed for 15 secs. 
Centrifugation of the homogenate was carried out at 12,500 rpm for 15 mins at 4°C. 
The clear layer containing RNA was pipetted into new tubes. RNA was precipitated 
with 500µl isopropanol by incubating for 15 mins at room temperature. The resultant 
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RNA pellet was obtained after centrifugation at 12,500 rpm for 15 mins at room 
temperature and was washed three times with 1 ml of 75% (v/v) ethanol before 
resuspension with 50 µl of RNase free water. DNA was removed using DNA free kit 
(Ambion) according to the manufacturer’s instructions. The isolated RNA was stored 
at -70ºC. 
2.2.4. Quantification and DNase treatment of RNA 
DNase treatment of isolated RNA removes contaminant genomic DNA from the 
RNA sample. A DNA-free kit (Applied Biosystems) was used to treat RNA 
according to the manufacturer’s instructions. 5µl of 10 × DNase buffer and 1µl of 
rDNase were added to the RNA and incubated for 30 mins at 37ºC. To stop the 
reaction, 5µl of DNase inactivation reagent was added and incubated for ~2mins at 
room temperature. DNAase inactivation Reagent was pelleted by centrifugation and 
the supernatant containing RNA was transferred to a new tube. RNA concentration 
was determined by using a Nanodrop spectrophotometer (Thermo Scientific) using 
the manufacturer’s software. 1.5µl of each undiluted RNA samples was analysed, 
recording the concentration in ng/µl and the A260/A280 ratio and 260/230 ratio 
recorded (a ratio of A260/A280 > 1.8 indicates that there is little protein 
contamination in a RNA sample). 
2.2.5. RNA integrity 
RNA integrity number (RIN) was measured with the Agilent RNA 6000 Pico kit 
using the Agilent Bioanalyser. Chips were prepared for all human brain RNA 
according to the manufacturer’s instructions. 550 µl of the RNA 6000 Pico gel 
matrix was placed in a centrifuge tube with a filter and centrifuged at 1500 ×g for 10 
mins at room temperature and was divided into 65µl aliquots. After the addition of 
1µl of the RNA 6000 pico dye concentrate to the 65µl aliquot of filtered gel, the gel-
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dye mix was vortexed and centrifuged at 13,000 ×g for 10 mins. 1µl (3 ng/µl) RNA 
from each sample was added in the wells of one chip followed by the addition 1 µl 
of diluted RNA 6000 ladder in the ladder well. The chips consist of interconnected 
microchannels that separate RNA fragments based on their size. The dye intercalates 
directly with RNA and pass detectors at different speeds. The software compares the 
unknown samples with to the ladder to determine the concentration of the unknown 
samples and to identify ribosomal RNA peaks (18S and 28S for eukaryotic RNA). In 
perfectly extracted RNA the 28S peak is twice as high as the 18S and the Agilent 
software measures the area under these peaks to calculate a RIN where 1 is most 
degraded and 10 being most intact. We tested our AD and control samples for RIN. 
RT-PCR was found to reliable at a RIN above 3.5 and only these samples were used 
in the splicing analysis.  
2.2.6. Reverse transcription of RNA  
Reverse transcription (RT) was performed using reagents from Taqman RT Kit (GE 
Healthcare). 0.5 µg of total RNA was reverse transcribed in a total volume of 10µl. 
Master mixes for each reaction are as follows: 
 
Reagent                                 Volume (µl)                    Final Concentration 
10 × Buffer                                       1                              1/10 dilution  
MgCl2 (25mM)                               2.2                             5.5mM 
dNTP mix                                       2.0                             500µM of each dNTP 
Oligo-dT                                         0.5                             2.5µM 
RNase inhibitor                               0.2                             0.4 U/µl 
Reverse transcriptase (50 U/µl)      0.25                           1.25 U/µl  
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A G-storm thermal cycler was used to perform the RT reaction with conditions as 
follows: 
25ºC for 10 minutes – oligo dT hybridisation 
48ºC for 30 minutes – reverse transcription 
95ºC for 5 minutes – denature reverse transcriptase 
4ºC for storage 
 
2.2.7. Polymerase chain reaction (PCR) 
PCR was performed with GoTaq polymerase reagents (Promega) using primers 
listed in Table 2.1. Master mixes for multiple reactions were prepared to avoid 
variability. For one reaction, the PCR mix was as follows: 
 
Reagent                          Volume (µl)                    Final Concentration 
5 × Buffer                               10                            1/5 dilution  
dNTP mix                                4                             200µM 
Forward primer                        5                             5.5mM 
Reverse primer                         5                             2.5µM 
H2O                                       15.5                           0.4 U/µl 
Taq polymerase                        0.5                          1.25 U/µl  
 
40 µl of the PCR mix was mixed with 10 µl of the RT reaction. PCR controls 
without RNA (no template condition) and no reverse transcriptase (no RT condition) 
were routinely carried out to detect DNA contamination in the RT-PCR reaction.  
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Products from completed PCR reactions were separated on 2% agarose gels 
containing ethidium bromide (a DNA intercalator) and were visualised under UV 
light.  
 
Quantifying of PCR products with DNA intercalators such as ethidium bromide is 
problematic when more than one PCR product arises due to alternative splicing 
because the signal intensity under UV light is proportional to the length of DNA as 
well as the amount present.  
 
To quantify ratios of alternatively spliced isoforms more accurately, our laboratory 
has developed a method where alternatively spliced variants can be visualised and 
measured on the Odyssey infrared imaging system. Primers were modified by 
attaching a fluorophore (DY682) at the 5’ end of the forward primer and 
manufactured by MWG Eurofins. The proportion of labelled to unlabelled forward 
primer has been optimised. The resulting PCR products were separated on 2% 
agarose gels and quantified with the Odyssey imaging system. Only one molecule of 
fluorophore incorporated into an individual molecule of the PCR product, 
independently of the length of the PCR product and therefore the ratio of intensities 
between PRC products reflects the molar ration of alternatively spliced isoforms. 
Amplification was performed according to the cycling parameters below. 
 
GAPDH primers 
1 cycle Denaturation 95ºC for 5 mins 
28 cycles Denaturation 94ºC for 30 sec 
Annealing 62ºC for 30 sec 
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Extension 72ºC for 1 min 
1 cycle Extension 72ºC for 10 mins 




1 cycle Denaturation 95ºC for 5 mins 
30 cycles Denaturation 94ºC for 30 sec 
Annealing 55ºC for 1 min 
Extension 72ºC for 2 min 
1 cycle Extension 72ºC for 10 mins 
1 cycle Storage 4ºC  
 
Tau 9- 13 
1 cycle Denaturation 95ºC for 5 mins 
28 cycles Denaturation 94ºC for 2 mins 
Annealing 60ºC for 30 sec 
Extension 72ºC for 20 sec 
1 cycle Extension 72ºC for 10 mins 
1 cycle Storage 4ºC  
 
Tau N term 
1 cycle Denaturation 95ºC for 5 mins 
30 cycles Denaturation 94ºC for 1 min 
 89
Annealing 65ºC for 1 min 
Extension 72ºC for 45 sec 
1 cycle Extension 72ºC for 10 mins 




1 cycle Denaturation 95ºC for 5 mins 
31 cycles Denaturation 94ºC for 1 min 
Annealing 60ºC for 1min 
Extension 72ºC for 1½min 
1 cycle Extension 72ºC for 10 mins 
1 cycle Storage 4ºC  
 
Table 2.4. PCR primer cycling parameters 
 
2.2.8. Quantitative RT-PCR 
Taqman RT Kit (GE Healthcare) was used to synthesize the first strand cDNA as 
described 2.2.6. Amplification and detection steps are performed concurrently for 
each cyle. qRT-PCR was performed with the Applied Biosystems 7900HT 
instrument. The fluorophore used in this study was SYBR Green (Roche 
Diagnostics). SYBR green does not fluoresce when free in solution and will bind to 
all double stranded DNA (dsDNA) molecules independent of sequence. 
Fluorescence emission occurs after binding to dsDNA due to conformational 
changes in the dye. The increase in SYBR green signal (measured at 530 nm) 
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correlates with the amount of PCR product amplified during the reaction and the 
number of cycles to reach a preset threshold is recorded (CT).qRT-PCR was 
performed in 384 well plates with 20 ng template cDNA. Dissociation curves were 
determined for each of the target genes (MAPT and APP) to show that only a single 
product was amplified from the primer pairs. Master mixes for multiple reactions 
were prepared to avoid variability. For one reaction the qRT-PCR mix was as 
follows: 
 
Reagent                           Volume (µl)                           Final Concentration 
SYBR Green                     5                                            1 ×      
Forward primer                 0.5                                         10µM 
Reverse primer                  0.5                                         10µM 
H2O                                   2                                        
cDNA                                2                                            10 ng/µl 
 
8 µl of the PCR master mix was added to 2 µl of the cDNA and all samples were 
measured in duplicates.  
1 cycle Denaturation 95ºC for 10 mins 
40 cycles Denaturation 94ºC for 15 sec 
Annealing 60ºC for 30 sec 
Extension 72ºC for 15 sec 
 
Table 2.5. qRT-PCR cycling parameters 
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2.2.9..Determination of housekeeping genes 
Primers and software for determining the optimal housekeeping genes for each brain 
area was analysed using a geNorm kit (Primerdesign, UK). geNorm enables the 
selection of the optimal set of reference genes from a series of tested candidate 
reference genes. A set of six genes were tested for each brain region. cDNA from 6 
samples of control and AD brains were tested for each region with primers for all six 
candidate genes.    
 
 





GenormPLUS software was used to rank candidate genes for stability across six brains 
with data from a qRT-PCR analysis according to the manufacturer’s protocol. The 
stability of each candidate gene was ranked with the least stable genes for the six 
brains on the left and most stable on the right (Figure 2.1). For each target gene, two 
of the most stable reference genes were used for a relative CT analysis. 
 
2.2.10. Validation of PCR primers 
The primers used for genes of interest for both qRT-PCR and RT-PCR were 
designed on the basis of the GenBank cDNA sequence using the primer designing 
tool Primer3. Each primer was tested for specificity using the NCBI Blast program. 
The primers were then tested using end point PCR, were cut out of agarose gels and 
sequenced. All sequenced PCR products were aligned to published sequence from 
ensemble. Primers used for qRT-PCR were also tested for amplification of a single 
product with the Applied Biosystem 7900HT machine.  
2.2.11. Cloning 
PCR products resulting from primer sets Tau N-term (0N, 1N and 2N), APP 
(APP770, APP 751 and APP695) and TDP-43 3’UTR alternative isoform PCR 
products were validated (Tau 9-13 and GAPDH primers have previously been 
validated). PCR products were cut out of 2% agarose gels; DNA was extracted from 
agarose and purified using the QIAquick gel extraction kit (Qiagen).  
 
Ligation 
The DNA was ligated into pGEM-T easy vectors (Promega). Ligation of cDNA 
insert (extracted PCR product) and vector was performed overnight on slush ice with 
1 µl T4 ligase and 1 µl ligase buffer (Promega) in a total volume of 10 µl. 100 ng of 
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vector DNA was used and the amount of insert DNA calculated according to the 
manufacturer’s instructions: 
 
         ng of vector × kb size of insert     ×       molar ratio of insert 
                 Kb size of vector                                vector                   
 
Transformation of E.coli cells 
20 ng of plasmid DNA was transformed into 50 µl of competent JM109 Escherichia 
coli (E. coli) cells (Promega), and incubated on ice for 20 mins. The E. coli cells 
were subsequently heat shocked at exactly 42ºC for 45 secs and returned to ice for 2 
mins. 950 µl of sterile LB medium without antibiotic was added to the bacterial 
suspension and incubated for at least 1 hour at 37ºC to allow for expansion of the 
bacteria containing the DNA insert. Bacteria were centrifuged for 5 mins at 8000 
rpm and re-suspended in 50 µ of LB broth. Cells were streaked out onto LB agar 
plates (LB/ampicillin/IPTG/X-Gal) and placed in incubator overnight at 37°C.  
 
IPTG/X-Gal allows colonies containing the DNA insert to be selected by blue/white 
selection. White colonies containing the PCR insert were selected and grown in 5 ml 
LB broth/ampicillin in a Unitron Infors AG shaker, overnight shaking 225 rpm at 
37°C.  
 
Plasmid DNA digestion by restriction endonucleases 
The presence of the cDNA insert was confirmed with small scale restriction enzyme 
analytical digest and agarose gel electrophoresis before sequencing. 1 µl of 1 unit/µl 
restriction enzyme (Promega), was used to digest cDNA inserts from 1 µg of 
plasmid DNA. With 2 µl 10 × buffer and ultra-pure water to produce a final volume 
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of 20 µl. Reactions were performed at 37ºC for 2 hours to allow for complete 
digestion of plasmid DNA followed by a denaturation step at 65ºC for 10 mins. 
Digest products were visualised on 2% agarose gels to confirm the presence and size 
of the cDNA insert. Samples were sent for sequencing (MWG ecofins) and the insert 
DNA sequence was compared and validated with cDNA sequences downloaded 
from ensembl. (http://www.ensembl.org/index.html)  
 
2.2.12.. Cell culture 
All materials used for cell culture were purchased sterile or sterilised by autoclaving 
at 121ºC for 15 mins. Regular tests for mycoplasma contamination were performed. 
All procedures were performed in class II microbiological safety cabinets. 
 
In this study translation was inhibited in SH-SY5Y cells by cycloheximide (CHO) 
treatment. SH-SY5Y cells are a third generation human neuroblastoma cell line that 
originated from the SK-N-SH line derived from a bone marrow biopsy in 1970 
(Biedler et al., 1973; Ross et al., 1983). 
 
Culture of cell lines 
Cells were cultured in DMEM/F-12 and supplemented with 15% (v/v) FBS. In 
addition, all media contained 100 units/ml penicillin, 100 mg/ml streptomycin and 2 
mM L-glutamine. Cells were maintained at 37°C in a humidified atmosphere of 5% 
CO2/ 95% air in a Heraeus Hera cell incubator. Cells were passaged at a sub-




Passaging of SH-SY5Y cells 
Cells were maintained by passaging when approximately 80% confluent. Culture 
medium was aspirated and the cells washed with HBSS. Cells were then trypsinised 
by the addition of Trypsin-EDTA solution and incubating at 37ºC until cells were 
fully detached. Cells were then re0suspended in culture medium to inactivate the 
trypsin. Cells were recovered by centrifugation at room temperature at 1000 rpm for 
5 mins using a Sorvall® Legend T centrifuge, re-suspended in 10 ml of fresh 
medium and resseded at ~1/10 dilution. 
Plating of cells 
For plating cells in six well plates, cells were washed in HBSS and detached from 
the flask surface by incubation with 1-2 ml of trypsin (0.05% (v/v) trypsin/EDTA) at 
37°C for 5 min.  When the cells were detached, 9ml of medium was added. The cell 
suspension was centrifuged at 500 × g for 5 min at room temperature and the 
supernatant removed.  The cell pellets were then resuspended in the appropriate 
volume of medium and plated according to protocol approximately one million cells 
per well of a 6 well plate. Cells were allowed to attach overnight and were used for 
experimental procedures after at least 12 hours from plating.   
 
Cycloheximide treatment of SH-SY5Y cells 
SH-SY5Y were plated in 6 well plates ~ 1 million per well. Once the cells had 
attached to the plate surface, the media was aspirated and new media was added, in 
the cycloheximide (CHX) condition, the media contained CHX at 10 µg/ml, control 
had new media. Cells were treated for 12 hours and the RNA was extracted.  
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2.2.13. Preparation of human brain homogenate 
Brain tissue was obtained from the London Neurodegenerative Diseases Brain Bank, 
Institute of Psychiatry, Kings College London. Ethical approval was obtained from 
the local Ethics Committee. 
 
0.2g of human brain samples from the amygdala was homogenised on ice with a 
mechanical homogeniser (Ultra Turrax® T8, Werke GmbH & Co., Germany) in 
autoclaved 1ml Tris buffer containing 50mM Tris/HCl pH 7.4, 150mM NaCl, 1mM 
PMSF and EDTA free Protease inhibitor tablets (Roche). The homogenate was 
centrifuged at 12,000 ×g for 20 mins at 4°C. Transfer 800µl of the supernatant into 
high speed centrifuge tubes for extraction of sarkosyl insoluble tau. Transfer the 
remainder of the supernatant to new tubes and 1x volume of the Tris buffer was 
added to these samples. This samples is the low centrifuge material and was used for 
western blotting at ~1µg/µl.  
 
Isolation of insoluble tau 
Sarkosyl was added to the 800µl high speed centrifugation sample for a final 
concentration of 1% (from 20% stock) and the solution was shaken for 30mins at 
room temperature. The samples were centrifuged at 47,000 rpm for 1 hour at 21ºC 
on a Beckman Coulter ultra-centrifuge. The pellet containing sarkosyl insoluble tau 
was collected and washed with 200µl of 1% sarkosyl and re-centrifuged at 47,000 
rpm for 10 mins. The wash step was repeated.  The resulting insoluble tau pellet was 
dissolved in 40µl of 8M guanidine and  2% ß-mercaptoethanol and allowed to mix 
for 1hour rocking at room temperature. 
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Protein quantification assay 
A pierce BCA assay was used to measure the concentration of protein in the samples 
from the low speed centrifugation. BSE standards of known concentration were 
made in 96 well plates and the unknown samples were added to wells at a 1 in 10 
concentration. The 96 well plate was incubated at 37°C for 30 mins and read on a 
spectrophotometer at 562nm.  
 
Dialysis and concentration of the sarkosyl insoluble samples 
Insoluble tau extracted from human brain is hyperphosphorylated. In order to 
determine the tau species present in these samples, phosphorylation is removed with 
lambda phosphatase. Lambda phosphatase enzymes are inhibited in the presence of 
strong denaturing agents such as guanidine. 10-12 of the insoluble tau samples were 
dialysed in 1 litre autoclaved dialysis buffer for ~4 hours. Dialysis buffer consisted 
of 50mM Tris/HCl  pH 8.0 and 0.1mM EDTA. Novagen D-Tube dialysis tubes were 
used and we followed the manufacturer’s instructions. 250µl of autoclaved H2O was 
pipetted into tubes and left for >5mins to re-hydrate the dialysis tube membranes. 
H2O was removed and the sarkysol insoluble samples were added and dialysed in 
dialysis buffer for 4 hours with stirring. Samples containing ~50µl of sarkosyl 
insoluble tau were recovered from the dialysis tubes. For analysis by western 
blotting, the whole sample from 0.2 g of tissue must be run in one lane and a total 
volume of 50µl is too much volume for this and needs to be reduced. Amicon ultra 
(molecular weight cut off 30 kDa) centrifugal concentrators were used to decrease 
volume according to the manufacturer’s instructions. 50µl samples were added to the 
centrifuge concentrator tubes and topped up with fresh dialysis buffer to 450µl total 
volume. Samples were spun at 14000 ×g for 15mins and result in a volume of  ~15-
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20µl of sample. To release sample the tubes were placed in the centrifuge upside 
down and spun at 1000 ×g for 2 mins. 
 
Dephosphorylation of samples with lambda phosphatase 
Both samples of insoluble tau and samples from the low speed centrifugation 
samples were dephosphorylated with lambda phosphatase (New England Biolabs).  
 
Buffer for lambda phosphatase 10× 
50mM HEPES pH 7.5 
100mM NaCl 
2mM DTT 
0.01% Brij 35 
 
The insoluble tau samples had a volume of ~ 15 µl, the low speed centrifugation 
samples had a variable volume and used at 1µg/µl. A master mix of 10 × buffer and 
10 × MgCl2 was made and 0.2µl of lambda phosphatase was added to the master mix 
per sample. For the insoluble tau samples 3 µl of the master mix and lambda 
phosphatase was added to each sample. Tubes were placed in a heat block for 2.5 – 3 
hours at 30°C. 
2.2.14. Western blotting 
2.5 µl of the 6 × sample buffer was added to each sample before western blotting. 
Proteins were separated by SDS-PAGE on 10% polyacrylamide gels (Protogel, 
National Diagnostics) using the Mini Protean III gel system (Biorad) and were 
transferred to a 0.45 µm pore size  nitrocellulose membrane (Schleicher and Schuel) 
using the wet transfer method (Bio-rad).  The nitrocellulose membrane and gel were 
 99
sandwiched between sponges and filter papers soaked in transfer buffer. Transfer 
was performed at 100V for 1 hour. Non-specific protein binding sites were blocked 
by incubation with 5% (w/v) skimmed milk in PBS + 0.1% (v/v) Tween-20 (PBST). 
The membrane was washed 3 × in PBST and incubated in DAKO/ GAPDH primary 
antibody (in PBS-T) overnight at 4 °C. Membranes were then washed (3 × 10 min) 
in PBST. Incubation with an appropriate species specific secondary antibody 
conjugated to a fluorescent label was performed at room temperature for one hour in 
5% (w/v) milk/ PBST. After three more washes in PBST and a final wash in PBS, 


















Chapter Three: Tau expression and splicing in brain 
regions affected in Alzheimer’s disease. 
 
Splicing mutations in a subset of FTDP-17 brains show that increases in 4R tau are 
pathological. Post-mortem brain samples from disease-affected areas of PSP and 
CBD brains show increases in 4R tau at the RNA level (Chambers et al., 1999; 
Takanashi et al., 2002; Umeda et al., 2004) and at the protein level (Buée and 
Delacourte, 1999; Luk et al., 2010). PiD can show increases in 3R tau isoforms (de 
Silva et al., 2006; Delacourte et al., 1996) although both 3R and 4R tau has been 
found in PiD (Arai et al., 2001; Taniguchi et al., 2004; Zhukareva et al., 2002) and 
this may be due to astrocytic inclusions (see Introduction). (Arai et al., 2001) These 
findings suggest that 4R/3R tau isoform imbalances may constitute a pathogenic 
pathway for tau pathology. In AD, it has been generally assumed that the 4R/3R 
ratio is in balance however there are a number of papers providing evidence that an 
increase in 4R isoforms occurs in a subset of neurons harbouring tau inclusions (see 
Introduction). The lack of consensus on the AD tau 4R/3R ratio may be, in part, due 
to the multiplicity of pathways operating in AD which results in heterogenous sets of 
AD samples.  
3.1. TDP-43 role in tau exon 10 alternative splicing 
Around 20-35% of AD cases have TDP-43 cytoplasmic inclusions and, to a much 
lesser extent, nuclear inclusions (Amador-Ortiz et al., 2007). Concomitant TDP-43 
pathology in AD cases is of particular interest because of its known role in 
regulation of RNA processing such as alternative splicing. TDP-43 clearance from 
the nucleus may result in a loss of function and impair splicing and transcription of 
target RNAs. Whether secondary pathologies such as TDP-43 contribute to changes 
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in MAPT splicing or expression in disease is an issue of considerable research 
interest.  
 
Many AD brains show co-existence of insoluble tau and TDP-43 however inclusions 
most likely represent an end stage of a molecular cascade and earlier steps in that 
cascade may be more directly linked to pathogenesis. It is therefore important to 
understand the mechanisms underlying all aspects of TDP-43 and tau processing and 
functioning. 
 
In this chapter the main research question was to investigate a possible association 
between TDP-43 dysfunction in disease brain and altered tau splicing, transcription 
and post-transcriptional processing.  
 
Tau splicing ratios of exons 2,3 and 10 were quantified at the RNA level in human 
control, Myotonic Dystrophy1 (DM), FTDP-17 and AD brains with and without 
TDP-43 inclusions in five different brain regions. Control status was confirmed by 
histolopathology examination carried out at Kings College Hospital  on sections 
prepared from paraffin embedded brain samples. Diagnosis was performed by a 
neuropathologist and all controls did not have plaques or tangles or AD-type changes 
that were not consistent with normal aging. A single DM1 case that was available to 
us was included in our sample set because tau exon 10 (4R) transcript expression has 
been reported to be decreased in DM1 (Jiang et al., 2000). DM1 is caused by an 
expansion mutation of CUG repeats in the 3’UTR of dystrophia myotonica protein 
kinase (DMPK) mRNA (Brook et al., (1992) and DM1 patients may carry several 
kilobases of CUG repeats. The nuclear retention of these transcripts results in DMPK 
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haploinsufficiency, however reduced DMPK protein does not cause the major 
symptoms of the disease (Fu et al., 1993; Jansen et al., 1996). CUG repeats form a 
double stranded hairpin structure which acts as a sink for CUG binding RBP such as 
muscleblind-like (MBNL) family and results in a loss of function of these splicing 
factors and may result in altered splicing of MAPT amongst other transcripts. 
Expression of expanded CUG repeats in the 3’UTR of DMPK activates protein 
kinase C (PKC) of which CUGBP1 is a target. Hyperphosphorylation of CUGBP1 
stabilises the protein and effectively results in up-regulation of CUGBP1 (Kuyumcu-
Martinez et al., 2007). 
 
4R/3R tau ratios in control and AD brains were correlated across the five different 
brain regions to test for consistency over the different brain regions. Total tau 
mRNA levels were quantified in affected and non-affected brains and relative MAPT 
expression was compared between control, FTDP-17 and AD group brains in five 
brain regions. Relative MAPT expression and splicing ratios were correlated with tau 
haplotype. Tau isoform ratios of soluble and insoluble protein were quantified in 
control and AD brain samples from the amygdala. Tau protein 4R/3R ratios were 
correlated with RNA 4R/3R ratios from the amygdala in control and AD brains. 
Finally, semi-quantitative measures of tau pathology were analysed in brain sections 
for differences between AD brains with TDP-43 inclusions and AD brains without 
TDP-43 inclusions in four brain regions (frontal and temporal cortex, amygdala and 
hippocampus). 
3.2. Determination of PCR conditions for detection of tau exon 10 RNA 
When using RT-PCR to quantify and calculate a ratio of multiple splicing products it 
is important to accurately measure the point at which the primers plateau for all PCR 
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products because each product may have a different plateau due to different cycling 
efficiencies and this will alter the splice ratio calculation. The RT-PCR reaction 
starts with an exponential increase and eventually plateaus due to decreasing reaction 
components and declining enzyme activity. In the exponential phase of the reaction, 
if the primer efficiency is 100%, then for every cycle there is a doubling of PCR 
product. Factors that impact efficiency include contaminants in the sample, PCR 
product length and RNA integrity (Fleige and Pfaffl, 2006; Tichopad et al., 2004; 
Tichopad et al., 2002).  
 
Another confounding factor in quantifying small differences in alternatively spliced 
products using DNA intercalators such as ethidium bromide is that the signal 
intensity under UV light is proportional to the length of DNA as well as the amount 
of DNA present. Since PCR products from alternatively spliced isoforms will differ 
in length, the amount of ethidium bromide intercalated in the larger PCR product 
will increase signal but will not accurately reflect the quantity relative to a smaller 
alternatively spliced product. In order to address this problem we designed and 
optimised a PCR protocol with modified PCR primers that allow the determination 
of molar ratios of PCR product.  
 
The presence or absence of tau exon 10 can be detected with a forward primer 
annealing to exon 9 and reverse primer annealing to tau exon 13 (tau 9-13 primer 
pair). A DY682 label was attached to the 5’ end of the forward primer (DY682 is a 
substitute for infra-red dye IRD700). PCR products containing the labelled forward 
primer can be quantified with an infra-red scanner (Figure 3.1A). The IR labelled 
primer modification gives an accurate access to the molar ratio of spliced isoforms as 
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the intensity of the fluorescence signal is independent of the length of the PCR 
product. The advantages of this technique are that RT-PCR is a standard technique 
which is easy to perform and the DY682 tag modification of the PCR forward primer 
is easy to get manufactured. Quantification of PCR products from alternatively 
spliced isoformsby other methodologies such as qRT-PCR requires at least two sets 
of primers and exon 10 in MAPT is particularly difficult to accurately quantify by 
qRT-PCR because of the inherent repeated nature of the microtubule domains, cross 
reactivity of tau4R specific primer for tau3R has been reported in previous 
publications using qRT-PCR (Connell et al., 2005; Takanashi et al., 2002). qRT-
PCR also requires determination of stable housekeeping genes and similar reaction 
efficiencies between primer pairs for accurate quantification. Using RT-PCR with a 
modified forward primer and primers that span alternative exons at least two PCR 
products are produced from a single primer pair. A molar ratio can be calculated 
from the two products and therefore there is no need for housekeeping genes.  
 
cDNA from human brain, adult mouse and rat brain and cultured SHSY-5Y cells 
were PCR amplified with the modified forward 9-13 primer pair and visualised with 
a IR scanner as well as with a UV trans-illuminator (compare above and below 
Figure 3.1A) In the human samples, two PCR products were found and these 
products were sequenced. The longer 368 base pair (bp) product contains tau exon 
10 and represents 4R tau, the shorter 275 bp product has no exon 10 and represents 
tau 3R. PCR products from adult mouse and rat brain show expression of tau E10 
inclusion (4R) only. The smaller sized bands (approx 182bp) visualised in the rat 
brain lanes are PCR products derived from mis-priming on the forward primer. Tau 
9-13 primers were designed primarily for use with human cDNA, and rat cDNA 
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varies from the human sequence in this region. cDNA from quadruplicate samples 
were analysed with the tau 9-13 primer pair at different numbers of cycles. 
Quantification of 3R and 4R in arbitrary fluorescent units was determined with 
Odyssey software and fluorescent unit vs cycle number was plotted. The linear range 
of the amplification curve was determined for the primer pair (Fig. 3.1B) which was 
between 25-30 cycles for both 4R and 3R transcripts. The number of cycles finally 








Figure 3.1. PCR products from modified DY682 forward primer 9-13 pair. 
1A. IR- labelled forward 9-13 primers were PCR amplified with cDNA from various 
sources. PCR products of 368bp correspond to tau transcripts that include exon 10 
(4R tau), products of 275bp correspond to transcripts excluding exon 10 (3R tau). 
1B. cDNA from quadruplicate samples were PCR-amplified at different numbers of 
cycles (25, 30, 35, and 40) and PCR products were quantified and plotted to 






3.3. Tau exon 10 expression in frontal cortex 
Tau mRNA and protein in the human frontal cortex has been found to be very highly 
expressed compared to all other brain regions tested including occipital cortex, 
putamen, cerebellum and white matter (Trabzuni et al., 2012). Tau pathological 
inclusions are present in the frontal cortex at later stages of AD corresponding to 
Braak stages V and VI (Braak and Braak, 1991; Braak et al., 2011). In FTLD-TDP, 
the frontal and temporal cortices have extensive TDP-43 pathology. TDP-43 
inclusions in AD brains are predominant in the hippocampus and amygdala and 
usually only sparsely found in the frontal and temporal cortex (Arai et al., 2009; Hu 
et al., 2008).  
 
Human brain samples from AD cases with TDP-43 inclusions (AD TDP+), AD 
cases without TDP-43 inclusions (AD TDP-), DM1, FTDP-17 cases and controls 
were identified from neuropathology reports. Brain samples were dissected from five 
brain areas, frontal and temporal cortices, amygdala, hippocampus and cerebellum at 
the IOP brain bank. All AD cases had been neuropathologically examined and 
confirmed AD cases and the presence or absence of pathological TDP-43 
immunoreactivity was also confirmed in these cases. The six FTDP-17 brains 
dissected, had been identified at the Institute of Neurology at Queens Square, 
London (Janssen et al., 2002; Lantos et al., 2002), all had the 10+16 mutation which 
increases expression of 4R tau isoforms (Hutton et al., 1998). Samples were stored at 
-80°C until analysis.  
 
RNA was extracted from all samples in all brain regions and RNA integrity (RIN) 
was measured for each sample. A RIN of 3.6 was an arbitrary cut-off that was 
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experimentally determined and RT-PCR with samples below this threshold were not 
reliable and therefore not included. Of the six FTDP-17, 10+16 brains sampled from 
the frontal cortex, only three had RIN above 3.6. RNA was reverse transcribed and 
the resulting cDNA was analysed by PCR with the modified DY682 forward primer 
9-13 pair. Throughout these experiments RNA corresponding to the housekeeping 
protein glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an 
endogenous RT-PCR loading control. PCR products were run on 2% agarose gels 
and scanned into an Odyssey IR reader (Figure 3.2 A). The 4R and 3R tau bands 
were quantified and a 4R/3R ratio was calculated for each sample and plotted on a 
scatter graph (Figure 3.2 C). In addition, sample group 4R/3R means were calculated 
(Figure 3.2 B). All group comparisons were tested by t-test. 
 
The three FTDP-17 samples had a 4R/3R tau ratio average of 2.8 (S.D. 0.28) 
compared to control average of 0.71 (S.D. 0.19) which was a highly significant 
increase in 4R/3R tau ratio compared to controls (p ≤ 0.0001). The FTDP-17 
samples used in this study were expected to show increases in 4R tau due to the 
mutation and were included as a positive control for the RT-PCR method. For 
example, Hutton et al. (1998) measured the 4R/3R ratio by RT-PCR in frontal cortex 
in two different 10+16 mutation brains and found one had a 4R/3R ratio of ~4 and 
the other ~2.  
 
The AD TDP- samples had a 4R/3R ratio average of 0.87 (S.D. 0.18; control 4R/3R 
ratio average 0.71) and was significantly increased compared to control (p = 0.035). 
The AD TDP+ samples had a 4R/3R ratio average of 1.0 (S.D. 0.29) and 4R tau 
isoforms were significantly different compared to controls (p = 0.005). There were 
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no differences found in 4R/3R ratio averages between the AD groups. The single 
DM1 sample we sampled showed a mean 4R/3R tau ratio of 0.73 and this was 
identical to the mean of the control samples (average ratio control = 0.71). No 
statistical analysis can be done with a single sample and therefore this sample was 











Figure 3.2. Tau exon 10 splicing in frontal cortex of control, DM1, FTDP-17 
and Alzheimer’s disease brain. 
(A) Exon 10 inclusion was assayed by RT-PCR with IR-labelled forward 9-13 
primer pair. 
(B) Mean 4R/3R ratios were calculated for each group ± SEM. Significance was set 
at p≤ 0.05, *** =  p≤ 0.0005. Significant differences shown in this graph are all case 
vs control. 









3.4. Tau exon 10 expression in the temporal cortex 
In AD, tau temporal cortex neuropathology is associated with Braak stages III-IV 
(Braak and Braak, 1991; Braak et al., 2011).  
 
For the temporal cortex, three FTDP-17 brains had a RIN above 3.6. RNA from the 
temporal cortex samples was reverse transcribed and amplified with the DY682 
labelled forward 9-13 primers. The PCR products were run on agarose gels (Figure 
3.3 A), the 4R and 3R bands were quantified and 4R/3R ratios were calculated and 
plotted (Figure 3.3 B and C). 
 
Similar to the frontal cortex, FTDP-17 brains have a 4R/3R ratio average of 3.2 
(S.D. 0.38) compared to control average ratio of 0.9 (S.D. 0.24) indicating a highly 
significant increase in 4R containing tau transcripts in the FTDP-17 brains compared 
to controls (p ≤ 0.001). For the AD groups ADTDP- 4R/3R ratio average was 1.1 
(S.D. 0.44) and the AD TDP+ 4R/3R average was 1.1 (S.D. 0.38) compared to the 
control 4R/3R average of 0.9 and these differences were not significant. There were 
no differences in 4R/3R ratio averages between AD groups. The DM1 brain showed 





Figure 3.3. Tau exon 10 splicing in temporal cortex of control, DM1, FTDP-17 
and Alzheimer’s disease brain. 
(A) Exon 10 inclusion was assayed by RT-PCR with IR-labelled forward primer 
pair. 
(B) Mean 4R/3R ratios were calculated for each group ± SEM. Significance was set 
at p≤ 0.05, *** =  p≤ 0.0005. Significant differences shown in this graph are all case 
vs control. 
(C) Scatter plots showing 4R/3R ratios for each brain sampled 
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3.5. Tau exon 10 expression in the amygdala 
The amygdala is consistently affected by tau pathology in AD and this may be due to 
its afferent connections to the entorhinal cortex (Vogt et al., 1990), which also shows 
extensive tau pathology and is considered one of the brain areas that is affected early 
in AD (van Hoesen et al., 1991). In AD brains with TDP-43 inclusions the amygdala 
is consistently affected (Amador-Ortiz et al., 2007; Arai et al., 2009). The amygdala 
may be highly susceptible to TDP-43 pathology because some brains have amygdala 
only TDP-43 pathology and it has been suggested that TDP-43 pathology starts in 
limbic regions and spreads into temporal and frontal regions at later stages in the 
disease course somewhat like tau Braak stages in AD (Hu et al., 2008). 
 
We checked for the presence or absence of TDP-43 pathology in brain sections 
(Section 3.19). In our samples amygdala brain sections were not available for all 
cases however all of the ADTDP+ cases sampled had TDP-43 inclusions in the 
amygdala. There was one case with “amygdala only” TDP-43 inclusions (sample 
A249/07).  
 
Splicing analysis showed two of the FTDP-17 cases have very high tau 4R/3R ratios 
compared to controls and one score is at normal 4R/3R ratio (sample A171/02; 
Figure 3.17). The 4R/3R ratio average for the FTDP-17 brains was 4.0 (S.D. 2.7) 
compared to a 4R/3R ratio average of 1.1 (S.D. 0.42) in controls.  
 
ADTDP- brains in the amygdala had a 4R/3R ratio average of 1.5 (S.D. 0.58) 
compared to control average of 1.1 (S.D. 0.42), 4R tau isoforms were significantly 
increased in the ADTDP- group compared to controls (p = 0.033). The ADTDP+ 
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brains also had a 4R/3R ratio average of 1.5 (S.D. 0.51), and this was borderline 
significant (p = 0.054). There were no differences between AD groups. The DM1 
brain showed a decrease in 4R containing PCR products (ratio = 0.86; control 














Figure 3.4. Tau exon 10 splicing in the amygdala of control, DM1, FTDP-17 and 
Alzheimer’s disease brain. 
(A) Exon 10 inclusion was assayed by RT-PCR with IR-labelled forward primer 
pair. 
(B) Mean 4R/3R ratios were calculated for each group ± SEM. Significance was set 
at p≤ 0.05. Significant differences shown in this graph are all case vs control. 






3.6. Tau exon 10 expression in the hippocampus 
The entorhinal cortex has major projections to the hippocampus called the perforant 
pathway and these structures are heavily affected in AD. TDP-43 inclusions are also 
prevalent in the hippocampus of TDP-positive AD cases. In our sample set all but 
one case had cytoplasmic TDP-positive inclusions in the hippocampus.  
 
The FTDP-17 samples had a 4R/3R ratio average of 4.2 (S.D. 0.39) compared to 
controls 4R/3R average of 0.9 (S.D. 0.24) and the increase in 4R transcript 
expression was highly significant (p ≤ 0.001). The ADTDP- brains had a 4R/3R ratio 
average of 1.3 (S.D. 0.35) compared to control 0.9 and was significantly different 
compared to controls (p = 0.01). The ADTDP+ brains had a 4R/3R ratio of 1.4 (S.D. 
0.55) and 4R transcripts were significantly higher in ADTDP+ brains compared to 
control (p = 0.01). There were no differences in 4R/3R ratios between ADTDP- and 
ADTDP+ brains. The DM1 brain actually showed an increase in 4R containing PCR 





Figure 3.5. Tau exon 10 splicing in the hippocampus of control, DM1, FTDP-17 
and Alzheimer’s disease brain.. 
(A) Exon 10 inclusion was assayed by RT-PCR with IR-labelled primer pair. 
(B) Mean 4R/3R ratios were calculated for each group ± SEM. Significance was set 
at p≤ 0.05, ** =  p≤ 0.005. Significant differences shown are all case vs control. 





3.7. Tau exon 10 expression in the cerebellum 
In the cerebellum of AD brains, diffuse Aβ plaques are very common but there is no 
accompanying dystrophic neurites, no cell loss and no reactive astrocytes or 
microglia associated with the diffuse plaques and no tau inclusions (Joachim et al., 
1989). TDP-43 inclusions are rarely found in the cerebellum of FTLD brains (King 
et al., 2011) and p62-positive, TDP-43-negative inclusions are associated with the 
C9ORF72 repeat expansion (Troakes et al., 2012). Because the cerebellum has 
comparatively low levels of neurodegeneration in AD brains this brain region was 
included as a non-affected control.  
 
Two of the FTDP-17 cases have very high 4R/3R ratios and one sample has a ratio 
within the control range (Figure 3.6C). The sample (A171/02) is the same as in the 
amygdala that also showed a normal 4R/3R ratio. The FTDP-17 4R/3R ratio average 
was 3.9 (S.D. 1.8) compared to the control 4R/3R ratio average of 1.2 (S.D. 0.38). 
 
The ADTDP- group had a 4R/3R ratio average of 1.8 (S.D. 0.59) compared to the 
control 4R/3R ratio average of 1.2 and 4R containing transcripts were significantly 
increased in the ADTDP- brains compared to control (p = 0.009). The 4R/3R ratio 
average in ADTDP+ brains was 1.8 (S.D. 0.57) and a t-test comparing ADTDP+ and 
control 4R/3R ratios showed a significant difference (p = 0.008) and indicated that 
4R containing transcripts were significantly increased in ADTDP+ brains compared 
to control. There were no differences in 4R/3R ratio between the AD groups. The 
DM1 brain showed an increase in transcripts containing exon 10 (DM1 ratio = 1.9 






Figure 3.6. Tau exon 10 splicing in the cerebellum of control, DM1, FTDP-17 
and Alzheimer’s disease brain. 
(A) Exon 10 inclusion was assayed by RT-PCR with IR-labelled primer pair. 
(B) Mean 4R/3R ratios were calculated for each group ± SEM. Significance was set 
at p≤ 0.05. Significant differences shown are all case vs control. 








3.8. Tau 4R/3R tau ratio correlation across brain regions 
The analysis of tau 4R/3R ratios in AD and control brains found significant increases 
in 4R transcript expression in the frontal cortex, amygdala, hippocampus and 




Figure 3.7. 4R/3R ratios in control and AD brains for five brain regions (FTDP-
17 data excluded). 
 
In both AD groups there was a noticeable group of brains that show high 4R 
transcript expression (Figure 3.7). To analyse this data further, individual 4R/3R 
ratios were ranked highest to lowest, for each brain region. Since there were no 
significant differences in 4R/3R ratios between the ADTDP- and ADTDP+ brains, 
the AD data was grouped together. The consistency of 4R/3R ratio for each 
individual in the AD group across each brain region was very apparent in this 
analysis. Those ranked high for tau 4R/3R ratio in one brain region remained so 
throughout all five brain regions measured. The consistency of 4R transcript 
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expression across brain regions was also found for those low 4R/3R ranking 
individuals.  
 
To test the observation that tau RNA 4R/3R ratios were consistent across brain 
regions, a correlation analysis was performed on individual 4R/3R ratio data from 
one brain region with the 4R/3R ratio from all of the other brain regions. Correlation 
analysis was performed with 4R/3R ratios from control and a separate analysis with 
4R/3R ratios from the combined AD brains.  
 
In the combined AD group there were highly significant 4R/3R ratio correlation 
coefficients between frontal, temporal, amygdala and hippocampus brain regions 
(Table 3.1). In these brain areas, high 4R transcript expression in the frontal cortex 
also showed high 4R transcript expression in all other brain regions tested and these 
results suggest that high 4R expressors comprise a subgroup of AD patients within 
our sample set. This high 4R expressor group contribute the significant increases 
found in all brain regions in our sample set 
 
The cerebellum, in general, showed much lower tau 4R/3R correlation coefficients 
with the frontal, amygdala and hippocampus and a non-significant result with the 
temporal cortex (Figure 3.8 and Table 3.1). 
 
Although the control sample set was smaller than the combined AD group, control 
brains also had high correlation coefficients in tau 4R/3R ratio that were significant 
for frontal, temporal, amygdala and hippocampus brain regions. The tau 4R/3R ratio 
between the frontal cortex and amygdala were not significantly correlated (Table 
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3.2). There was a wide variability in the magnitude of correlation between the 
cerebellum and the other brain regions with the amygdala and cerebellum having 
very high correlation coefficients and the other regions showing borderline or not 
significant correlation with the cerebellum (Figure 3.9 and Table 3.2).  
 
Correlation analysis carried out on the control 4R/3R data shown in the graphs in 
Figure 3.9, were to the same scale as the combined AD graphs in Figure 3.8. 
Consistent with the significant increases in 4R/3R tau ratios seen in most brain 
regions in AD brains, the AD scatter graphs show a wider distribution of 4R/3R ratio 
data points indicating higher tau 4R expression compared to controls (compare 







Figure 3.8. Scatter graphs of 4R/3R RNA expression ratios across the brain 








Figure 3.9. Scatter graphs of 4R/3R RNA expression ratios across the brain 
regions in control brains. 
 
Table 3.2. Correlation coefficients of 4R/3R expression acorss brain regions in 
control brains. 
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3.9. Tau exons 2 and 3 expression 
N-terminal inserts of tau may determine the spacing between microtubules (Chen et 
al., 1992; Frappier et al., 1994). They also play a role in modulating aggregation 
properties of tau (Zhong et al., 2012), and may be involved in signalling through src 
mediated interaction with the cell membrane (Butner and Kirschner, 1991; Lee et al., 
1998). The H2 haplotype is associated with higher expression of tau exon 3 (Caffrey 
et al., 2008; Trabzuni et al., 2012) which is interesting because H2 haplotype has a 
negative association with PSP and CBD and therefore suggests a protective role.  
 
In this section the research question is does TDP-43 dysfunction in disease alter tau 
exon 2 and 3 splicing in AD brain? The expression levels of tau exons 2 and 3 were 
measured in control, ADTDP- and ADTDP+ human brains in five brain regions. 
3.10. Determination of PCR conditions for tau exon 2 and 3 
A primer pair for detection of tau exon 2 and 3 were chosen from previously 
published work (Leroy et al., 2006). The forward primer was modified by adding a 
DY682 tag onto the 5’ end. For the tau N-terminal primer pair we initially found 
three PCR products corresponding to 0N, 1N and 2N tau isoforms (Figure 3.10A). 
Three PCR products of 284, 197 and 110 bp were found and sequenced. The 284 bp 
product includes tau exons 2 and 3 (2N), the 197 bp product has only exon 2 present 
(1N) and the 110 bp product has no N-terminal inserts (0N). cDNA was analysed 
with the DY682 labelled forward primer tau N-terminal pair for a different number 
cycles. Arbitrary fluorescent units for quadruplicate samples of the three N-terminal 
PCR products were measured by Odyssey software. Fluorescent units were plotted 
against differing cycle numbers and the linear range of the PCR amplification curve 
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Figure 3.10. Determination of tau exons 2 and 3 primer amplification.  
(A) The IR labelled forward primer N-terminal pair were tested with cDNA from 
frontal cortex human brain. PCR products of 284bp correspond to tau transcripts 
with two N-terminal exons (2N tau), products of 197bp correspond to transcripts 
with only exon 2 (1N tau) and PCR products of 110bp correspond to transcripts with 
no N-terminal exons (0N tau).   (B) cDNA from quadruplicate samples were PCR 
amplified at different number of cycles (25, 30, 35, 40). PCR products were 







3.11. Tau exon 2 and 3 alternative splicing 
cDNA from human brain samples from five brain regions (frontal, temporal, 
amygdala, hippocampus and cerebellum) were analysed by PCR  with the DY682 
labelled forward tau N terminal primers to measure alternative splicing of tau exons 
2 and 3. In this analysis, a doublet in the bands corresponding to 2N and 1N tau 










Figure 3.11. Tau exon 2 and 3 expression in the human cerebellum. 
cDNA from the cerebellum was amplified by RT-PCR with IR labelled forward 
primer N-term pair to visualise tau exon 2 and 3 expression. PCR products were 
separated by agarose gel electrophoresis and scanned with an IR reader (Odyssey). A 
















Five PCR products were not expected from this primer pair and in order to confirm 
their identity all five bands (2N larger, 2N, 1N larger, 1N and 0N) were cut from an 
agarose gel and the PCR products were sub-cloned and sequenced. The sub-cloned 
PCR products were run on an agarose gel to check their length before sequencing 
(Figure3.12A), however we were not able to isolate the lager 1N band for 
sequencing at this time. Sequencing results showed that the larger 2N band was tau 
with 1 N-terminal repeat (1N) but with an intronic sequence spliced in (Figure 
3.12C). The intronic sequence was 135 base pairs long and is found in intron 1 of 
MAPT. In order to rule out any PCR artefacts, a new forward PCR primer was 
designed that spanned tau exon 1 and the putative exon found in intron 1. cDNA 
from the human cerebellum was analysed by PCR  with the new primer pair. Two 
PCR products were found (Fig 3.12B), these were sequenced and, consistent with 
previous sequencing results, the larger band (263bp) corresponded to tau 1N with the 
intron 1 exon. The shorter band (176bp) corresponded to tau 0N and also contained 









Figure 3.12. Sequence of PCR products containing a cryptic tau exon.  
PCR products were excised from agarose gels and sub-cloned for sequencing (A).  
(B) PCR products from tau exon1 intron1 spanning primer show two PCR products 
containing a cryptic exon from intron 1 of MAPT. The sequence in black is MAPT 
exon 1, the sequence in grey is a cryptic exon spliced in from intron 1.  The 





The presence of the intron 1 containing tau transcripts meant that all of the analysis 
of tau exon 2 and 3 could not be quantified because in the tau 1N bands there were 
also 0N tau (that include intron1) transcripts. Similarly for the 2N bands there were 
1N tau containing intron 1 transcripts (although more distinguishable). In order to 
quantify these PCR products, greater separation of the bands by longer 
electrophoresis time would be necessary.  
3.12. Total MAPT mRNA expression  
Altered total mRNA levels of MAPT expression may also be a risk factor in AD and 
other tauopathies. TDP-43 could potentially regulate MAPT expression levels by 
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binding to pyrimidine-rich sequences on the MAPT gene and potentially repress 
transcription. Previously TDP-43 has been shown to inhibit HIV1 gene expression 
possibly by preventing the assembly of a functional transcription initiation complex 
(Ou et al., 1995). The promoter region of MAPT has multiple pryrimidine 
transcription factor binding sites (Andreadis et al., 1996; Maloney and Lahiri, 2012) 
and therefore altered nuclear TDP-43 levels may impact on MAPT transcriptional 
regulation. In addition, TDP-43 may regulate MAPT transcript levels through the 
role TDP-43 plays in stabilising mRNA (Ayala et al., 2011; Strong et al., 2007). 
 
qRT-PCR was used to measure total levels of tau mRNA in five brain regions 
(frontal and temporal cortex, amygdala hippocampus and cerebellum). cDNA from 
the splicing analysis of tau was also used for this analysis. qRTPCR is a very 
sensitive technique and relies on measuring the increase in a fluorescent signal 
which is proportional to the amount of cDNA produced during each PCR cycle. 
Cycles continue until the fluorescent signal reaches a cycling threshold (CT). To 
determine relative expression of the gene of interest, the CT value is normalised to a 
reference gene. Reference gene expression should ideally be constant across the 
samples being compared. However expression of traditionally used reference genes 
can be variable and altered by disease state. Reference gene expression stability 
therefore needs to be checked for the specific sample set and normalisation should be 
performed using more than one reference gene (Vandesompele et al., 2002). The two 
most stable reference genes for each brain region were identified with primers and 
software (qbasePLUS) from Primerdesign (UK). For the total tau RNA analysis, tau 
primers were used with a forward primer spanning exons 11 and 12 and a reverse 
primer spanning exons 12 and 13. This primer pair had been previously tested and 
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shown to produce a single qRT-PCR product and the identity of the PCR product 
was confirmed by sequencing. All samples were run in duplicate with SYBR green. 
The average cycle threshold (CT) was calculated for target and reference genes. The 
average CT for target samples was divided by the geometric mean of the two 
reference genes and each point plotted giving a target gene expression relative to 
reference gene expression for each sample (Fig 3.13). 
 
The analysis showed that tau expression was the same across control and disease 
conditions and there were no significant differences found in tau expression in 
disease groups compared to controls in any brain region, by one way ANOVA. 
There were also no differences in ADTDP+ compared to ADTDP- groups in any 
brain region by t-test. This suggests that TDP-43 misregulation in AD brain does not 
play a role in altering tau transcription. The CT values plotted are relative to 
different sets of reference genes in each brain region and therefore levels of tau 





Figure 3.13. Total tau expression in AD and control brain. 
RNA was isolated from post-mortem brain tissue and reverse transcribed. 20ng/µl of 
cDNA was used for qRTPCR analysis in duplicate. Each data point represents one 
sample, relative CT was calculated by dividing target CT by the geometric mean of 
the two reference genes. 
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3.13. MAPT haplotypes 
The H1 haplotype of MAPT is associated with increased risk of developing PSP 
(Baker et al., 1999; Hoglinger et al., 2011), CBD (Houlden et al., 2001), PD (Golbe 
et al., 2001; Lill et al., 2012) and AD (Gerrish et al., 2012). The mechanism of 
pathogenesis for the association with disease is not known, however studies in post-
mortem brain samples have shown that tau exon 10 containing RNA is increased in 
homozygous H1 haplotypes (Caffrey et al., 2006). Allele-specific PCR 
quantification in post mortem brain samples show that H1 haplotype expresses 
higher total tau than controls and higher 4R containing transcripts than controls 
(Myers et al., 2007). Another intriguing result has been the association of H2, which 
is negatively associated with PSP and CBD, with increases in tau exon 3 (Caffrey et 
al., 2008; Trabzuni et al., 2012). These findings demonstrate that genetic variability, 
most likely within the MAPT locus, alters tau splicing and/or expression and is a 
significant contributor to the risk of developing tauopathy. 
 
We determined the MAPT H1, H2 haplotype in all our samples. Genomic DNA was 
extracted from cerebellar samples from control and AD cases (n = 42). The H2 
haplotype can be identified by a 238 bp deletion within intron 9 not present in the H1 
haplotype (Baker et al., 1999). H1 and H2 haplotypes were determined by 
visualising a PCR product on agarose gel (Figure 3.14 and Table 3.3). Further sub-
haplotyping of our H1 samples would have been desirable but with such a small 






Figure 3.14. Haplotype analysis of samples. 
DNA was extracted from the cerebellum of all brain samples. Primers spanning the 
238bp deletion were used to distinguish H2 alleles from H1. The H2 haplotype with 





SAMPLE HAPLOTYPE CATEGORY SAMPLE HAPLOTYPE CATEGORY 
A239/03 H1/H1 CONTROL A283/09 H1/H2 AD TDP+ 
A359/08 H2/H2 CONTROL A188/10 H1/H1 AD TDP+ 
A308/09 H1/H2 CONTROL A168/10 H1/H2 AD TDP+ 
A292/09 H1/H1 CONTROL A267/09 H1/H2 AD TDP+ 
A123/09 H1/H1 CONTROL A308/07 H1/H1 AD TDP+ 
A048/09 H1/H2 CONTROL A122/09 H1/H1 AD TDP+ 
A063/10 H1/H2 CONTROL A037/04 H1/H1 AD TDP- 
A057/10 H1/H1 CONTROL A039/02 H1/H1 AD TDP- 
A310/09 H1/H1 CONTROL A331/07 H1/H2 AD TDP- 
A303/09 H1/H2 CONTROL A098/04 H1/H2 AD TDP- 
A065/11 H1/H1 CONTROL A191/07 H1/H1 AD TDP- 
A346/10 H1/H1 CONTROL A192/07 H1/H1 AD TDP- 
A136/10 H1/H1 CONTROL A210/05 H1/H1 AD TDP- 
A249/07 H1/H2 AD TDP+ A240/06 H1/H1 AD TDP- 
A205/07 H1/H2 AD TDP+ A141/07 H1/H1 AD TDP- 
A349/08 H1/H1 AD TDP+ A050/04 H1/H1 AD TDP- 
A348/07 H1/H1 AD TDP+ A058/07 H1/H1 AD TDP- 
A063/09 H1/H1 AD TDP+ A160/06 H1/H1 AD TDP- 
A076/09 H1/H1 AD TDP+ A187/07 H1/H1 AD TDP- 
A169/10 H1/H1 AD TDP+ A122/04 H2/H2 AD TDP- 
A114/10 H1/H1 AD TDP+ A065/04 H1/H1 AD TDP- 
 




Homozygosity for the tau H1haplotype has been shown to be associated with the 
increased risk of developing PSP and CBD. We tested tau haplotype for association 
with AD, by chi-square. No significant association was found for AD and presence 
of H1 alleles in this analysis.  
 
CONDITION %H1H1 %H1H2 %H2H2 
Control 64.3 28.6 7.1 
AD 69 27.6 3.4 
 
Table 3.4. Proportion of MAPT haplotype alleles.   
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3.14. Correlation tau RNA expression with haplotype 
Previous studies have suggested that the tau H1 haplotype expresses higher levels of 
MAPT mRNA transcripts than the H2 haplotype in brain and it was suggested that 
this increase in tau expression could explain the risk association between tauopathies 
and the H1 haplotype (Myers et al., 2007).  
 
A test for an association between MAPT haplotype and MAPT mRNA expression 
was performed with the qRT-PCR data used before from the total tau expression 
levels by disease category (Fig. 3.13). Relative CT values for AD and control groups 
were analysed, the FTDP-17 samples were excluded for this analysis. Because our 
sample size is small and the H2/H2 haplotype is quite rare, there were very few cases 
for this haplotype and therefore the H2/H2 homozygotes were combined with the 
H2/H1 homozygotes for the statistical analysis. A t-test was performed on relative 
CT values from the two haplotype groups for each brain region. No significant 
differences between tau haplotype and total tau expression were found for any brain 
region (Fig. 3.15). This analysis shows that no particular tau haplotype was 
associated with an increase in total tau expression, H1 homozygotes and 
heterozygotes were not significantly different compared to H2 homozygotes in all 





Figure 3.15. Association of MAPT expression with MAPT haplotype. 
Control and AD groups were combined and relative CT tau expression from the 
qRT-PCR experiment (Figure 3.13) was used for the association with tau haplotype.  
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Homozygosity of the H1allele may also be associated with increases tau 4R 
expression in brain (Caffrey et al., 2006). A test for association between MAPT 
haplotype and 4R/3R tau ratio in all five brain regions was performed using data 
from the MAPT splicing assays in five brain regions (Fig. 3.2 – 3.6).  Both AD and 
control groups were analysed and FTDP-17 and DM1 cases were excluded. As done 
previously, H2/H2 homozygotes were combined with H2/H1 heterozygotes for the 
statistical analysis. A t-test was performed on the data for each brain region, Fig 3.16 
shows a representative scatter graph of results from the hippocampus. No significant 
differences were found between H1 homozygotes vs combined H2 homozygotes and 




Figure 3.16. Tau 4R/3R ratio by tau haplotype from the hippocampus. 






3.15. Analysis of tau protein in Alzheimer’s disease affected brain 
TDP-43 plays a role in post-transcriptional processing of particular transcripts such 
as NEFL which is stabilised by TDP-43 binding to its 3’UTR (Strong et al., 2007). In 
addition, TDP-43 plays a role in the microRNA synthesis pathway and regulates 
expression of a number of miRNA species (Buratti et al., 2010). These finding 
suggest that TDP-43 mislocation into cytoplasmic aggregates may alter target 
transcript levels. In this section the first research question is does TDP-43 regulate 
post-transcriptional processing of tau transcripts? Quantification of MAPT exon 10 
expression at the RNA level showed a sub-group of AD cases with consistently high 
4R expression across all of the brain regions measured. The second question is: is 
there a the relationship between tau RNA expression and tau protein levels in control 
and AD brain? 
 
The same set of brain tissue samples that were used for RNA extraction and tau 
4R/3R analysis were used for protein analysis. The amygdala and hippocampus have 
previously been shown to be predominantly affected by TDP-43 pathology and 
contain the most severe aberrant TDP-43 immunoreactivity in AD brain (Arai et al., 
2009; Hu et al., 2008). All of our samples had abnormal TDP-43 immunoreactivity 
in the amygdala and therefore this region was chosen for the analysis of tau protein. 
 
The same set of AD, control and FTDP-17 samples that were used for RNA 
extraction and tau 4R/3R analysis were used for protein analysis. Samples were 
homogenised and subjected to a low speed centrifugation (12000 ×g) and the 
supernatant containing both soluble and insoluble tau (Greenberg and Davies, 1990) 
was collected. For the extraction of insoluble tau, 1% sarkosyl was added to 
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supernatant from the low speed centrifugation and then the samples were centrifuged 
at 100,000 ×g. The resulting pellet contains detergent insoluble tau and was 
solubilised with 8M guanidine.  
 
Isoforms of tau in brain exist in multiple phosphorylation states. Insoluble tau 
deposited in AD was found to differ from soluble tau by increased phosphorylation 
resulting in a reduction of the electrophoretic mobility of tau on western blots 
(Hanger et al., 1991). Lambda protein phosphatase is widely used for tau 
dephosphorylation in brain and releases phosphate groups from phosphorylated 
serine, tyrosine and threonine residues in protein. The low speed centrifugation 
fraction and guanidine solubilised tau were dephosphorylated with lambda 
phosphatase (Material and Methods).  
 
To test if the subgroup of high 4R tau expressors found at the RNA level were also 
found at the protein level, low speed centrifugation fraction from the amygdala were 
analysed by western blotting using a C-terminal antibody that recognises all isoforms 
of tau (DAKO). ADTDP-, ADTDP+, FTDP-17 and control brains were analysed. 






Figure 3.17. (and Figures 3.18 and 3.19) Tau protein isoform expression in the 
amygdala. 
0.2g of brain from the amygdala from each brain was homogenised. Samples were 
subjected to a low speed centrifugation and dephosphorylated with lambda 
phosphatase. 15µg of protein were separated on 10% (w/v) SDS-PAGE gels. 
Proteins were transferred to nitrocellulose membranes and incubated in C-terminal, 
isoform independent antibody (DAKO). The membrane was also incubated with 







Figures 3.18. and 3.19. See legend for Fig. 3.17 above. 
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Tau immunoreactivity was detected and quantified by using the Odyssey Infrared 
Imaging System and the Odyssey software. Each tau isoform was quantified, a 
4R/3R ratio was calculated and each data point was plotted against group (Fig. 3.20). 
A one-way ANOVA comparing 4R/3R ratio between control ADTDP-, ADTDP+ 
and FTDP-17 was performed on the data and was highly significant (p ≤ 0.0001). 
Group comparisons were analysed by t-tests.  
 
Similar to the results seen at the RNA level in the amygdala, two of the FTDP-17 
data points clearly show increased tau protein 4R/3R ratios, but a FTDP-17 case with 
a 4R/3R RNA ratio (sample A171/02) within the control range also has a control 
range protein 4R/3R ratio. The FTDP-17 brains had an average total tau protein 
4R/3R ratio of 1.3 (when all three 4R/3R ratios were included) compared to control 
4R/3R ratio average of 0.7. The ADTDP- group had a 4R/3R ratio average for total 
tau protein of 0.62 and the ADTDP+ 4R/3R ratio average was 0.66. A t-test analysis 
showed that the 4R/3R tau protein ratio from control samples and both AD groups 
were not significantly different. There were no differences in total tau protein 4R/3R 
ratios between ADTDP- and ADTDP+ groups. 
 
These results show that control and AD group brains do not show differences in 
4R/3R tau protein ratios. This suggests that altered TDP-43 post-transcriptional 




Figure 3.20. Tau 4R/3R ratio in low speed centrifugation fraction from the 
amygdala. 
Tau 4R and 3R bands were quantified and normalised to GAPDH from western blots 
(Figures 3.16, 3.17 and 3.18). A 4R/3R tau protein ratio was calculated and plotted 




3.16. Tau protein and RNA 4R/3R correlation 
A sub-group of AD cases showed increases of 4R tau transcripts compared to 
control, there were however, no differences found in tau 4R/3R ratios in the AD 
group compared to control at the protein level. 
 
Altered tau 4R/3R ratios have been shown at the protein level in various tauopathies 
(for reviews and references therein see (Ballatore et al., 2007; Hernández and Avila, 
2007)) but few studies have correlated MAPT RNA and protein levels in disease 
(Luk et al., 2010). In order to determine the relationship between MAPT RNA and 























Control AD TDP+ AD TDP- FTDP-17
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on 4R/3R ratio data from RNA and protein measures from the amygdala. The 
correlation analysis was performed for control samples and a separate analysis for 
the combined AD groups. No significant correlation between tau protein from the 
low speed centrifugation and tau RNA was found in the combined AD groups or 
controls in our samples from the amygdala. A trend line in the combined AD groups 
shows that there is a broad relationship between increasing gene expression and 
increasing protein levels, whereas the trendline in controls suggests a decreasing or 





Figure 3.21. Tau protein RNA 4R/3R ratio correlation in AD and control brain. 
Tau RNA 4R/3R data for the amygdala was correlated with low speed fraction tau 
protein 4R/3R ratio data in control brains (n = 12) and combined AD brains (n = 18). 




3.17. Insoluble tau in control, AD and FTDP-17 brain 
PHFs found in NFTs and neuritic plaques are composed of detergent-insoluble 
highly phosphorylated tau. Insoluble tau extracted and dephosphorylated from 
tauopathy brains show distinctive patterns characteristic of each tauopathy. For 
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example dephosphorylated insoluble tau from AD brains show all six tau isoforms 
(Hanger et al., 2002; Umeda et al., 2004) and CBD and PSP brains show a 
predominance of 4R over 3R (de Silva et al., 2003; Hanger et al., 2002; Liu et al., 
2001; Takahashi et al., 2002).  
 
In the previous section, 4R/3R protein ratios from the low speed fraction were not 
increased in AD brains compared to control and the total tau protein 4R/3R ratio did 
not correlate with RNA 4R/3R ratio in control or AD brains in the amygdala. The 
research question is firstly does TDP-43 misregulation alter tau insoluble tau ratios 
and secondly what is the relationship between tau 4R/3R insoluble protein and 







Figure 3.22. (and Figures 3.23 and 3.24) Isoform composition of insoluble tau 
extracted the amygdala. 
To enrich the PHF content, supernatants from the low speed centrifugation were 
treated with 1% (v/v) sarkosyl and subjected to high speed centrifugation. The 
resulting pellet was washed with 1% (v/v) sarkosyl and denatured with 8M 
guanidine. Insoluble tau in guanidine was dialysed and dephsphorylated with lambda 
phosphatase. Proteins were separated on 10% (w/v) SDS PAGE and transferred to 





Figure 3.23. See the legend for Fig. 3.22 
 
 
Figure 3.24. See the legend for Fig. 3.22. 
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Figure 3.25. Tau 4R/3R ratio from sarkosyl insoluble fraction in the amygdala. 
Insoluble tau 4R/3R ratios from AD TDP- (n = 11) and AD TDP+ (n = 9) were 
calculated from western blots (figures 3.22, 3.23 and 3.24) and plotted. A t-test 





Insoluble tau was isolated from control and AD brains from the amygdala using a 
previously published protocol with some modifications (Liu et al., 2001), as detailed 
in Materials and Methods. 4R and 3R tau isoforms were quantified in control, FTDP-
17, ADTDP- and ADTDP+ brain samples and 4R/3R tau ratios were calculated.  
 
Normally a 4R/3R ratio of case versus control is reported, however in this analysis 
control insoluble tau 4R/3R ratio is not a meaningful comparator because insoluble 
tau in control brain is extremely variable with none in some cases and very high 
4R/3R ratios in others. The control samples that had sarkosyl insoluble tau staining 
(A063/10, A057/10, A310/09, A065/11 in Figure 3.22 and A123/09 in Figure 3.23) 
shows that these brains had NFT pathology in the amygdala and this was confirmed 













pathology present in the amygdala and hippocampus corresponding to normal aging 
Braak stage 2. 
 
The sarkosyl insoluble 4R/3R average for ADTDP- brains was 0.75 and the 
ADTDP+ average was 0.71. A t-test performed on the data showed there were no 
differences in 4R/3R sarkosyl insoluble tau ratios between the AD brains measured 
(Figure 3.23).  
 
Two FTDP-17 samples had measurable sarkosyl insoluble tau 4R/3R ratios samples 
A171/02, (Figure 3.22) and A174/99 (Figure 3.24), sample A074/00 had tau protein 
concentration too low to detect (Figure 3.23). Sample A171/02 was the FTLD-17 
brain that had a control range 4R/3R ratio at the RNA level and in the low speed 
centrifugation protein sample. This sample had a tau sarkosyl insoluble 4R/3R ratio 
of 1.17. The other FTDP-17 sample, A174/99, had a tau sarkosyl insoluble tau 
4R/3R ratio of 16.9.  
 
In section 3.19, a semi-quantitative immunohistological analysis of tau pathology 
from these brains is presented. The control brains that show the presence of sarkosyl 
insoluble tau in the amygdala by western blotting, also show tau pathology positive 
scores in the immunohistology analysis and the correlation between these two 




3.18. Sarkosyl insoluble tau and RNA 4R/3R correlation 
Tau RNA 4R/3R ratios from the amygdala were correlated with sarkosyl insoluble 
tau protein 4R/3R from the amygdala to test if expression of 4R tau RNA isoforms 
in AD brains have a relationship with deposition of 4R tau protein into pathological 
inclusions. Since no differences were found in sarkosyl insoluble tau 4R/3R ratios 
between ADTDP- and ADTDP+ brains, these groups were combined. A significant 
positive correlation was found between 4R/3R insoluble tau ratio and 4R/3R RNA 
tau ratio (p = 0.003; n = 20) showing that increases in 4R/3R RNA ratio are 
associated with increases in insoluble tau 4R/3R ratio (Figure 3.26). These results 
suggest that the subgroup of high 4R RNA expressors also show high insoluble tau 
suggesting that in a subset of AD brains, increases in 4R RNA translate into 
increases of 4R tau protein sequestered into insoluble tau deposits in the amygdala.  
 
 




3.19. Immunohistochemical analysis of tau pathology in AD brains 
The hippocampus and entorhinal cortex are brain regions that are vulnerable to tau 
pathology in AD brain and usually show very high TDP inclusion counts in TDP-43 
positive AD brains (Hu et al., 2008). This is a different TDP-43 inclusion 
distribution to that generally seen in FTLD and ALS (Arai et al., 2009; Higashi et al., 
2007; Hu et al., 2008; King et al., 2010; Lippa et al., 2009). The distribution of TDP-
43 pathology in FTLD is predominantly in the frontal and temporal cortices while 
ALS shows TDP-43 inclusions predominantly in lower motor neuron nuclei and 
spinal cord (Geser et al., 2009b). It has been suggested that TDP-43 pathology in AD 
progresses from limbic regions into the temporal and frontal cortex at later stages of 
the disease (Higashi et al., 2007; Hu et al., 2008; King et al., 2010), although some 
cases have very severe frontal and little limbic TDP pathology (Kadokura et al., 
2009).  
 
At present the relationship between tau and TDP-43 pathologies is not clear.  
Since tau pathology appears to start in the entorhinal cortex and progresses to the 
hippocampus via synaptic connections, it may be that these neurons which are 
selectively vulnerable to tau pathology trigger TDP-43 pathology in a sub-group of 
TDP positive AD brains. This raises the question: do a sub-group of TDP positive 
AD brains have a pattern of tau pathology that is different to that in ADTDP 
negative brains? 
 
The cases we had previously analysed for tau splicing and protein 4R/3R ratios were 
assessed for severity of tau pathology by examining brain sections on slides that had 
previously been prepared for routine diagnostic examination. The presence and 
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extent of tau AT8 immunoreactivity was semi-quantitiatively measured on all brain 
sections that were available. AT8 recognises a phospho-epitope at serine 202 and 
threonine 205 which are specifically phosphorylated in late stage NFTs 
(Augustinack et al., 2002). AT8 immunoreactivity in control and AD cases was 
measured in frontal, temporal, amygdala and hippocampus with a semi-quantitative 
scale of 0-3 with 0 = no pathology, 1 = rare or mild, 2 = moderate, 3 = severe (Table 
3.5). Tau pathology types included tangles, threads, neurites, neuritic plaques and 
glial inclusions and a global AT8 immunoreactivity score (overall tau). A scoring of 
the amount of neuronal loss by hematoxylin and eosin stain (H&E) occurring 
predominantly in cortical layers 3 and 5 was also assessed. On the same set of slides, 
TDP-43 pathology status was confirmed. For this purpose, brain sections were 
stained with a phospho-TDP-43 serines 409/410 antibody that specifically detects 
ubiquitin-positive TDP-43 in inclusions and does not detect non-aggregated nuclear 
TDP-43. 
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Control 0 10 13 13 13 13 13 13 
Control 1 2 0 0 0 0 0 0 
Control 2 1 0 0 0 0 0 0 
Control 3 0 0 0 0 0 0 0 
Totals 13 13 13 13 13 13 13 
AD+ 0 0 0 0 0 0 0 2 
AD+ 1 3 0 0 0 0 0 8 
AD+ 2 6 0 1 1 7 4 0 
AD+ 3 2 11 10 10 4 7 0 
Totals 11 11 11 11 11 11 10 
AD- 0 2 0 0 0 0 1 5 
AD- 1 7 3 3 4 4 7 8 
AD- 2 5 7 4 6 8 3 0 
AD- 3 0 4 7 3 1 3 0 
Totals 14 14 14 13 13 14 13 
 


















Control 0 11 12 13 13 13 13 13 
Control 1 1 1 0 0 0 0 0 
Control 2 1 0 0 0 0 0 0 
Control 3 0 0 0 0 0 0 0 
Totals 13 13 13 13 13 13 13 
AD+ 0 0 0 0 0 0 0 0 
AD+ 1 1 0 0 0 0 0 11 
AD+ 2 5 0 2 0 2 1 0 
AD+ 3 5 11 9 11 9 10 0 
Totals 11 11 11 11 11 11 11 
AD- 0 0 0 0 0 0 0 2 
AD- 1 4 1 0 1 0 2 12 
AD- 2 4 6 4 5 8 5 0 
AD- 3 6 7 10 8 6 7 0 
Totals 14 14 14 14 14 14 14 
 


















Control 0 5 4 3 3 4 10 12 
Control 1 6 4 6 4 8 2 0 
Control 2 1 4 3 5 0 0 0 
Control 3 0 0 0 0 0 0 0 
Totals 12 12 12 12 12 12 12 
AD+ 0 0 0 0 0 0 0 2 
AD+ 1 0 0 0 0 1 2 7 
AD+ 2 7 0 1 0 3 4 1 
AD+ 3 4 11 10 11 7 5 0 
Totals 11 11 11 11 11 11 10 
AD- 0 0 0 0 0 0 0 2 
AD- 1 3 0 1 0 2 4 5 
AD- 2 1 3 2 1 2 0 1 
AD- 3 4 5 5 7 4 4 0 
Totals 8 8 8 8 8 8 8 
 



















Control 0 5 3 3 4 4 12 12 
Control 1 5 4 4 3 5 1 1 
Control 2 3 3 1 2 4 0 0 
Control 3 0 3 5 4 0 0 0 
Totals 13 13 13 13 13 13 13 
AD+ 0 0 0 0 0 0 0 0 
AD+ 1 0 0 0 0 0 1 10 
AD+ 2 1 0 0 0 1 4 0 
AD+ 3 10 11 11 11 10 6 0 
Totals 11 11 11 11 11 11 10 
AD- 0 0 0 0 0 0 2 2 
AD- 1 0 0 0 1 0 6 12 
AD- 2 1 2 0 5 6 4 0 
AD- 3 13 12 14 8 8 2 0 
Totals 14 14 14 14 14 14 14 
 
Table 3.5. Frequencies of semi-quantitative scores of tau AT8 immunoreactivity in ADTDP+, ADTDP- and control brains.
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Differences in the severity of tau pathology between the ADTDP+ and ADTDP- 
groups were tested with Mann Whitney-U non- parametric tests. In this analysis 
(summarised in Table 3.5), ADTDP+ brains had significantly higher tau AT8 
immunoreactivity in overall tau, threads, neurites and neuritic plaques compared to 
ADTDP- brains in the frontal cortex. ADTDP+ brains also had significantly higher 
neuronal loss compared to ADTDP- brains in the frontal cortex. In the temporal 
cortex, ADTDP+ brains had higher tau immunoreactivity in overall tau compared to 
ADTDP- brains, with only borderline differences in threads and plaques. ADTDP+ 
brains had significantly higher neuritic plaque immunoreactivity compared to 
ADTDP- brains in the hippocampus and only borderline differences in threads. This 
analysis suggests that the severity of tau pathology, at least in the frontal and temoparl 
cortices of ADTDP+ brains, is significantly higher than that in ADTDP- brains. 
Because the tau count data is semi-quantitative, this analysis probably has significant 
ceiling effects and may well underestimate the comparative levels of tau 
immunoreactivity seen in some brains and hence the differences between the two AD 
groups may actually be higher in some of the brain regions. Since the prevalence of 
TDP-43 pathology may be associated with increased age, a t-test for age and AD 
group was performed and was not significant. This sample set is fairly small and may 
be underpowered to detect any differences (for information regarding age, post-








AD+ AD- FRONTAL TEMPORAL AMYGDALA HIPPOCAMPUS 
Neuronal loss 0.044* 0.609 0.717 0.936 
Overall tau 0.002* 0.033* 0.177 0.574 
Tangles     0.244 0.687 0.31 0.999 
Threads 0.002* 0.075 0.657 0.075 
Neurites 0.047* 0.107 0.545 0.166 
Plaques 0.006* 0.075 0.657 0.011* 
Glial 0.483  0.572 0.965 0.585 
 
Table 3.6. Table of p values for semi-quantitative scoring of ADTDP+ and 
ADTDP-brain sections. 
 
Tested with Mann Whitney-U. p values with * are significant. 
 
 
3.20. Regression analysis of tau sarkosyl insoluble 4R/3R ratio and semi-quantitative 
tau pathology 
Previously a correlation between sarkosyl-insoluble tau 4R/3R ratios and tau RNA 
4R/3R ratio was demonstrated (Figure 3.26). Linear regression was used to test if the 
tau sarkosyl insoluble 4R/3R ratio was an accurate predictor of tau immunoreactivity 
score for all of the semi-quantitative tau measurements in the amygdala. For this 
analysis the lowest score category was considered as the baseline (where there were 
low frequencies in a category, it was combined with an adjacent category). None of 
the 4R/3R ratios in sarkosyl insoluble predicted tau immunoreactivity count material 
for any tau parameter. Linear regression was used to test if the 4R/3R ratios from low 
speed total tau protein were predictors of tau immunoreactivity score and we found no 
evidence that tau scores were associated with total tau protein levels. 
 
3.21.Summary 
In this section we found altered splicing levels of exon 10 in a subset of AD cases. 
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- Tau 4R/3R RNA ratios in the frontal cortex, amygdala, hippocampus and cerebellum 
were significantly increased in AD brains compared to control. A subset of ~5 AD 
cases showed consistently high tau 4R transcript expression across all brain regions 
tested. 
- Tau 4R/3R RNA expression was significantly associated with 4R/3R tau ratio from 
insoluble material in the amygdala. This shows that the subgroup of high 4R transcript 
expressors also have high levels of 4R tau in insoluble deposits. 
- The increases in 4R transcript expression in the subgroup of AD cases were not due 
to misregulation by TDP-43 or tau haplotype. The subset of high 4R transcript 
expressors were from both ADTDP- and ADTDP+ groups and no significant 
differences were found between the AD groups for tau 4R/3R ratios. H1 homozygotes 
showed tau 4R/3R ratios not significantly different from a combined group of H2 
homogygotes and H1/H2 heterozygotes. 
- There were no significant differences in total tau RNA expression between ADTDP-
, ADTDP+ and control groups in any brain region. In addition, H1 homozygotes 
showed no significant differences in total tau expression compared to a combined 
group of H2 homogygotes and H1/H2 heterozygotes.  
- In AD brains with aberrant TDP-43 immunoreactivity there was greater severity of 










4R/3R RATIO CONTROL ADTDP- ADTDP+ FTDP-17 DM1 
Frontal 0.71 (0.19) 0.87* (0.18) 1.0*  (0.29) 2.8*  (0.28) 0.73 
Temporal 0.9 (0.24) 1.1  (0.44)  1.1  (0.38) 3.2*  (0.38) 0.69 
Amygdala 1.1 (0.42) 1.5*  (0.58) 1.5*  (0.51) 4.0*  (2.7) 0.86 
Hippocampus 0.9 (0.24) 1.3*  (0.35) 1.4*  (0.55) 4.2*  (0.39) 1.4 
Cerebellum 1.2 (0.38) 1.8*  (0.59) 1.8*  (0.57) 3.9*  (1.8) 1.9 
 
Table 3.7. 4R/3R ratio in disease groups and control. 
Values with * indicate significant increases in 4R tau compared to control. Numbers 

















Chapter 4: APP expression and splicing in affected brain 
regions in Alzheimer’s disease. 
 
 
There are three main isoforms of APP expressed in the CNS derived from the 
alternative splicing of exons 7 and 8. APP770 contains both exons 7 and 8, APP751 
contains exon 7 and APP695 contains neither exon 7 nor 8. The APP695 isoform is 
the major neuronal species. The APP770 and APP751 isoforms contain a Kunitz 
family of protease inhibitors domain (KPI) domain in exon 7 and increased levels of 
KPI containing APP RNA isoforms have been found in AD brains and suggest that 
mis-regulation of alternative splicing of APP may contribute to AD.  
 
Mis-regulation of TDP-43 in TDP-proteinopathies may alter levels and/or splicing 
either directly for specific TDP-43 targets or indirectly by altering levels and/or 
splicing of multiple RBP and transcription factors. RT-PCR was performed in control, 
ADTDP- and ADTDP+ human brain samples from five brain regions with primers 
spanning APP exons 7 and 8 in order to test an association between misregulation of 
TDP-43 and altered splicing of APP. An IR-labelled forward primer was used in this 
analysis to improve the accuracy of quantification.  
 
Trisomy of the chromosome 21 where APP is located results in DS and AD pathology 
and suggests that increased levels of APP expression are associated with AD 
pathology. Levels of total APP RNA expression in five brain regions were quantified 
by qRT-PCR. 
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In order to determine if changes in alternative splicing in tau correlate with alternative 
splicing in APP a correlation between APP exons 7 and 8 and tau exon 10 expression 
in AD and control brains was performed.  
 
4.1. Determination of PCR cycling parameters for APP primers in human brain 
For the detection of APP isoforms arising from alternative splicing of exons 7 and 8, a 
APP primer pair from previously published work was used (Golde et al., 1990). The 
forward primer binds a sequence on exon 6 and the reverse primer binds to a sequence 
on exon 9. cDNA from human frontal cortex and HeLa cells were amplified with the 
APP 6-9 primer pair. PCR products were run on 1.5% agarose gels and three PCR 
products were detected and sequenced. The 313 bp product contains exons 7 and 8 
and corresponds to APP770, the 256bp product has only exon 7 and corresponds to 
APP751 and the 88bp product has neither exons 7 or 8 and corresponds to APP695 
(Figure 4.1). A DY 682 tag was added to the 5’ end of the forward primer to improve 
the accuracy of quantification. The linear range of the APP 6-9 primer pair was 





Figure 4.1. Determination of APP primer linear phase. A. IR- labelled APP 
primers were tested with cDNA from human brain and HeLa cells. PCR products of 
88bp correspond to APP695, products of 256bp correspond to APP751 and products 
of 313 bp correspond to APP770. B. cDNA from quadruplicate samples were 
analysed by PCR at different number of cycles (25, 30, 35, 40) and PCR products 





4.2. APP isoform expression in frontal cortex 
cDNA from control, ADTDP- and ADTDP+ brain samples from the five brain 
regions (frontal and temporal cortex, amygdala, hippocampus and cerebellum) used 
for the tau splicing analysis were also used for APP splicing analysis. RNA extracted 
from all brain samples had previously been tested for a RIN above 3.6. cDNA from 
frontal cortex was amplified with the IR-labelled forward APP 6-9 primers and PCR 
products were run on 1.5% agarose gels. Three APP PCR products corresponding to 
APP695, APP751 and APP770 were quantified and percentage of each isoform was 
calculated (Figure 4.2).  
 
In the frontal cortex the proportion of APP695 was around 60% for all conditions 
(Table 4.1). APP751 accounted for around 30% of total APP expression and APP770 
was around 10% in all conditions. Statistical analysis was carried out by t-test 
comparing the percentage of each APP isoform by disease condition (control, 
ADTDP- and ADTDP+). No significant differences in expression for any of the APP 
isoforms was found in the frontal cortex.  
 
FRONTAL AVE% 
695 751 770 
Control 56.2 33.4 10.4 
ADTDP- 60.5 28.9 10.6 
ADTDP+ 56.3 30.8 12.9 
 
Table 4.1. Percent average of APP isoforms in the frontal cortex 
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Figure 4.2. APP isoform expression in frontal cortex. 
A.APP isoform ratios were assayed by RT-PCR with IR-labelled forward primer pair. 
B. Mean percentages for each APP isoform was calculated for each group ± SEM. 
Significance was set at p = 0.05. Significant differences shown in this graph are all 





4.3. APP isoform expression in the temporal cortex 
In the temporal cortex, cDNA was analysed with the IR labelled forward APP 6-9 
primers and PCR products were run on 1.5% agarose gels. Each APP isoform was 
quantified and a percent expression calculated (Figure 4.3 and Table 4.2). The 
proportions of APP isoform expression in the control temporal cortex were slightly 
different from that in the frontal cortex with the average percent APP 751 remaining 
at around 30% however there was an increase in APP770 to around 14% and a 
decrease in APP 695 to around 55% (Table 4.2).  
 
In the ADTDP+ brains the APP695 percent proportion was reduced significantly 
compared to controls and there was a corresponding significant increase in APP751  
compared to control (p = 0.012 and p = 0.001, respectively). In the ADTDP- brains 
there was a significant increase in APP751 isoforms compared to control (p = 0.015), 
and there was a trend for a decrease in APP695 however this was not significant. 
There were no differences between the two AD groups for any of the APP isoforms. 
 
TEMPORAL AVE% 
695 751 770 
Control 54.7 31 14.3 
ADTDP- 46.7 38.3* 15 
ADTDP+ 41.4* 42.4* 16.2 
 
Table 4.2. Percent average APP isoforms in the temporal cortex. 





Figure 4.3. APP isoform expression in human temporal cortex. 
A.APP isoform ratios were assayed by RT-PCR with IR-labelled forward primer pair. 
B. Mean percentages for each APP isoform was calculated for each group ± SEM. 
Significance was set at p = 0.05. Significant differences shown in this graph are all 





4.4. APP isoform expression in the amygdala 
In the amygdala control brains show expression of the APP770 isoform at a much 
higher proportion compared to frontal cortex (15% in the amygdala compared to 10% 
in the frontal cortex). In addition APP695 only contributes around 41% as a 
proportion of total while the APP751 isoform is around 43% (Table 4.3). 
  
In the ADTDP- brains there was a significant decrease in APP695 (p = 0.044) and a 
significant increase in APP751 in the (p = 0.05) compared to control. Even though 
there was an increase in the APP770 isoform expression in both ADTDP- and 
ADTDP+ brains this trend was not significant. For the ADTDP+ samples there was a 
trend for a decrease in APP695 and a trend for an increase in KPI containing APP 
isoforms however these differences were all not significant compared to control. 
There was also a borderline significant difference in APP751 expression between the 
ADTDP+ and ADTDP- brains (p = 0.038). 
 
AMYGDALA AVE% 
695 751 770 
Control 41.4 43.6 15 
ADTDP- 33.5* 49.4* 17.1 
ADTDP+ 39 43.1 17.9 
 
Table 4.3. Percent average APP isoforms in the amygdala. 




Figure 4.4. APP isoform expression in the human amygdala. 
A.APP isoform ratios were assayed by RT-PCR with IR-labelled forward primer pair. 
B. Mean percentages for each APP isoform was calculated for each group ± SEM. 
Significance was set at p = 0.05. Significant differences shown in this graph are all 






4.5. APP isoform expression in the hippocampus 
In control brains the proportions of APP695 isoform expression was around 50% 
while APP751 was around 37 percent and APP770 13% (Table 4.4). 
 
Both ADTDP+ and ADTDP- brains showed significant decreases in APP 695 
compared to controls (p = 0.035 and p = 0.005 respectively) and significant increases 
in APP751 compared to controls (p = 0.024 and p = 0.021 respectively) in the 
hippocampus. The decrease in APP695 isoform expression is clearly visible in the AD 
group brains (Figure 4.5) compared to control brains. APP770 was also significantly 
increased in ADTDP- brains compared to control (p = 0.016) and there was a trend 
for increased APP770 expression in ADTDP+ brains that was not significant. There 
were no differences between AD groups in any APP isoform expression. 
 
HIPPOCAMPUS AVE% 
695 751 770 
Control 49.2 37.6 13.2 
ADTDP- 35.8* 46* 18.2* 
ADTDP+ 38* 46.5* 15* 
 
Table 4.4. Percent average APP isoforms in the hippocampus. 





Figure 4.5. APP isoform expression in the human hippocampus. 
A.APP isoform ratios were assayed by RT-PCR with IR-labelled forward primer pair. 
B. Mean percentages for each APP isoform was calculated for each group ± SEM. 
Significance was set at p = 0.05. Significant differences shown in this graph are all 





4.6. APP isoform expression in the cerebellum 
cDNA from the cerebellum was amplified with the IR labelled forward APP 6-9 
primers and PCR products were run on 1.5% agarose gels. A very different APP 
isoform expression proportion is found in the control cerebellum. APP695 comprises 
around 81% of the total APP751 around 12% and APP770 only 6.5% (Table 4.4). 
No significant differences were found in the cerebellum for any APP isoform. 
 
CEREBELLUM AVE% 
695 751 770 
Control 81.2 12.3 6.5 
ADTDP- 80.4 13.6 6 
ADTDP+ 80.8 14.9 4.3 
 
Table 4.5. Percent average APP isoforms in the cerebellum. 





Figure 4.6. APP isoform expression in the human cerebellum. 
A.APP isoform ratios were assayed by RT-PCR with IR-labelled forward primer pair. 
B. Mean percentages for each APP isoform was calculated for each group ± SEM. 
Significance was set at p = 0.05. Significant differences shown in this graph are all 





4.7. APP and tau splicing correlation 
A correlation analysis was performed to examine the relationship between tau 4R/3R 
RNA ratio and APP RNA isoform expression. Separate correlation analyses of control 
and AD brain were carried out between percent expression of each of the APP 
isoforms with percent expression of tau exon 10 in five brain regions. 
 
Differences in APP751 isoform between ADTDP- and ADTDP+ in the amygdala 
were only marginally significant and were no significant differences in tau 4R 
transcript expression in any brain region and therefore the two AD groups (ADTDP- 
and ADTDP+) were combined for the correlation analysis. Correlation analysis was 
carried out in all brain regions for control brains and there were no significant 
correlation found in any brain region (Figure 4.7 and 4.8). For the AD samples, 
significant correlations were found in the amygdala and hippocampus. In the 
combined AD group, percent APP751 expression showed a significant positive 
correlation with percent tau 4R expression in the amygdala (Figure 4.7 and Table 4.1) 
and hippocampus (Figure 4.8 and Table 4.1). APP770 showed a significant positive 
correlation with percent tau 4R expression in the amygdala and a trend for a positive 
association that was not significant in the hippocampus. APP695 expression showed a 
highly significant negative association with tau exon 10 expression in the amygdala 
and hippocampus. 
 
In AD samples from the temporal cortex, APP751 and APP770 isoforms showed a 
trend toward positive association with tau exon 10 and APP695 showed a trend 
toward negative association with tau exon 10 in line with results from the amygdala 
and hippocampus however these result were not significant (Table 4.1). 
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The analysis shows that in the amygdala and hippocampus of AD brains, high 4R tau 
expression is related to high APP751 and APP770 expression and low APP695 
expression and this relationship is specific to AD brains because no significant 




Figure 4.7. APP 770, 751 and 695 are highly correlated with tau 4R expression in 














Figure 4.8. APP 751 and APP 695 expression are correlated with 4R tau 










REGION AD CASES CORRELATION COEFFICIENTS 
Amygdala 
Percent APP770  
r = 0.622 
p = 0.0015** 
n = 23 
Percent APP751 
r = 0.6413 
p = 0.001** 
n = 23 
Percent APP695 
r = -0.7954 
p < 0.00001*** 
n = 23 
Hippocampus 
Percent APP770  
r = 0.2297 
p = 0.2802 
n = 24 
Percent APP751 
r = 0.4791 
p = 0.0179* 
n = 24 
Percent APP695 
r = -0.437 
p = 0.0327* 
n = 24 
Temporal 
Percent APP770  
r = 0.3622 
p = 0.082 
n = 24 
Percent APP751 
r = 0.3084 
p = 0.1426 
n = 24 
Percent APP695 
r = -0.3732 
p = 0.0725 
n = 24 
 
Table 4.1. Correlation coefficients and P values for correlation of percentage 
APP isoforms and percentage tau 4R in the amygdala, hippocampus and 
temporal cortex in AD brains. 
 
 
4.8. Total APP mRNA expression  
Total RNA levels of APP were measured by qRT-PCR. Samples were run in duplicate 
and the average cycle threshold (CT) was calculated for target and two reference 
genes. The average CT for target samples was divided by the geometric mean of the 
two reference genes and each point plotted giving a target gene expression relative to 
reference gene expression (Figure 4.9). There were no significant differences in APP 
expression by one way ANOVA in disease groups compared to controls in any brain 
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region. There were also no differences in ADTDP+ compared to ADTDP- groups by 





Figure 4.9. Total APP mRNA expression in AD and control brain. 
RNA was isolated from post-mortem brain tissue and reverse transcribed. 20ng/µl of 
cDNA was used for qRTPCR analysis in duplicate. Each data point represents one 
sample, relative CT was calculated by dividing target CT by the geometric mean of 
the two reference genes. 
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4.9. Summary 
The overall consistent finding in the splicing analysis is that APP751 was 
significantly increased in the temporal cortex, amygdala and hippocampus in 
ADTDP- and ADTDP+ brains compared to control (with only a trend in the amygdala 
of ADTDP+ brains). APP695  was significantly reduced or showed a trend for being 
reduced in the temporal cortex, amygdala and hippocampus in ADTDP- and 
ADTDP+ brains compared to control. In the hippocampus APP770 was significantly 
increased compared to control. This analysis showed no trend in APP splicing 
changes due to the presence or absence of TDP-43 inclusions. Other studies have 
shown APPKPI containing transcripts are increased in AD and the results from our 
splicing analysis of APP isoforms in AD and control samples were consistent with 
these previous findings. 
 
Correlation of tau exon 10 expression with each APP isoform expression was carried 
out in control brains and combined AD group brains in five brain regions. For the AD 
brains, the amygdala and hippocampus showed highly significant positive correlations 
between APP751 and APP770 and 4R tau RNA expression (in the hippocampus 
APP770 showed a trend with tau 4R RNA expression). Both the amygdala and 
hippocampus showed highly significant negative correlation between APP695 and 4R 
tau RNA expression. In control brains no significant correlation between tau isoform 
expression and APP isoform expression was found in any brain region. 
 
There were no differences in total APP RNA expression between control and AD 
brains. No differences in total APP expression was found between ADTDP- and 
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ADTDP+ brains and suggests that TDP-43 mis-regulation is has no effect on APP 

























Chapter Five: 3’UTR splicing of TDP-43 in brain regions 
affected in Alzheimer’s disease 
 
Examination of the human genomic TARDBP sequence shows that there are four 
potential polyadenylation sites (PAS), defined by a (A)AATAAA(A) sequence in the 
3’UTR of TDP-43. In HEK 293 cells, two major isoforms of TDP-43 are detected by 
northern blotting, V1pA1 which utilises the first PAS (pA1) and V1pA4 which 
utilises the fourth PAS (pA4) (Ayala et al., 2011). The pA1 isoform is three times 
more abundant in HEK 293 cells compared to the pA4 isoform (Ayala et al., 2011). 
Nothing has been demonstrated regarding utilisation of PAS three (pA3) however 
there is 100% homology of PAS one, two and four with the mouse TDP-43 genomic 
sequence and in mice, pA3 is not present. 
 
Autoregulation by coupling nonsense mediated decay (NMD) with alternative 
splicing (AS) has been demonstrated for many RNA binding proteins (RBP) and is a 
ubiquitous mechanism for maintaining constant levels of RBP inside cells. In HEK 
293 cells, TDP-43 autoregulates through two different mechanisms and both involve 
TDP-43 protein binding to a TDP-43 binding region (TDPBR) in the 3’UTR of the 
TDP-43 transcript. The first mechanism involves the splicing of two cryptic introns, 
one in TDP-43 exon 6 (intron 6 is spliced out in this transcript), and one in the 3’UTR 
(intron 7 is spliced out), result in NMD of these transcripts. This TDP-43 isoform is 
called V2 and is expressed at a low level, at least in HEK 293 cells (Introduction and 
Figure 1.3).  
 
A novel second mechanism for TDP-43 autoregulation has been demonstrated, also in 
HEK 293 cells, where TDP-43 transcripts that have only intron 7 spliced out are 
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retained in the nucleus and thus are not available for translation (Avendaño-Vázquez 
et al., 2012). Splicing of intron 7 in the 3’UTR removes pA1 and therefore these 
transcripts utilise the non-optimal second PAS (pA2) and are called isoform pA2. 
(Avendaño-Vázquez et al., 2012). To our knowledge no study has yet determined if 
the same autoregulatory splicing demonstrated in HEK 293 cells also occurs in human 
brain. Human TARDBP EST in the Ensembl data base show a sequence that 
corresponds to the V2 isoform. There are three other transcripts are described as being 
subject to NMD however no EST exists for the pA2 isoform. This may be due to 
incomplete transcript sequences of all TDP-43 transcripts that occur in brain tissue. 
 
Misregulation of TDP-43 by sequestration into cytoplasmic inclusions may alter auto-
regulatory RNA processing of TDP-43 transcripts. In support of this, Mishra et al. 
(2007) quantify RNA levels in FTLD-TDP-43 and MND human brain samples with 
microarrays and found TDP-43 RNA levels are 1.5 fold increased compared to 
control. The question this section answers, is TDP-43 3’UTR splicing altered in TDP-
43 proteinopathies? 
 
5.1. Determination of the PCR cycling conditions for the TDP-43 pA2 splice isoform 
PCR primers were designed to amplify a region of cDNA spanning the second splice 
site (intron 7) in the 3’UTR of TDP-43. For accurate quantification of molar ratios of 
PCR product the forward primer had a DY682 label attached to the 5’ end. cDNA 
from human brain was analysed with the IR labelled forward primer and the resulting 
PCR products were sequenced (Figure 5.1). PCR products of 1176 bp (3’UTR) 
corresponds to a full length TDP 3’UTR utilising the fourth polyadenylation site 
(pA4). The database sequence (NCBI and Ensembl) predicts a PCR product of 1206 
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bp however our sequenced PCR product did not include a 30 bp sequence found 
within the published sequence. There may be sequence discrepancy between the 
published sequenced and what occurs in neuronal transcripts. Alternatively, secondary 
DNA structure may result in the polymerase skipping over this sequence. The 472bp 
product (TDP pA2) is the intron 7 spliced 3’UTR of TDP-43. A smaller product (**) 
is a mis-primed product where the forward primer binds to a sequence present within 
intron 7. These primers specifically exclude detection of the V2 isoform because the 
forward primer binds to a 3’UTR sequence that is spliced in the V2 isoform. cDNA 
was amplified with the TDP3’UTR with a labelled forward primer with a different 
number cycles. TDP-43 3’UTR and pA2 arbitrary fluorescent units for quadruplicate 
samples were measured by Odyssey software. Fluorescent units were plotted against 
cycle number and the linear range of the PCR amplification curve was determined for 
the TDP 3’UTR primer pair (Figure 5.1). The number of cycles used in the final 








Figure 5.1. Determination of TDP-43 3’UTR primer linear phase. IR- labelled 
TDP-43 3’UTR primers were tested with cDNA from human brain. cDNA from 
quadruplicate samples were analysed by PCR at different cycles (25, 30, 35, 40) and 
PCR products were quantified and plotted to determine linear and plateau stages. The 
number of cycles finally used for quantification was 31 cycles. 
 
 
5.2. The TDP pA2 transcript is not degraded by NMD in SH-SY5Y cells. 
Autoregulation of RBP commonly occurs through coupling alternative splicing with 
NMD (AS-NMD). In HEK 293 cells the TDP-pA2 transcript was found not to be 
degraded by NMD. NMD can be demonstrated in a particular transcript by treating 
cells with a translation inhibitor such as cycloheximide (CHX), extracting RNA, and 
quantifying any putative NMD transcript(s) by RT-PCR. Since NMD is a translation 
dependent process, when translation is inhibited by CHX, transcripts that would 
normally be degraded by NMD will show an increased signal compared to no CHX 
treated (control) condition. In SH-SY5Y cells the pA2 transcript was only slightly 
increased when treated with CHX (Figure 5.2) and there was no significant difference 
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between pA2/3’UTR ratio in control and CHX treated cells. This demonstrates that 
the TDP-pA2 transcript was not degraded by the NMD pathway. This result is in line 
with results in HEK 293 cells where it has been demonstrated that only the V2 
transcript is degraded by NMD (Ayala et al., 2011). Autoregulation of the intron 7 




Figure 5.2. Cycloheximide treatment in SHSY5Y cells. 
SH-SY5Y cells were treated with 10µg/ml of CHX for 12 hours. RNA was extracted 
for the cells and reverse transcribed. PCR with IR-labelled primers spanning the 
intron 7 splice site in the 3’UTR of TDP-43. Quantification of PCR products show no 





5.3. TDP-pA2 RNA expression in frontal cortex 
Nuclear clearance of TDP-43 in TDP-43 proteinopathies may result in impaired TDP-
43 autoregulatory 3’UTR splicing. TDP-43 3’UTR splicing is a direct target for TDP-
43 protein regulation and the question this section asks is does cytoplasmic 
mislocalisation of TDP-43 protein have an effect on downstream splicing events on a 
known TDP-43 splicing target?  cDNA from five brain areas was used for this 
analysis. All samples had a RIN of 3.6 or higher.  
TDP-43 3’UTR splicing was quantified by amplifying cDNA from control, ADTDP- 
and ADTDP+ brains with primers that span intron 7. A DY-682 labelled forward 
primer was used for accurate quantification. A pA2/3’UTR ratio was calculated for all 
samples in five brain regions frontal and temporal cortex, amygdala, hippocampus 
and cerebellum. 
  
For all the brain regions tested there were no significantly different isoform ratios 
between control, ADTDP- and ADTDP+ brains by one way ANOVA. Of note is that 
there was a consistent trend for a decrease in TDP-pA2/3’UTR ratio in the AD group 
with TDP-43 inclusions for all brain regions except for the frontal cortex where 
control, ADTDP- and ADTDP+ samples have essentially equal TDP-pA2/3’UTR 
ratios. The decrease in TDP-pA2/3’UTR ratio in the ADTDP+ was not significant in 





Figure 5.3. TDP-43 isoform expression in the frontal cortex. 
pA2/3’UTR isoform ratios were assayed by RT-PCR. 
Mean percentages for each APP isoform was calculated for each group ± SEM. 








Figure 5.4. TDP-43 isoform expression in the temporal cortex. 
pA2/3’UTR isoform ratios were assayed by RT-PCR. 
Mean percentages for each APP isoform was calculated for each group ± SEM. 






Figure 5.5. TDP-43 isoform expression in the amygdala. 
pA2/3’UTR isoform ratios were assayed by RT-PCR. 
Mean percentages for each APP isoform was calculated for each group ± SEM. 







Figure 5.6. TDP-43 isoform expression in the hippocampus.  
pA2/3’UTR isoform ratios were assayed by RT-PCR. 
Mean percentages for each APP isoform was calculated for each group ± SEM. 





Figure 5.7. TDP-43 isoform expression in the cerebellum.  
pA2/3’UTR isoform ratios were assayed by RT-PCR. 
Mean percentages for each APP isoform was calculated for each group ± SEM. 




5.4. pA2/3’UTR analysis in FTLD 
AD brains with TDP-43 inclusions show a consistent reduction in the pA2/3’UTR 
ratio compared to control and ADTDP- brains however this result was not significant.  
This result suggests that TDP-43 pA2 isoforms are lower in brains with TDP-43 
inclusions and is indicative of misregulation of TDP-43 autoregulation in brain 
harbouring TDP-43 inclusions. The small magnitude of effect may be due to a 
variable amount of TDP-43 inclusions in AD brains. In addition, in the AD brains we 
tested, TDP-43 pathology was predominantly confined to limbic structures. On the 
other hand, FTLD-TDP brain have widespread TDP-43 pathology and samples from 
the IOP brain bank were used to quantify TDP-43 pA2/3’UTR ratios. The question we 
ask in this section is TDP-43 autoregulatory splicing regulation altered in FTLD-TDP 
cases?  
 
Only four FTLD-TDP brains had an RIN of 3.6 or greater for the analysis and RNA 
was extracted from different regions of same four brains. The four brain regions 
included were frontal and temporal cortex, amygdala and hippocampus, regions with 
extensive TDP-43 pathology in FTLD-TDP. Brain sample F2 has a PRGN mutation. 
All the other FTLD-TDP-43 cases, at that time, had no other known mutations. 
Referring to the FTLD-TDP samples in Figure 5.8, from left to right F2, F3, and F5 
are from the frontal cortex, the next F2, F4 and F5 are from the temporal cortex, the 
next F5 is from the amygdala and F2 and F5 are from the hippocampus. Control 
brains were matched by brain area accordingly. Because the four FTLD brains 
contributed 3’UTR/pA2 splicing ratios to the analysis more than once and therefore 
were not independent, a hierarchical analysis was used to analyse differences between 
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the two groups and found an overall significant decrease of TDP pA2/3’UTR ratio in 
the FTLD group compared to controls (p = 0.058 log transformed data). There was a 
~9% decrease in pA2 transcripts in the FTLD-TDP-43 brains compared to control. 
The hierarchical analysis showed a significant decrease in the temporal lobe TDP 
pA2/3’UTR ratio compared to control (p = 0.037 log transformed data) and this was 
due mainly to a single data point (F4) which has subsequently identified as having the 









Figure 5.8. TDP-43 isoform expression in FTLD human brain samples. 
pA2/3’UTR isoform ratios were assayed by RT-PCR. 
Mean percentages for each APP isoform was calculated for each group ± SEM. 





TDP-43 3’UTR splicing has been demonstrated in HEK cells to be a key regulator of 
TDP-43 transcript stability. The existence of TDP-43 3’UTR splicing has not yet been 
demonstrated in human brain tissue. PCR amplification of human brain cDNA with 
primers spanning the intron 7 3’UTR splice site (pA2) confirm that this splicing event 
occurs in all regions tested in the human brain. In HEK 293 cells pA2 transcripts are 
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not subject to NMD and we show that the pA2 transcript is not subject to NMD in 
SHSY-5Y cells.  
  
TDP-43 3’UTR splicing ratios were quantified in control, ADTDP- and ADTDP+ 
human brain samples from five brain regions. No significant differences in 
pA2/3’UTR ratios were found between control, ADTDP- and ADTDP+ brains. A 
consistent non-significant decrease in the pA2 transcript was found in ADTDP+ 
brains.  
 
TDP-43 pA2/3’UTR ratios were quantified in FTLD-TDP-43 samples from the 
frontal and temporal cortex, amygdala and hippocampus. A hierarchical analysis 
found a significant ~9% decrease of pA2 transcripts when pA2/3’UTR ratios from all 
brain regions were included. Hierarchical analysis showed a significant decrease in 
pA2 transcripts specific to the temporal cortex. This decrease may be due to one 
sample with the C9ORF72 mutation however it has only been demonstrated in one 











Chapter six: Limitations of the use of post-mortem tissue for 
gene expression studies 
 
6.1 Variables affecting post-mortem tissue 
 
Gene expression analysis of post-mortem brain tissue is widely used to validate data 
from cellular and animal models as well as to inform in vitro functional studies.  
 
Comparison of expression profiles between disease and control brain tissue presents 
specific difficulties due to a number of different variables, both pre- and post-mortem, 
that potentially impact on the measurement of parameters such as RNA levels and/or 
splicing patterns. These variables can be divided into three categories: 
 
1) Variables affecting brain tissue after death such as post mortem interval that 
potentially alter transcript stability in both disease and control samples. 
 
2) Variables affecting brain tissue before death such as agonal state that potentially 
alter transcript expression in both disease and control samples. 
 
3) Variables affecting brain tissue before death that predominantly alter transcript 
levels in disease brain, especially in neurodegenerative conditions such as AD, and 





6.1.1 Post Mortem interval  
 
Post mortem interval (PMI) refers to the time elapsed between death and the time 
when the tissue is frozen or fixed. Long PMIs could result in degradation of specific 
transcripts or alter the integrity of all transcripts. The consequences of RNA integrity 
on PCR-based quantification of gene expression has been clearly demonstrated where 
poor RNA integrity requires a larger number of cycles to reach threshold values in 
qRT-PCR analyses (Fleige and Pfaffl, 2006). Therefore variable PMI has the potential 
to contribute to variability in total levels of RNA transcripts as well as the level of 
specific transcripts. 
 
Many early studies on human cerebral cortex using a variety of quantification 
methods including in situ hybridisation (Harrison et al., 1995), RT-PCR (Johnson et 
al., 1986) and microarrays (Popova et al., 2008; Tomita et al., 2004) showed no 
correlation between levels of mRNA and PMI. RNA integrity in many studies was 
also found not to be affected by PMI (Barton et al., 1993; Durrenberger et al., 2010; 
Popova et al., 2008; Ross et al., 1992). These data suggest that pronounced 
degradation of RNA does not take place in the initial post-mortem period, however 
the above studies used different methods to measure RNA levels and often had small 
sample sizes. By contrast, other studies do show an effect of long PMIs on levels of 
RNA with generally decreasing levels of specific transcripts and RNA integrity with 
increasing PMIs (Birdsill et al., 2011; Ferrer et al., 2008). In the case of specific 
transcripts, an effect of PMI length on APP transcripts has been reported; Burke et al. 
(1991) demonstrated a negative correlation between PMI length and stability of 
APP751 transcripts, however the sample size used in this study was small and 
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APP695 and APP770 transcripts were not decreased with increasing PMI. Clark et al. 
(1989) showed that total levels of APP transcripts were not degraded after PMIs of up 
to 22 hours in parietal cortex tissue.  
 
The PMIs of the samples used in our study ranged from 3 hours to 120 hours; control 
tissue had and average PMI of 33.9 hours while AD cases had an average of 37 hours. 
Thus, the average PMI for disease and control samples used in this study are 
comparable. We found very stable levels of tau expression in control and AD brain in 
all the brain regions tested (Figure 3.13). This is in agreement with an earlier study 
showing that MAPT RNA levels were not altered for PMIs averaging around 50 hours 
in a large set of human brain samples (Trabzuni et al., 2011). Of note is a study 
conducted by BrainNet Europe analysing frontal gyrus, corpus callosum, thalamus 
and cerebellum from 193 brain samples from nine Brain Banks (Durrenberger et al., 
2010). This study found no effect of PMI length on levels of commonly used 
housekeeping genes analysed by qRT-PCR, at least for PMIs of less than 2 days, and 
no effect of PMI length on RNA integrity. A possible reason for this is RNA is 
remarkably stable after death and this may be because degradation of RNA is energy-
dependent and ceases rapidly after death. Alternatively, RNase inhibitors may persist 
longer than RNases after death in brain tissue or that once RNA stops being translated 
it is less susceptible to RNases (Barton et al., 1993).  
 
Taken together this suggests that PMI does not contribute in a major way to 
differences found in total transcript levels for PMIs within the range of our study.  
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6.1.2 Agonal state and tissue pH 
 
Agonal factors are the specific combination of conditions such as prolonged terminal 
phase, seizures, hypoxia and pyrexia leading up to death. The number of agonal 
factors the patient has experienced in the terminal phase has been found to be 
negatively correlated with RNA expression, RNA integrity or both (Bahn et al., 2001; 
Durrenberger et al., 2010; Harrison et al., 1995; Johnston et al., 1997; Kingsbury et 
al., 1995; Tomita et al., 2004). 
 
Using a 4-point scale, Hardy et al. (1985) showed that a quick death (either violent or 
by natural causes) was associated with higher brain tissue pH than slow death. A 
longer terminal phase was associated with increased concentration of lactic acid 
causing acidosis. Hypoxia-inducible factor 1α (HIF-1α) levels have been found to be 
significantly increased in tissue from patients that have had agonal events such as 
coma, respiratory illness or long ventilation (Durrenberger et al., 2010). HIF-1α is 
usually rapidly degraded by the proteasome in normal aerobic conditions, however, in 
hypoxic conditions, HIF-1α is stabilised and activates genes essential to the cellular 
adaptation to low oxygen conditions (Dery et al., 2005). These results show that the 
increase in acidity in brain tissue is correlated with hypoxic conditions (Durrenberger 
et al., 2010) and that the increase in brain acidity is associated with decreased RNA 
integrity which may explain why decreased RNA levels are found in tissue from 
individuals with a complex agonal phase. However not all studies have found a 
correlation between RNA integrity and brain tissue pH (Sherwood et al., 2011) and 
these authors highlight the difficulty of quantifying agonal factors. For example, 
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hypoxia or dehydration are often scored using clinical notes however these notes may 
not give details of severity or length of particular agonal factors. 
 
RNA integrity is profoundly affected by high brain acidity resulting in RNA 
degradation whereas less acidic conditions (pH values above a threshold of around 
5.9) causes negligible RNA degradation (Trabzuni et al., 2011).  
 
We measured the pH of the samples used in this study (Table 2.3) and found that only 
one sample had a pH lower than 5.9, the threshold below which acidity profoundly 
affects RNA integrity. We also measured RNA integrity number (RIN) for RNA from 
all brain regions and only used samples with a RIN of 3.6 or above. We found that 
samples with a RIN lower than 3.6 had decreased levels of tau RNA and 
quantification was unreliable and therefore a RIN of 3.6 was chosen as a cut-off for 
all samples.  
 
We quantified total levels of tau and APP by qRT-PCR analysis relative to two house-
keeping genes that were determined to have the most stable expression for each brain 
region analysed. Normalisation to stable housekeeping genes eliminates effects of 
variable RNA integrity in qRT-PCR-based analyses (Durrenberger et al., 2010; Fleige 
and Pfaffl, 2006). For splicing analysis we quantified tau, APP and TDP-43 isoform 
ratios. Measuring ratios mitigates the effects of variable RNA integrity in RNA 
analyses because transcripts for all isoforms will be affected approximately equally. 
 
Sample selection on the basis of RIN and pH as well as calculation of isoform ratios 
mitigated the contribution of variable RNA integrity to the parameters measured and 
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therefore our results are unlikely to have been confounded by pre-mortem RNA 
degradation due to the agonal state.  
 
Post mortem interval and agonal state affect both control and disease brain and can be 
controlled for by using selected samples and more than one methodology for 
measuring transcript levels or alternative splicing. It should be mentioned that other 
variables such as the number of freeze-thaw cycles that tissue samples have 
undergone or the effect of medication prior to death may also impact on RNA levels 
and these variables are not included in our analyses.  
 
6.1.3 Changes in cell population in Alzheimer’s disease 
 
Neurodegeneration by definition is a reduction in the neuronal population. Neuronal 
loss has been found in the hippocampus, subiculum, dentate gyrus and entorhinal 
cortex of AD cases compared to controls (Braak and Braak, 1991; Gomez-Isla et al., 
1997; Simic et al., 1997; West et al., 1994). Using stereology Gomez-isla et al., 
(1997) showed a decrease of 53% of neurons in the superior temporal sulcus of AD 
brain compared to control. There is also a consistent finding of reduced 
immunostaining for synaptophysin, a synaptic marker in AD brain compared to 
control (Brun et al., 1995; Gomez-Isla et al., 1997). The reduction in synaptic 
connections and reduction in branching is considered to be the predominant cause of 
memory loss in AD (Walsh and Selkoe, 2004). These findings show that populations 
of neurons and glia are altered in AD brain and differences in transcript or isoform 
expression found in post-mortem tissue from AD brain could reflect differences in 
cell populations. To some extent, neuronal loss takes place in normal aging however it 
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is generally considered to be rather small (Pakkenberg and Gundersen, 1997; 
Pakkenberg et al., 2003; Pannese, 2011; Tang et al., 1997) and in AD, the loss of 
neurons appears to be accelerated.  
 
Astrocytes are specialised glial cells that perform many essential functions in the CNS 
(for review see Sofroniew and Vinters (2010)). They respond to insults through a 
process of reactive astrogliosis which, in AD brain, involves hypertrophy of the 
astrocyte cell body and processes, proliferation. Aβ plaques are surrounded by dense 
layers of processes from astrocytes. Inflammatory signalling by both microglia and 
astrocytes also recruit more astrocytes to sites of damage.  
 
In our study no differences in levels were found in AD cases compared to control 
cases for either tau or APP by qRT-PCR which is consistent with other studies 
(Hyman et al., 2005; Ingelsson et al., 2006; Ingelsson et al., 2007; Matsui et al., 
2007). For splicing, we found modest increases in 4R/3R tau ratios in AD cases 
compared to control. However we found no differences in total levels of tau. We also 
found increases in KPI-containing APP isoforms in AD cases compared to control. 
RNA from the same set of brain samples was used for analysis of total levels of APP 
and tau expression and splicing analysis. The change in APP splicing could be 
interpreted as reflecting the loss of neurons and increase in glial cells in AD brain, 
since neurons predominantly express APP695 whereas the APP751 and APP770 





6.1.4 Inflammation in AD 
 
Evidence for an inflammatory response in AD has been demonstrated by increased 
levels of chemokines and cytokines and the presence of proinflammatory markers on 
microglia such as interleukin-1 (IL-1), interleukin-6 (IL-6), Tumour Necrosis Factor-α 
(TNF-α) and toll-like receptors (Wyss-Coray and Rogers, 2012). Microglia are the 
main phagocytic cells of the CNS. Like macrophages from other tissues, microglia are 
very plastic and are able to dramatically alter their phenotype and exhibit a range of 
behaviours and morphologies in response to environmental stimuli (Cameron and 
Landreth, 2010). In the normal brain, microglia carry out tissue maintenance and 
immune surveillance and are found with a ramified morphology associated with the 
resting state. Tissue damage elicits a rapid redirection of processes to the area of 
damage and, if sustained, promotes the migration of cells to the affected area 
(Davalos et al., 2005). Engagement of the host defence mechanism converts the 
resting microglia into an activated phenotype and involves the production and 
secretion of cytokines and chemokines to mobilise the immune response.   
 
Amyloid plaques in AD brain are surrounded by activated microglia (for reviews 
Cameron and Landreth (2010), Boche et al. (2013), Khandelwal et al. (2011)). 
Increases in proinflammatory factors are found in AD including elevated levels of 
TNF-α in the serum (Fillit et al., 1991) as well as IL-6 in brain tissue (Bauer et al., 
1992; Bauer et al., 1991). In addition, Aβ induces the expression of toll-like receptors 
in AD and in mouse models of AD (Fassbender et al., 2004; Letiembre et al., 2009; 
Liu et al., 2005; Walter et al., 2007). 
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The promoter region of the APP gene contains regulatory elements responsive to 
cytokines and treatment of cells with TGFβ1, TNF-α (Ge and Lahiri, 2002) and IL-1 
(Goldgaber et al., 1989) increases APP expression in vitro. In addition, the NF-κB 
transcription factor binding site, which is present in the MAPT promoter region 
(Maloney and Lahiri, 2012), is involved in neuroinflammatory signalling pathways 
(Bales et al., 2000) suggesting that inflammatory signalling in AD brain has the 
potential to regulate levels of and/or splicing of tau, APP or other transcripts. For 
example, induction of acute inflammation in mouse brain increased expression of 
KPI-containing APP isoforms in the cerebellum however total levels of APP were 
unchanged (Brugg et al., 1995). Furthermore cytokines induce increases in APP 
protein levels in primary human astrocytes (Rogers et al., 1999). These results show 
that cytokines are likely to impact on the levels of APP isoforms and may account for 
the increases in APP751 and APP770 that we observed in AD brain although we did 
not find changes in KPI-containing APP isoforms in the cerebellum in the AD cases 
we analysed.  
 
Paracrine neuroinflammatory signalling between neurons and microglia linked to p38 
MAPK signalling increases tau phosphorylation in mouse brain (Bhaskar et al., 2010) 
however no changes in tau isoform expression due to inflammatory signalling has 
been reported (Bhaskar et al., 2010; Kitazawa et al., 2005) suggesting that glial-
derived cytokines do not alter splicing or total levels of tau. 
 
Using microarrays, Cribbs et al. (2012) found that components of the inflammation 
and complement pathways were increased significantly in brain from AD patients and 
from aged individuals compared to brains from young normal individuals. In addition, 
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significant increases in glial activation, complement factors, inflammatory mediators 
and brain atrophy were found in non-demented aged individuals (Lu et al., 2004; 
Lucin and Wyss-Coray, 2009; Streit et al., 2008) suggesting that expression of 
inflammation-related genes undergo extensive changes in the course of normal aging 
and in AD and that general activation of inflammation signalling may not be 





Findings from genome-wide association studies show that complex neurological 
diseases involve DNA sequence variants whose products act through complex 
pathways. Inherited genetic variability in gene expression or splicing, or both, 
contributes to disease risk. However measuring disease-specific changes at the RNA 
level in post mortem-human brain presents specific challenges. Human brain tissue 
can only be utilised at the end stage of a disease process and the disease course and 
RNA degradation arising after death affect measures of RNA levels. Nonetheless, 
meaningful data have been derived from expression analysis in post-mortem brain 
including in a recent study that confirmed the microglial/complement pathway and the 
role of TREM2 as strongly associated with the pathophysiology of late onset AD 
(Zhang et al., 2013). Bioinformatic tools have been developed to differentiate between 
pathologically relevant changes and secondary changes due, for example, to 
differences in cell population in neurodegenerative disease. Analysis of publically 
available transcriptome-wide gene expression data of AD and control post-mortem 
brain tissue has found regulatory genes predicted to mediate the transcriptional 
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changes observed in APOE4 carriers and LOAD patients including ITM2B, FYN and 
RNF219 (Rhinn et al., 2013). Thus, the effect of variables affecting gene expression 
in post-mortem disease brain can be mitigated through experimental design, the use of 
multiple controls and appropriate data analysis methods. 
 
6.2 Experimental follow-up of expression studies in post-mortem material. 
 
It is not possible to manipulate or perturb the human brain and measure a response to 
probe molecular mechanisms and test hypotheses and therefore results arising from 
studies in post-mortem material have to be followed up using cellular or animal 
models.  
 
Here, we have shown that the potential loss of TDP-43 nuclear function that may 
result from cytoplasmic aggregation of TDP-43 does not alter total tau levels or exon 
10 splicing and taken together these results suggest that TDP-43 does not have a 
direct effect on tau expression or splicing. This is consistent with a previous study that 
showed that knockdown of TDP-43 using antisense oligonucleotides does not alter 
transcription levels of tau in mice (Polymenidou et al., 2011). However, unlike mouse 
tau, TDP-43 could potentially play a role in the regulation of the splicing of human 
tau. TDP-43 binds predominantly to intronic regions (Tollervey et al., 2011a), regions 
that are not very highly conserved between human and mouse. Tau splicing is partly 
regulated by elements within the intronic region, thus TDP-43 could have a 
differential effect on tau splicing between human and mouse. Consequently, analysis 
of tau expression and splicing relevant to human disease, and how it may be regulated 
by TDP-43, requires cellular or animal model expressing human tau.  
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6.2.1 Experimental models of human tau expression and splicing 
 
Several human neuroblastoma cell lines exist, most notably SH-SY5Y cells. While 
these cells are suitable to analyse regulation of expression levels of the MAPT genes, 
they are not ideal to study tau splicing as they express mainly tau 3R (Smith et al., 
1995). Induced pluripotent stem cells (iPS cells) derived from normal individuals or 
AD patients could be an ideal alternative, but no data has been published to date on 
tau expression in these cells. Tau expression can be analysed in non-neuronal cells 
transfected with constructs comprising a minimal MAPT promoter upstream of a 
reporter gene such as luciferase. Tau splicing can be analysed in non-neuronal cells 
transfected with MAPT mini-genes containing exon 10 or exons 2 and 3 with flanking 
intronic sequences in non-neuronal cells. Minigenes are widely used to measure the 
activity of splicing factors on specific exons, including tau exon 10 (Chapple et al., 
2007; Wang et al., 2005). 
 
Many transgenic mouse lines expressing human tau have been generated, but most 
express tau cDNAs under a heterologous promoter and are therefore not suitable to 
study regulation of transcription or splicing. On the other hand, htau mice express the 
entire human MAPT gene, with 14 exons and 7kb of promoter sequence in a mouse 
Mapt null background (Andorfer et al., 2003). Adult htau mice express all tau 
isoforms and are a good mouse model to analyse and manipulate tau splicing (Avale 
et al., 2013). 
 
Another popular vertebrate animal model is the zebrafish, Danio rerio, due to the ease 
of its experimental manipulation. However, the zebrafish only has one mapt isoform 
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listed in the Ensembl database. Secondly, as mentioned above, splicing is partly 
regulated by elements within intronic regions and these regions are not very highly 
conserved between human, mouse and zebrafish. Thus, this suggests that mapt 
expression in the zebrafish is unlikely to mimic human MAPT regulation.  
 
6.2.2 Experimental analysis of the potential role of TDP-43 in the regulation of tau 
expression and splicing 
 
TDP-43 expression can be manipulated in the cellular and animal models described 
above by different methods; expression of MAPT and splicing patterns of tau exons 2, 
3 and 10 can be analysed by quantitative and semi-quantitative RT-PCR, as described 
in this thesis and by reporter gene assays, as appropriate. 
 
In human neuronal cells, such as differentiated SH-SY5Y cells or iPS cells, TDP-43 
levels can be increased by transfection of a TDP-43 cDNA or decreased by RNA 
interference following delivery of siRNAs or shRNA directed against TDP-43 
mRNA. The same procedures can be applied to non-neuronal cells co-transfected with 
tau minigenes or tau reporter genes. Although these experiments are very informative 
about a possible role of a specific splicing factor on a particular exon, overexpression 
is artificial and may not reflect actual expression patterns in neurons. In addition, 
overexpression or down-regulation of a protein can result in cellular stress that can, in 
turn, affect splicing (Maracchioni et al., 2007). Therefore some caution needs to be 
taken in the interpretation of results from this type of experiment. 
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As indicated above, htau mice represent a good animal model of human MAPT 
expression. TDP-43 can be overexpressed or down-regulated in these animals by 
crossing them with TDP-43 overexpressing mice or TDP-43 knock-out mice. 
However, TDP-43 overexpression results in a pathological phenotype and 
heterozygous Tdp-43 knock-out mice show widespread expression of TDP-43 and 
therefore cannot be used as a TDP-43 knockdown mouse model (Sephton et al., 
2010); homozygous Tdp-43 knock-out mice are not viable. An alternative would be 
down-regulation of TDP-43 by direct injection of antisense oligonucleotides as 
reported (Polymenidou et al., 2011). 
 
Due to the differences in human MAPT and zebrafish mapt gene, the zebrafish might 
not be the most suitable model to analyse the potential role of TDP-43 in tau RNA 
processing. However TDP-43 can be easily manipulated in the zebrafish. The 
zebrafish genome has two orthologs of the human TDP-43 gene (tardbp and tardbpl), 
when both are knocked out, the embryos die at 8 days post fertilisation (Schmid et al., 
2013). Knockdown of tardbp in zebrafish embryos using morpholinos result in a 
motor phenotype and shortened motor axons however the levels of mapt in these 
models was not reported (Kabashi et al., 2010; Schmid et al., 2013).  
To conclude, carefully controlled analysis of post-mortem material combined with 
mechanistic analysis in animal and cellular models can provide robust results that 
could be ultimately translated into diagnostic tools and, hopefully, therapeutic 
strategies. 
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We quantified MAPT and APP splicing isoform ratios and total RNA levels in AD 
and control brain. In frontal, amygdala, hippocampus and cerebellum of AD brains 
tau 4R/3R ratios were significantly increased compared to controls and tau 4R/3R 
ratios were highly correlated across five brain regions in AD brains. A subgroup of 
AD brains showing consistently high 4R transcript expression in all brain regions 
measured were the major contributors to the increases in 4R transcripts found in the 
AD group however altered tau splicing ratios were not associated with TDP-43 
inclusions in this subgroup.  
 
APP751 isoform expression was significantly increased and APP695 significantly 
decreased compared to control in the temporal cortex, amygdala and hippocampus. 
APP770 was significantly increased in the hippocampus in AD brain compared to 
control.  
 
The percentage of tau 4R also positively correlated with percentage APP751 and 
percentage APP770, and negatively correlated with percentage APP695 in the 
amygdala and hippocampus.  
 
AD brains with TDP-43 inclusions were associated with increased severity of tau 
pathology in the frontal and temporal cortex however the severity of tau patholgy did 
not associate with either 4R tau expression or insoluble 4R tau in AD brain. 
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These results show that a subgroup of AD cases have increased 4R tau expression 
which correlated with increased expression of APPKPI isoforms. 4R/3R RNA tau 
ratios correlated with 4R/3R tau ratios from insoluble material in AD brains from the 
amygdala showing that imbalances in 4R/3R ratios at the RNA are reflected in 
imbalances in 4R/3R ratios at the insoluble protein level.  
 
We found reduced TDP-43 3’UTR splicing ratios in FTLD brains compared to control 
brains and a consistent trend for reduced TDP-43 3’UTR splicing ratios in AD cases 
with TDP-43 inclusions compared to AD cases without TDP-43 inclusions and 
control showing that sequestration of TDP-43 into cytoplasmic inclusions alters TDP-
43 3’UTR splicing. TDP-43 protein regulates its own expression by 3’UTR splicing 
of TDP-43 transcripts which targets particular mRNAs for nuclear retention or to a 
NMD pathway. These findings suggest that TDP-43 autoregulation in FTLD and AD 
brain are altered and that transcript and protein levels of TDP-43 may be altered in 
FTLD and AD brains with TDP-43 inclusions however we did not directly measure 
TDP-43 RNA or protein levels.  
 
7.2. Lack of association between TDP-43 pathology and Tau and APP Splicing in 
Alzheimer’s disease 
 
7.2.1. Tau exon 10 and TDP-43 pathology 
4R expression was significantly higher in AD brain compared to control and 4R 
expression was highly correlated between brain regions. We show that within our 
samples, a subset of ~5 AD cases have increased tau 4R expression and two 
mechanisms may account for this:  
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1) Genetic variation on MAPT locus and we tested for an association with exon 10 
expression and total tau levels associated with a particular tau haplotype. 
2) Misregulation of TDP-43 may alter splicing and/or transcription of multiple genes 
directly and indirectly. We determine if an association exists between misregulation 
of TDP-43 in AD and altered tau splicing ratios. 
 
7.2.2. Influence of MAPT haplotype on tau splicing  
In the combined control and AD group brains no association was found between 
relative tau expression and MAPT haplotype in any brain region by qRT-PCR. We 
also found expression of tau 4R/3R ratios were not associated with a particular tau 
haplotype in any brain region tested by RT-PCR. A caveat to the interpretation of 
these results is that we had a small sample size which may not be representative of a 
wider population.  
 
Other studies using allele specific assays have shown that the H1 allele results in a 
1.29 fold increase in 4R tau expression compared to the H2 allele in the frontal cortex 
of PSP brains (Caffrey et al., 2006). In addition, 25% increases in 4R expression and 
11-13% increases in total MAPT expression have been found in H1c haplotype 
(Myers et al., 2005).  
 
However other studies using allele specific expression in PSP brain samples found no 
differences in MAPT expression ratios between H1c and H2 alleles in H1c/H2 
heterozygotes (Hayesmoore et al., 2009). More recently, using exon arrays, Trabzuni 
et al. (2012) found no differences in either H1 or H2 haplotype on total MAPT 
expression in human brain. Instead, they found increased expression of tau exon 3 
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was associated with H2 haplotype. The association between splicing of different tau 
exons and tau haplotype may be explained by co-regulation of tau exons 2,3 and 10 
by shared splicing factors.  
 
Different promoter regions have been shown to regulate alternative splicing through 
two different mechanisms (Kornblihtt, 2005). Firstly, transcription factors at a 
particular promoter region may directly bind different splicing factors and certain 
transcription factors may also be involved in the mechanics of alternative splicing 
events. Secondly, the rate of transcription elongation may determine alternative exon 
usage with fast elongation associated with exon skipping and slow/pausing elongation 
associated with exon inclusion (Kornblihtt, 2005). An additional mechanism may be 
that transcripts from alternative promoters have alternative 5’UTR start sites or 
3’UTR end sites and these play a role in recruiting splicing factors that determine 
subsequent alternative exon usage (Pal et al., 2011). 
 
Tau exon 2 and 10 are regulated by several splicing factors mainly by inhibition 
(Andreadis et al., 1995). Tau exon 2 expression may be correlated with exon 10 
expression because both exons share splicing factors SRp30c, SRp55 and tra2β1 
although these factors exert differing effects on each exon (Wang et al., 2005). 
SRp30c and SRp55 both inhibit the inclusion of exons 10 and 2 by binding to silencer 
elements (ESS), one within exon 2 and another within exon 10. Tra2β1 inhibits exon 
2 inclusion by forming a complex with SRp30c and SRp55 at the exonic silencer 
while tra2β1acts as a exon 10 activator, increasing exon 10 inclusion by blocking the 
binding of the two inhibitors SRp30c and SRp55 at the ESS within exon 10 (Wang et 
al., 2005). Tau exon 3 is also regulated by SRp30c, SRp55 however for exon 3 both 
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SRp30c and SRp55 increase inclusion of exon 3 (Arikan et al., 2002). Coordinated 
splicing of exons 2,3 and 10 could be achieved by recruitment of particular 
transcription factors and splicing factors to the promoter region of MAPT. 
 
The promoter sequence of MAPT spans ~4868bp and contains multiple putative 
transcription factor binding sites some of which differ according to tau haplotype 
(Maloney and Lahiri, 2012). SNPs or insertions/deletions (indels) in the MAPT 
promoter region associated with H1 or H2 haplotype may alter the recruitment of 
transcription and splicing factors that coordinate MAPT splicing. 
 
The mechanism of risk association for H1 tau haplotype could be related to genetic 
variation in the promoter region in H1 and H2 and/or variation around exon 10 that 
potentially alter tau splicing or expression. In our AD and control samples we found 
that the H1 haplotype was not associated with altered ratios of tau exon 10 or 
increased expression compared to H2 homozygotes and heterozygotes.  
 
7.2.3. Possible direct effect of TDP-43 on tau splicing  
The increases in 4R transcripts found in the frontal cortex, amygdala, hippocampus 
and cerebellum were found in AD cases from both ADTDP- and ADTDP+ cases. In 
the AD brains, a very high 4R/3R ratio correlation was found between frontal, 
temporal, amygdala and hippocampus. The cerebellum showed significant increases 
in 4R transcripts in AD brain compared to control however the cerebellum showed 
less significant 4R/3R correlations with the other brain regions and this may be 
because this region has no tau pathology. This analysis shows that tau 4R expression 
was very consistent across brain regions and that the significant increases in 4R 
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transcripts were the contributed by the high 4R expressor group in all brain regions 
tested. 
 
TDP-43 has RNA binding specificity to UG repeats (Buratti et al., 2001) and MAPT 
contains at least two UG repeat regions, one in an intronic 5’UTR region and another 
in intron 9. The sequence in intron 9 
-CGUGUGUGUGUGUGUGUGUGUGUGUGUGUGGGCGCAC- suggests a TDP-
43 binding site that has potential to regulate exon 10 splicing. However the MAPT 
intron 9 UG repeats in the human sequence are around 7000 base pairs from exon 10.  
We found no evidence that misregulation of TDP-43 alters splicing of tau exon 10 and 
therefore the putative TDP-43 binding site in intron 9 has no direct effect in tau exon 
10 splicing regulation.  
 
Cytoplasmic TDP-43 inclusions result in nuclear clearance of TDP-43 protein from 
the nucleus (Neumann et al., 2006) however it is not known what effect this has on 
the role of TDP-43 in RNA processing. Global changes in altered splice isoforms 
have been found in AD and FTLD brain by microarray (Tollervey et al., 2011b) 
however splicing changes specific for FTLD-TDP were not found when compared to 
AD brain, even in genes known to be targets for TDP-43 alternative splicing 
regulation. Altered splicing of specific exons were associated with altered levels of 
splicing factors such as a 1.6 fold increase in polypyrimidine tract binding protein 1 
(PTBP1/PTB/hnRNPI), and decreases in PTBP 2 transcripts (Tollervey et al., 2011b). 
These results suggest that multiple trans-acting splicing factors, that include TDP-43, 
are altered in AD and FTLD.  
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7.2.4. Definition of an Alzheimer’s disease subgroup with high exon 10 inclusion 
Although we found no association between misregulation of TDP-43 and level of 
exon 10 inclusions in AD brain, we do find increased levels of tau exon 10 containing 
transcripts in a subgroup of AD cases. Intronic and exonic mutations within the MAPT 
gene also cause imbalances in tau isoform expression and are associated with tau 
pathology. It is not known how splicing imbalances result in tau pathology however 
overexpression of a particular isoform may promote seeding of tau aggregation. It is 
not clear if splicing imbalances are found in AD and tau pathology in AD may result 
from Aβ production and cause a different mechanism of tau pathology. Our results 
show that splicing imbalances found in a subset of AD cases may also contribute to 
tau pathology.  
 
Three AD subtypes have previously been identified based on a ratio of hippocampal 
to cortical tau pathology and severity of lesions for each case has been found in post-
mortem brain (Murray et al., 2011b).  Another study which associated cognitive 
symptoms with MRI volumetric analysis in autopsied brain confirmed the three AD 
subtypes (Whitwell et al., 2012). AD cases can show unusual clinical symptoms that 
include PPA and others more typical of FTLD (Bigio et al., 2010; van der Zee et al., 
2008a) although the majority of AD cases have an amnestic presentation. The three 
subtypes; limbic-predominant, hippocampal sparing and typical AD show consistent 
correlation with the clinical heterogeneity found in AD. Almost all of the limbic 
predominant AD had an amnestic presentation while hippocampal sparing (cortical 
predominant) showed significantly more association with focal cortical syndromes 
such as PPA, semantic dementia and Parkinson’s disease dementia (Murray et al., 
2011b). In limbic predominant AD, TDP-43 pathology was significantly more 
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common compared to hippocampal sparing AD, although no different to typical AD. 
We cannot comment if the high 4R expressor AD group we found has any particular 
clinical phenotype or pattern of pathology because this was not included in this study. 
The high 4R expressor group needs to be validated in another independent sample set. 
 
7.2.5. Possible direct effect of TDP-43 misregulation on APP splicing ratios  
We showed significant increases in APP751 and significant decreases in APP695 in 
the temporal cortex, amygdala and hippocampus in AD brains compared to control. In 
addition, a significant increase in APP770 isoform was found in the hippocampus of 
AD brains compared to control however no pattern emerged that clearly showed that 
any of these splicing changes were associated with TDP-43 misregulation. The 
increases in KPI containing APP transcripts in AD brain are in line with previous 
studies, Tharp et al. (2012) showed decreases in APP695  and increases in APP770 in 
the frontal cortex of AD brains compared to control by qRT-PCR. Increases in 
APP770 and APP751 transcripts have also been found in the temporal cortex of AD 
brains compared to control also by qRT-PCR (Matsui et al., 2007). Taken together 
these studies show consistent increases in APPKPI transcripts and particularly 
APP770 transcripts in AD brain compared to control.  
 
The APP gene has canonical TDP-43 binding sites in intron 1, two in intron 4 and two 
in intron 13, however no association between TDP-43 misrgulation and altered APP 
splicing was found in our samples and show that these putative TDP-43 binding sites 
on the APP gene are not involved in APP exons 7 and 8 splicing regulation.  
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7.2.6. Correlation between tau and APP splicing 
In our study, for the combined AD brain cases we found a significant positive 
correlation between percentage tau 4R expression and percentage APP751 isoform 
expression and a significant negative correlation between percentage tau 4R 
expression and percentage APP695 in the amygdala and hippocampus. A significant 
positive correlation between percentage tau 4R expression and percentage APP770 
isoform expression was found in the amygdala. These correlations were not found in 
control brains and show that the subgroup of high tau 4R expressors also show 
correlated splicing changes in APP isoform expression.  
 
The molecular basis for the correlated changes in splicing of tau and APP may be due 
to altered levels of trans-splicing factors that have a role in splicing of both 
transcripts. Only a few studies have looked at RBP that play a role in alternative 
splicing of the APP exon 7, SC35, hnRNPA1 and CELF 1 have all been shown to 
alter splicing of exon 7 or 8 using minigenes (Donev et al., 2007; Poleev et al., 2000). 
SC35 is regulated by glycogen synthase kinase-3β (GSK-3β) and has been found to 
have differential effects on tau exon 10 either inclusion (Hernández et al., 2004) or 
weak inhibition of exon 10 (Andreadis, 2005). hnRNPA1 and CELF 1 have no effect 
on tau exon 10 in vitro (Gao et al., 2000; Hernández et al., 2004; Kondo et al., 2004) 
suggesting that altered levels of these splicing factors in disease would not affect tau 
exon 10 splicing and would not result in correlated splicing changes in tau and APP. 
 
More recent work on alternative splicing of APP shows that exons 7 and 8 may be 
regulated by miRNA in vivo (Smith et al., 2011a). Dicer knock-out mice have reduced 
levels of microRNA and these mice display increased APP transcripts containing 
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exons 7 and 8 compared to wild type mice (Smith et al., 2011a). When miR-124 was 
over-expressed in Neuro2A cells, APP transcripts containing exons 7 and 8 were 
increased suggesting that splicing of exons 7 and 8 may be regulated by particular 
microRNA possibly by regulating the levels of polypyrimidine tract binding protein 1 
(PTBP1/PTB/hnRNPI), a splicing factor which has previously been identified as a 
target of miR-124 (Makeyev et al., 2007). These authors also found levels of miR-124 
was reduced in AD brain compared to control quantified by qRTPCR, suggesting that 
decreases of miR-124 cause altered PTBP1 levels which target APP exon 7 and 8 and 
alter alternative splicing of these exons in AD.   
 
microRNA may also play a role in tau exon 10 regulation. Fetal mouse expression of 
tau is exclusively 3R and changes to exclusive 4R expression during post natal 
development. Smith et al. (2011b) found that during the post natal switch, miR-132 
increased ~16 fold and correlated with expression of 4R tau transcription expression. 
These authors found that miR-132 specifically targets polypyrimidine tract binding 
protein 2 (PTBP2/brPTB/nPTB), and that miR-132 is significantly reduced in PSP 
brain. These findings suggest that altered microRNA expression may also be 
responsible for altered exon 10 expression in disease.  
 
Taken together these results show that tau exon 10 and APP exon 7 are at least 
partially regulated by PTBP2 and PTBP1 respectively. Levels of PTBP1 and PTBP2 
expression may be regulated through a miRNA pathway and particular miRNAs were 
shown to be reduced in disease. Regulation of RBPs is complex involving both 
transcriptional and post-transcriptional processes, both PTBP1 and PTBP2 have been 
shown to autoregulate levels of its own transcript as well as cross regulate each other 
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(Boutz et al., 2007; Spellman et al., 2007; Spellman et al., 2005; Wollerton et al., 
2004) through an AS-NMD mechanism (see Introduction). Tollervey et al., (2011b) 
found increases in PTBP1 and reduced PTBP2 transcript expression in AD and FTLD 
brains. Regulation of tau exon 10 and APP exon 7 KPI domain may be due to splicing 
factors whose levels are closely related through cross-regulation and suggest that in 
the subset of high 4R expressor brains we found, perturbations in a splicing factor 
pathway involving microRNA and PTBP1 and 2 may be involved. TDP-43 may play 
a role in altering miRNA levels in disease. TDP-43 associates with the Drosha 
complex (see Introduction), involved in production pre-miRNA in the nucleus 
suggesting that misregulation of TDP-43 could alter production of miRNA.  
 
7.2.7. Regulation of APP splicing  
Autosomal dominant mutations in the APP gene lead to early onset dementia (Goate 
et al., 1991). These mutations alter processing of APP resulting in increases in Aβ 
production (Haass et al., 1994; Nilsberth et al., 2001). However linkage to a locus in 
the APP gene associated with an increased risk for late onset AD has not been found 
(Butler et al., 2009). Common SNPs on the APP gene also did not show any 
significant association with AD (Gerrish et al., 2012; Nowotny et al., 2007).  
 
No studies to our knowledge have shown an association between genetic variation on 
the APP gene and altered splicing. Sequencing of the entire APP locus has revealed a 
number of SNPs in the promoter region of APP that may increase APP expression and 
are associated with AD (Brouwers et al., 2006; Guyant-Maréchal et al., 2007; Lv et 
al., 2008) however the SNPs differ in each of these studies and suggest that these 
SNPs are weakly associated with an increase in disease risk.  
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Taken together these results show that genetic variation in both APP and tau may be 
only weakly associated with increased risk for AD. Sequencing of multiple genomes 
has revealed that novel SNPs occur regularly in individuals (Bras et al., 2012). These 
results suggest that disease related genetic mechanisms may be conferred by both 
common and rare SNPs that co-occur at particular loci and the combined effect of 
these SNPs will modulate association with risk (Singleton and Hardy, 2011). In our 
subset of AD cases that show correlated altered splicing ratios, common SNPs as well 
as rare SNPs/indels on both APP and MAPT could contribute to alter splicing and it 
would be interesting to sequence these cases to see if they have SNPs in common. 
 
7.2.8. Alternative splicing of tau exons 2 and 3 in Alzheimer’s disease 
 
Quantification of exons 2 and 3 could not be done reliably because of the presence of 
an intron 1 containing transcript. A transcript with the exact tau intron 1 exon was 
found in the BLAST EST data base accession number DA117257.1. In a paper that 
accompanies this EST, the authors suggest that this transcript is produced using an 
alternative promoter site in the MAPT gene (Kimura et al., 2006). The DA117257.1 
EST was produced using the oligo capping method where 5’cap on the RNA 
transcript is removed by enzymes and replaced with an oligo-cap (Maruyama and 
Sugano, 1994). The published DA117257.1 EST sequence in the BLAST database 
contains a MAPT 5’UTR sequence, exon 1, intron 1 (where it remains in frame) exon 
2, does not include exon 3 and ends at exon 4. It is unknown if this transcript is 




Our results suggest that the use of different promoters produce novel alternatively 
spliced isoforms of MAPT. Ratios of alternative spliced transcripts containing tau 
exons 2,3 and/or 10 could also be modulated by the use of different MAPT promoters. 
And therefore genetic variation in the promoter region of MAPT could potentially 
alter not only transcription levels but also splicing isoform ratios of MAPT.  
 
7.2.9. Tau exon 10 splicing in FTDP-17  
We found a range of 2.8-4.2 4R/3R average ratios in the brain region tested however 
some individual brains had 4R/3R ratios of 6.6 in the amygdala and 5.1 in the 
hippocampus which is above a theoretical maximum 4R/3R ratio of 3. These results 
may be due to inaccuracies of the technique however Hutton et al. (1998) also found 
4R/3R ratios of ~6 in 10+14 FTDP-17 brains in the frontal cortex by RT-PCR. It is 
possible that expression of the mutant allele decreases stability of 3R transcripts or 
increases 4R expression in the normal allele however no mechanism has been 
described for this.  
 
In our study it was apparent that one of the FTDP-17 cases had tau RNA and protein 
4R/3R ratios within the control range. We have not directly tested each of the FTPD-
17 sample for the presence of the 10+16 mutation however sequencing of intron 10 to 
determine if all our FTDP-17 samples have the 10+16 mutation needs to be done to 
confirm this case. 
    
 227
7.2.10. Tau exon 10 splicing in Myotonic Dystrophy, type 1 
The single DM1 sample in our study showed decreased exon 10 containing transcripts 
in the temporal cortex and amygdala and increases in the hippocampus and 
cerebellum. In DM1 temporal cortex decreased levels of tau exons 2 and 10 and APP 
exon 7 have been found (Jiang et al., 2004). However Dhaenens et al. (2008) found 
only 2 brains in 5 had reduced expression of transcripts containing tau exon 10 while 
reductions in transcripts containing tau exon 2 were reliably reduced in five brain 
regions suggesting that reduction in E10 containing transcripts occur only in a subset 
of DM1 brains. Our results are consistent with Dhaenens et al., (2008) and show no 
consistent decrease in 4R containing transcripts across the different brain regions in 
our DM1 brain. Myotonic dystrophy type 1 (DM1) is primarily a muscle wasting 
disease but also involves CNS pathology. NFT are found in the hippocampus and 
cortical regions (Maurage et al., 2005; Sergeant et al., 2001; Vermersch et al., 1996). 
DM1 is caused by an expansion mutation of CTG repeats in the 3’UTR of dystrophia 
myotonica protein kinase (DMPK) mRNA (Brook et al., 1992) which alters the levels 
of available muscleblind-like family splicing factors and phosphorylation of CUG 
binding protein 1 (CUGBP1; also known as CELF1). 
 
7.3. Lack of correlation between tau and APP transcript levels and TDP-43 
pathology 
 
7.3.1 Lack of correlation between Tau transcription and TDP-43 pathology 
Levels of total MAPT expression were measured by qRT-PCR and no differences in 
MAPT expression were found between control and ADTDP+ and ADTDP- samples in 
any brain region. This suggests that TDP-43 misregulation in AD does not play a role 
in altering levels of transcription of MAPT.  
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In frontal or temporal cortex other studies have also shown no differences normalised 
total MAPT RNA levels in AD brain compared to control by qRT-PCR (Hyman et al., 
2005; Ingelsson et al., 2006; Ingelsson et al., 2007) however in these studies found no 
increases in 4R tau transcripts in AD brains. The difference between these results and 
our results may be due to the fact that these studies have looked at changes in 3R and 
4R transcript expression in the frontal and temporal cortex. We found small increases 
in 4R transcript expression in the frontal cortex but not in the temporal cortex and 
these areas may be highly variable in 4R/3R tau expression particularly in disease. 
Ingelsson et al. (2006) also measure 4R and 3R transcript expression in single NFT 
bearing neurons in the hippocampus by laser capturing microscopy coupled with 
qRT-PCR from six AD brains. This analysis showed no differences in 4R or 3R tau 
transcript expression compared to controls however our analysis demonstrates that 
4R/3R tau ratio expression is very stable across brain regions and only a subset of AD 
brains have increased 4R/3R ratios and a sample size of six AD brains may not be 
enough to demonstrate a difference. 
 
7.3.2. Lack of correlation between APP transcription and TDP-43 pathology 
We found no differences in total APP expression were found between control, 
ADTDP+ and ADTDP- and control samples in any brain region. In DS patients over 
50 years of age, plaques are similar in form, number and regional distribution to AD 
(Mann and Esiri, 1989).Triplications of chromosome 21 cause DS and show that 
increases in APP expression may increase risk to develop AD (Singleton et al., 2004). 
however either no differences (Matsui et al., 2007) or decreases (Tharp et al., 2012) in 
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total APP RNA expression in AD brain compared to control have previously been 
found by qRT-PCR. 
 
7.4. The role of TDP-43 in splicing misregulation in post-translational processing 
of MAPT 
 
4R/3R ratios of tau protein from low speed centrifuge and 4R/3R ratios from 
insoluble material were quantified from human brain in the amygdala. No differences 
in 4R/3R ratios were found in insoluble tau protein or from low speed centrifuge tau 
protein between ADTDP- and ADTDP+ brains in the amygdala. 4R/3R RNA ratio 
correlated with 4R/3R insoluble tau protein ratio in the amygdala and suggests that 
the stoichiometry of tau protein aggregates relates to the stoichiometry at the RNA 
level. Total levels of tau RNA were not different between control, ADTDP- and 
ADTDP+ brains showing that in the subgroup of AD cases with increases in 4R 
expression the 4R to 3R tau ratio were altered and not levels of total MAPT. Soluble 
tau ratios in AD brains were no different to control and did not correlate with RNA 
expression and this may be due to various post-transcriptional influences. These 
influences include RNA concentration and factors that influence the velocity of 
ribosomal translation including RNA secondary structure (Brockmann et al., 2007). In 
human post-mortem brain samples heterogeneity of cell type may also contribute to 
the lack of association between RNA and protein levels (Chen-Plotkin et al., 2010; 
Okaty et al., 2011). 
 
Luk et al. (2010) correlated relative 4R and 3R RNA levels with combined soluble 
and insoluble protein 4R and 3R levels from PSP brains and found only a very broad 
non-significant trend for increases in both 3R and 4R tau RNA isoforms to associate 
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with increases of 3R and 4R protein. In this study the authors did not correlate tau 
RNA ratios with insoluble protein ratios.  
 
A relationship between altered splicing ratios at the RNA level and increases in 4R 
protein isoforms has been demonstrated in FTDP-17 cases with splicing mutations 
(Connell et al., 2005; Umeda et al., 2004). These mutations cause neurodegeneration 
and therefore suggest that an excess in either 3R or 4R tau isoforms are associated 
with neurodegeneration. Our study shows that a sub-group of AD cases also show 
increased expression of 4R transcripts which are translated in insoluble tau deposits 
suggesting a common mechanism of neurodegeneration in tauopathies.   
 
7.4.1. 3R and 4R isoforms at the protein level 
The correlation between high 4R RNA expression and 4R found in insoluble material 
suggests that the imbalanced expression of one tau isoform may seed formation of 
aggregates. The majority of FTDP-17 mutations promote tau exon 10 inclusion and 
therefore an excess of 4R tau, however there are a few mutations such as L266V, 
G272V E10+19 and E10+29 which promote exon 10 exclusion resulting in an excess 
of 3R isoforms (Bronner et al., 2005; Hogg et al., 2003; Stanford et al., 2003).  
 
4R and 3R isoforms have different aggregation properties that may also be dependent 
on exons 2 and 3 (Adams et al., 2010; Zhong et al., 2012). Propagation of tau 
aggregates has been shown in vitro and in vivo (de Calignon et al., 2012; Dinkel et al., 
2011; Liu et al., 2012) and suggest that tau aggregation seeded in the entorhinal cortex 
could spread via synaptic connections to limbic, temporal and frontal regions.  
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On the other hand, functional differences of the two isoforms may provide clues into 
the disease process. For example, 4R isoforms display different MT stabilising and 
mitochondrial transport properties compared to 3R isoforms. (Drechsel et al., 1992; 
Stoothoff et al., 2009).  
 
Our results suggest that imbalances in tau exon 10 expression in a subset of AD cases 
may share the same pathogenic mechanism as FTLD cases. 
 
7.5. The role of TDP-43 modulating tau pathology 
 
We found tau AT8 immunoreactivity scores were higher in the frontal and temporal 
cortices, in particular, threads and neuritic plaques were found to be significantly 
higher in ADTDP+ brains compared to ADTDP- brains. Higher AT8 staining relates 
to severity of tau inclusions and therefore the ADTDP+ brains had significantly 
greater severity of tau pathology compared to ADTDP- brains in the frontal and 
temporal cortex.  
 
We found no differences in severity of tau pathology in the amygdala or 
hippocampus, however there were significant ceiling effects in the semi-quantitative 
scoring of tau severity in the amygdala and hippocampus and therefore our results 
may underestimate the severity of tau pathology in these regions.  
 
Arai et al. (2009) found that in the amygdala, hippocampus, and temporal cortex of 
AD brains, Braak NFT stage was higher in cases with pTDP-43 pathology compared 
to those without however these authors note that the ADTDP+ group were on average 
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older than the ADTDP- group and therefore aging may account for the increases in 
Braak stage found in ADTDP+ cases. There were no differences in age between 
ADTDP- and ADTDP+ cases in our analysis however disease duration and other co-
pathologies such as Lewy bodies that may contribute to tau pathology were not 
measured in our study (Popescu et al., 2004). 
 
In AD brains with TDP-43 inclusions, the amygdala and hippocampus are 
consistently affected with TDP-43 pathology (Amador-Ortiz et al., 2007; Arai et al., 
2009; Hu et al., 2008). TDP-43 inclusions in AD cases are also consistently associated 
with HS and it has been proposed that tau and TDP-43 pathologies combine and may 
cause greater neuronal loss in the hippocampus (Probst et al., 2007). HS in AD is 
regarded as neuronal loss in the hippocampus disproportionate to the amount of NFT 
present in the hippocampus (Amador-Ortiz et al., 2007; Pao et al., 2011).  
 
These findings have remarkable parallels with Lewy body (LB) and tau co-existent 
pathology within the amygdala of AD and PiD brains (Popescu et al., 2004) and 
suggest that limbic regions have a propensity for co-pathologies. Around 50% of AD 
cases also have LBs (Jellinger, 2004) and LBs colocalise with NFT in many cases 
(Galpern and Lang, 2006; Popescu et al., 2004). Lewy bodies are composed 
predominantely of α-synuclein and are the pathological hallmark of a group of 
diseases collectively known as synucleinopathies which include Parkinson’s Disease 
(PD), Dementia with Lewy bodies (DLB) and multiple system atrophy.  
 
The association between tau and α-synuclein suggests that tau inclusions could 
directly or indirectly promote the fibrillation of α-synuclein to form LBs in regions 
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with abundant NFT, and suggest that tau and may also promote TDP-43 inclusion 
formation. Tau and α-synuclein aggregation is dependent on altered conformation of 
proteins into β-sheet aggregates. The prion domain of TDP-43 is also capable of 
altered conformation into β-sheets (Fuentealba et al., 2010; Soto, 2012; Udan and 
Baloh, 2011) and suggests that tau may cross-seed TDP-43 aggregation. 
 
Cross-seeding of aggregated proteins has been demonstrated between Aβ and α-
synuclein (Tsigelny et al., 2008). These authors demonstrated that Aβ and α-synuclein 
directly interact in the brains of patients with Lewy body disease and in APP/ α-
synuclein double knock-in mice and form ring-like structures (Tsigelny et al., 2008).  
 
Convincing evidence has been accumulating that Aβ and tau aggregation are 
propagated by mechanisms that are similar to the infectivity of prions (for recent 
reviews see (Soto, 2012; Walker and LeVine, 2012)) suggesting that once aggregation 
is initiated at one foci, it spreads to other brain regions via synaptic connections 
(de Calignon et al., 2012; Liu et al., 2012).  
 
At present it is not clear why co-pathologies occur in some AD brains and not others.  
TDP-43 inclusions in AD may be due to a propensity for aggregation that has no 
interaction with tau. The association we found between TDP-43 pathology and 
increased tau severity suggests that there is an interaction, however if TDP-43 
exacerbates tau pathology or high concentration of β-sheet containing tau aggregates 
causes cross-seeding of TDP-43 pathology is not known. Another possibility is altered 
levels of a co-factor in disease that results in aggregation in both TDP-43 and tau.  
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We found no relationship between severity of tau pathology and tau protein 4R/3R 
ratios from insoluble or from low speed centrifuge material. These results suggest that 
high levels of 4R tau protein were not associated with the level of AT8 
immunoreactivity however total levels of insoluble tau protein may be a better 
correlate with the severity of tau pathologybecause in AD both 3R and 4R isoforms 
are found in insoluble NFTs. TDP-43 misregulation does not alter tau protein or RNA 
isoform levels through altered transcription or post-transcriptional processing and 
therefore the association between increased severity of tau pathology and presence of 
TDP-43 inclusions may not be dependent on altered tau splicing ratios or transcript 
expression however immunohistology with antibodies that recognise 4R or 3R tau 
could be carried out. Our results are in line with Ingelsson et al. (2006) where they 
correlated 4R and 3R levels of RNA expression with stereologically measured tau 
NFT density in the temporal cortex and found no association.  
 
7.6. Autoregulation of TDP-43 in Alzheimer’s disease 
 
The 3’UTR of TDP-43 is a confirmed autoregulatory splicing target of TDP-43 in 
HEK 293 cells (Avendaño-Vázquez et al., 2012; Ayala et al., 2011; Polymenidou et 
al., 2011; Tollervey et al., 2011a) and we show that a 3’UTR spliced TDP-43 isoform 
pA2 is produced in human brain. We found a consistent decrease in the pA2 transcript 
in AD brains with TDP-43 inclusions compared to control and AD brains without 
TDP-43 inclusions however these results did not reach significance. A significant 
reduction in pA2 transcripts was found in FTLD-TDP samples from the frontal and 
temporal cortices, hippocampus and amygdala. The significant finding in the temporal 
cortex was predominantly due to a single sample which has the C9ORF72 
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hexanucleotide repeat. These results show that a detectable altered splicing ratio was 
found for a confirmed TDP-43 target and suggests that there is a loss of TDP-43 
function in TDP-proteinopathies. The reduction in the pA2 TDP-43 isoform may be 
due to a reduction of TDP-43 splicing activity because of nuclear clearance of TDP-
43 protein into inclusions. The significance of the reduction in pA2 isoforms in the 
C9ORF72 sample needs to be validated in more samples. 
 
Mishra et al. (2007) has found TDP-43 transcripts were increased 1.5 fold in FTLD-
TDP brains compared to controls measured by microarray. Our results demonstrate 
altered autoregulation of TDP-43 and suggest that TDP-43 RNA and possibly protein 
levels are altered in TDP-43 proteinopathies.  
 
7.7. Future directions 
 
We have shown a sub-grouping of AD cases however our sample size is small and 
therefore these findings should be replicated in a larger sample of AD and control 
cases. Altered splicing found in the AD subgroup may be due to cis- acting elements 
or trans- acting factors. We were not able to show differences in splicing or 
transcription for the tau H1 haplotype compared to the H2 haplotype however a larger 
sample is needed for this analysis. Other common or rare SNPs or indels may alter 
splicing in the AD subgroup and sequencing of the promoter region of tau and APP as 
well as intronic and exonic regions around exon 10 of tau and exons 7 and 8 of APP 
may show if genetic variation in these genes contribute to altered splicing ratios found 
these cases. Levels of splicing factors have been shown to be altered in 
neurodegenerative disease. Global changes in RNA levels of splicing factors could be 
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measured by microarray in our AD subgroup compared to AD and control groups. 
Specific splicing factors that were found to be reduced could be further tested by 
qRT-PCR and protein levels measured by western blotting.   
 
We show that TDP-43 3’UTR splicing was significantly reduced in FTLD cases 
compared to controls and in AD brains with TDP-43 inclusions there was a consistent 
trend for reduced TDP-43 3’UTR splice isoforms compared to controls and AD cases 
without TDP-43 inclusions however this finding was not significant. TDP-43 3’UTR 
splicing is the key event in autoregulation of TDP-43 and in HEK cells two routes 
have been reported, nuclear retention being the predominant mechanism and only 
minor involvement of NMD. We found 3’UTR splicing occurs in human brain and 
may be altered in disease and further investigation of the role of TDP-43 




This study aimed to analyse tau and APP splicing in relation with the presence of 
TDP-43 pathology and the molecular pathology in AD. 
 
Altered tau splicing causes neurodegeneration in FTDP-17 and splicing imbalances 
are associated with other tauopathies however it was not clear if altered tau splicing 
plays a role in AD. We found that a subset of AD cases can be defined by imbalances 
in tau 4R expression. We also found that increased expression of tau 4R isoforms at 
the RNA level correlated with increased insoluble tau 4R and show that the 
stoichiometry of tau protein aggregates reflects the stoichiometry at the RNA level. 
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Imbalances in tau isoform ratios at the RNA level are also found at the insoluble tau 
protein level in FTDP-17 brains. Our results show that the pathway toward tau 
pathology associated with tau splicing imbalances also contributes to AD pathology in 
a subset of AD cases. 
 
Increased severity of tau pathology was associated with the presence of TDP-43 
inclusions and this association suggests an interaction between the two pathologies.  
 
No association was found between TDP-43 inclusions and altered tau and APP 
splicing or transcription however we found correlated increases in 4R and APP exon 7 
isoforms in a subset of AD cases.  
 
Autoregulatory splicing in AD brain with TDP-43 inclusions was not significantly 
altered compared to control and AD brain without TDP-43 inclusions however there 
was a consistent trend for a reduction in TDP-43 isoforms associated with 
autoregulation. There was significantly reduced expression of the pA2 isoform in 
FTLD brain compared to control showing that FTLD-TDP brains have altered TDP-
43 autoregulation. Whether this is due to a reduction of TDP-43 splicing activity 
because of nuclear clearance of TDP-43 protein into inclusions is not known. This 
analysis suggests that TDP-43 autoregulation is altered in TDP-43 proteinopathies and 
possibly more severely in brains harbouring the C9ORF72 expansion and is worth 
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